<html lang="en" class="js"><head><link rel="preload" href="/static/fonts/HardingText-Regular-Web-cecd90984f.woff2" as="font" type="font/woff2" crossorigin=""><script async="" src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2"></script><script type="text/javascript" async="" src="https://pagead2.googlesyndication.com/tag/js/gpt.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-MRVXSHQ"></script><script type="text/javascript" src="https://www.nature.com/UUeTZjJfm7fsAl4Qq00JEsY5NHNvCub9ok890qjaNQJn33OA22YIdu673NkVXym62mKT9LeqZwe96M2o18adDw=="></script><script src="https://cmp.nature.com/production_live/en/consent-bundle-8-85.js" onload="initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"></script>
    <title>Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma | Nature Medicine</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/nm.rss">


    
        

        <script id="save-data-connection-testing">
            function hasConnection() {
                return navigator.connection || navigator.mozConnection || navigator.webkitConnection || navigator.msConnection;
            }

            function createLink(src) {
                var preloadLink = document.createElement("link");
                preloadLink.rel = "preload";
                preloadLink.href = src;
                preloadLink.as = "font";
                preloadLink.type = "font/woff2";
                preloadLink.crossOrigin = "";
                document.head.insertBefore(preloadLink, document.head.firstChild);
            }

            var connectionDetail = {
                saveDataEnabled: false,
                slowConnection: false
            };

            var connection = hasConnection();
            if (connection) {
                connectionDetail.saveDataEnabled = connection.saveData;
                if (/\slow-2g|2g/.test(connection.effectiveType)) {
                    connectionDetail.slowConnection = true;
                }
            }

            if (!(connectionDetail.saveDataEnabled || connectionDetail.slowConnection)) {
                createLink("/static/fonts/HardingText-Regular-Web-cecd90984f.woff2");
            } else {
                document.documentElement.classList.add('save-data');
            }
        </script>
    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin="">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480">

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"article","legacy":{"webtrendsPrimaryArticleType":"research","webtrendsSubjectTerms":"cancer-microenvironment;immunotherapy;translational-research;tumour-immunology","webtrendsContentCategory":null,"webtrendsContentCollection":null,"webtrendsContentGroup":"Nature Medicine","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Article","status":null}},"article":{"doi":"10.1038/s41591-022-01916-x"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":true,"legacy":{"webtrendsLicenceType":"http://creativecommons.org/licenses/by/4.0/"}}},"contentInfo":{"authors":["Nathalie Scholler","Regis Perbost","Frederick L. Locke","Michael D. Jain","Sarah Turcan","Corinne Danan","Edmund C. Chang","Sattva S. Neelapu","David B. Miklos","Caron A. Jacobson","Lazaros J. Lekakis","Yi Lin","Armin Ghobadi","Jenny J. Kim","Justin Chou","Vicki Plaks","Zixing Wang","Allen Xue","Mike Mattie","John M. Rossi","Adrian Bot","Jérôme Galon"],"publishedAt":1661731200,"publishedAtString":"2022-08-29","title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","legacy":null,"publishedAtTime":null,"documentType":"aplusplus","subjects":"Cancer microenvironment,Immunotherapy,Translational research,Tumour immunology"},"journal":{"pcode":"nm","title":"nature medicine","volume":"28","issue":"9","id":41591,"publishingModel":"Hybrid Access"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":null},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"nature-onwards-journey","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"BR","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://collect.nature.com',
        imprint: 'nature'
    });
</script>

<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card--major .c-card__title,.c-card__title,.u-h2,.u-h3,h2,h3{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.u-h3,h3{font-size:1.25rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}html{line-height:1.15;text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-size:2rem;letter-spacing:-.0390625rem;line-height:2.25rem}.c-card--major .c-card__title,.u-h2,.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-card--major .c-card__title,.u-h2,h2{font-weight:700;-webkit-font-smoothing:antialiased;font-size:1.5rem;line-height:1.6rem}.u-h3{font-size:1.25rem}.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h4,h5,h6{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,h3{font-family:Harding,Palatino,serif;font-size:1.25rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,h3{font-weight:700;-webkit-font-smoothing:antialiased;letter-spacing:-.0117156rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;letter-spacing:-.0117156rem}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-code-block{border:1px solid #eee;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#069;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex-basis:75%;flex-shrink:0;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-recommendations-column-switch .c-meta{margin-top:auto}.c-article-recommendations-card__meta-type,.c-meta .c-meta__item:first-child{font-weight:700}.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a{color:inherit}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}p{overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad__label{color:#333;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;font-weight:400;line-height:1.5;margin-bottom:4px}.app-author-list{color:#6f6f6f;font-family:inherit;font-size:1rem;line-height:inherit;list-style:none;margin:0;padding:0}.app-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .app-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.app-author-list>li:not(:first-child):not(:last-child):before{content:", "}.app-author-list>li:not(:only-child):last-child:before{content:" & "}.app-author-list--compact{font-size:.875rem;line-height:1.4}.app-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .app-author-list__hide{display:none;visibility:hidden}.js .app-author-list__hide:first-child+*{margin-block-start:0}.c-meta{color:inherit;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{fill:currentcolor;display:inline-block;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{margin:4px 4px 0;fill:#888;height:10px;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px 8px;line-height:1.4;list-style:none;margin:0 -8px;padding:0}@media print{.c-header__menu{display:none}}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px 4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}@media print{.c-header__dropdown{display:none}}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px 16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:100%}.u-button svg,.u-button--primary svg{fill:currentcolor}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{-webkit-appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px 13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #069;border-radius:2px;color:#069;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-list-reset{list-style:none;margin:0;padding:0}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.c-nature-box svg+.c-article__button-text,.u-ml-8{margin-left:8px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box--access-to-pdf{display:none}@media only screen and (min-width:1024px){.c-nature-box--mobile{display:none}}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-c9121fecab.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href="/static/images/favicons/nature/apple-touch-icon-f39cb19454.png">
<link rel="icon" type="image/png" sizes="48x48" href="/static/images/favicons/nature/favicon-48x48-b52890008c.png">
<link rel="icon" type="image/png" sizes="32x32" href="/static/images/favicons/nature/favicon-32x32-3fe59ece92.png">
<link rel="icon" type="image/png" sizes="16x16" href="/static/images/favicons/nature/favicon-16x16-951651ab72.png">
<link rel="manifest" href="/static/manifest.json" crossorigin="use-credentials">
<link rel="mask-icon" href="/static/images/favicons/nature/safari-pinned-tab-69bff48fe6.svg" color="#000000">
<link rel="shortcut icon" href="/static/images/favicons/nature/favicon.ico">
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content="/static/browserconfig.xml">
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">


<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>



<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h.indexOf('preview-www.nature.com') > -1) return;

            var e = d.createElement(t),
                    s = d.getElementsByTagName(t)[0];

            if (h.indexOf('nature.com') > -1) {
                if (h.indexOf('test-www.nature.com') > -1) {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                } else {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                }
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }

        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-c8a573ca90.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-d17603b9e9.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-e9d2061c95.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-1cbf3a8b56.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-5bb959eaa1.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-994fde5b1d.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-464a2af269.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-98fb9b653b.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-23597ae350.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-6532c6f78b.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script><script id="js-position1" data-test="global-article-js" defer="" src="/static/js/global-article-es6-bundle-c8a573ca90.js"></script><script id="js-position2" data-test="shared-js" defer="" src="/static/js/shared-es6-bundle-e9d2061c95.js"></script><script id="js-position3" data-test="header-150-js" defer="" src="/static/js/header-150-es6-bundle-5bb959eaa1.js"></script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","description":"Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment with similar efficacy across conventional LBCL subtypes. Toward patient stratification, we assessed whether tumor immune contexture influenced clinical outcomes after axi-cel. We evaluated the tumor microenvironment (TME) of 135 pre-treatment and post-treatment tumor biopsies taken from 51 patients in the ZUMA-1 phase 2 trial. We uncovered dynamic patterns that occurred within 2 weeks after axi-cel. The biological associations among Immunoscore (quantification of tumor-infiltrating T cell density), Immunosign 21 (expression of pre-defined immune gene panel) and cell subsets were validated in three independent LBCL datasets. In the ZUMA-1 trial samples, clinical response and overall survival were associated with pre-treatment immune contexture as characterized by Immunoscore and Immunosign 21. Circulating CAR T cell levels were associated with post-treatment TME T cell exhaustion. TME enriched for chemokines (CCL5 and CCL22), γ-chain receptor cytokines (IL-15, IL-7 and IL-21) and interferon-regulated molecules were associated with T cell infiltration and markers of activity. Finally, high density of regulatory T cells in pre-treatment TME associated with reduced axi-cel–related neurologic toxicity. These findings advance the understanding of LBCL TME characteristics associated with clinical responses to anti-CD19 CAR T cell therapy and could foster biomarker development and treatment optimization for patients with LBCL. Analysis of tumor biopsies from the pivotal phase 1/2 ZUMA-1 trial identifies pre-treatment T cell–related characteristics that are associated with clinical response and neurologic toxicity after anti-CD19 CAR T cell therapy in patients with large B cell lymphoma.","datePublished":"2022-08-29T00:00:00Z","dateModified":"2022-08-29T00:00:00Z","pageStart":"1872","pageEnd":"1882","license":"http://creativecommons.org/licenses/by/4.0/","sameAs":"https://doi.org/10.1038/s41591-022-01916-x","keywords":["Cancer microenvironment","Immunotherapy","Translational research","Tumour immunology","Biomedicine","general","Cancer Research","Metabolic Diseases","Infectious Diseases","Molecular Medicine","Neurosciences"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig3_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig4_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig5_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig6_HTML.png"],"isPartOf":{"name":"Nature Medicine","issn":["1546-170X","1078-8956"],"volumeNumber":"28","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group US","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Nathalie Scholler","affiliation":[{"name":"Kite, a Gilead company","address":{"name":"Kite, a Gilead company, Santa Monica, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Gilead Sciences","address":{"name":"Gilead Sciences, Foster City, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Regis Perbost","affiliation":[{"name":"Veracyte SAS","address":{"name":"Veracyte SAS, Marseille, France","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Frederick L. Locke","url":"http://orcid.org/0000-0001-9063-6691","affiliation":[{"name":"Moffitt Cancer Center","address":{"name":"Moffitt Cancer Center, Tampa, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Michael D. Jain","url":"http://orcid.org/0000-0002-7789-1257","affiliation":[{"name":"Moffitt Cancer Center","address":{"name":"Moffitt Cancer Center, Tampa, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Sarah Turcan","affiliation":[{"name":"Veracyte SAS","address":{"name":"Veracyte SAS, Marseille, France","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Corinne Danan","affiliation":[{"name":"Veracyte SAS","address":{"name":"Veracyte SAS, Marseille, France","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Edmund C. Chang","affiliation":[{"name":"Kite, a Gilead company","address":{"name":"Kite, a Gilead company, Santa Monica, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Sattva S. Neelapu","url":"http://orcid.org/0000-0003-1045-4914","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","address":{"name":"The University of Texas MD Anderson Cancer Center, Houston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"David B. Miklos","url":"http://orcid.org/0000-0003-0717-4305","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Caron A. Jacobson","affiliation":[{"name":"Dana-Farber Cancer Institute","address":{"name":"Dana-Farber Cancer Institute, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Lazaros J. Lekakis","affiliation":[{"name":"University of Miami Health System, Sylvester Comprehensive Cancer Center","address":{"name":"University of Miami Health System, Sylvester Comprehensive Cancer Center, Miami, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Yi Lin","affiliation":[{"name":"Mayo Clinic","address":{"name":"Mayo Clinic, Rochester, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Armin Ghobadi","affiliation":[{"name":"Washington University School of Medicine","address":{"name":"Washington University School of Medicine, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jenny J. Kim","affiliation":[{"name":"Kite, a Gilead company","address":{"name":"Kite, a Gilead company, Santa Monica, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Justin Chou","affiliation":[{"name":"Kite, a Gilead company","address":{"name":"Kite, a Gilead company, Santa Monica, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Vicki Plaks","affiliation":[{"name":"Kite, a Gilead company","address":{"name":"Kite, a Gilead company, Santa Monica, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Zixing Wang","affiliation":[{"name":"Kite, a Gilead company","address":{"name":"Kite, a Gilead company, Santa Monica, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Allen Xue","affiliation":[{"name":"Kite, a Gilead company","address":{"name":"Kite, a Gilead company, Santa Monica, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Mike Mattie","affiliation":[{"name":"Kite, a Gilead company","address":{"name":"Kite, a Gilead company, Santa Monica, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"John M. Rossi","affiliation":[{"name":"Kite, a Gilead company","address":{"name":"Kite, a Gilead company, Santa Monica, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Adrian Bot","affiliation":[{"name":"Kite, a Gilead company","address":{"name":"Kite, a Gilead company, Santa Monica, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Capstan Therapeutics","address":{"name":"Capstan Therapeutics, San Diego, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jérôme Galon","url":"http://orcid.org/0000-0001-9635-1339","affiliation":[{"name":"Veracyte SAS","address":{"name":"Veracyte SAS, Marseille, France","@type":"PostalAddress"},"@type":"Organization"},{"name":"INSERM, Sorbonne Université, Université Paris Cité, Centre de Recherche des Cordeliers, Equipe Labellisée Ligue Contre le Cancer, Laboratory of Integrative Cancer Immunology","address":{"name":"INSERM, Sorbonne Université, Université Paris Cité, Centre de Recherche des Cordeliers, Equipe Labellisée Ligue Contre le Cancer, Laboratory of Integrative Cancer Immunology, Paris, France","@type":"PostalAddress"},"@type":"Organization"}],"email":"jerome.galon@crc.jussieu.fr","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>




    
    
    


    
    <link rel="canonical" href="https://www.nature.com/articles/s41591-022-01916-x">
    
    
    <meta name="journal_id" content="41591">
    <meta name="dc.title" content="Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma">
    <meta name="dc.source" content="Nature Medicine 2022 28:9">
    <meta name="dc.format" content="text/html">
    <meta name="dc.publisher" content="Nature Publishing Group">
    <meta name="dc.date" content="2022-08-29">
    <meta name="dc.type" content="OriginalPaper">
    <meta name="dc.language" content="En">
    <meta name="dc.copyright" content="2022 The Author(s)">
    <meta name="dc.rights" content="2022 The Author(s)">
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="dc.description" content="Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment with similar efficacy across conventional LBCL subtypes. Toward patient stratification, we assessed whether tumor immune contexture influenced clinical outcomes after axi-cel. We evaluated the tumor microenvironment (TME) of 135 pre-treatment and post-treatment tumor biopsies taken from 51 patients in the ZUMA-1 phase 2 trial. We uncovered dynamic patterns that occurred within 2 weeks after axi-cel. The biological associations among Immunoscore (quantification of tumor-infiltrating T cell density), Immunosign 21 (expression of pre-defined immune gene panel) and cell subsets were validated in three independent LBCL datasets. In the ZUMA-1 trial samples, clinical response and overall survival were associated with pre-treatment immune contexture as characterized by Immunoscore and Immunosign 21. Circulating CAR T cell levels were associated with post-treatment TME T cell exhaustion. TME enriched for chemokines (CCL5 and CCL22), γ-chain receptor cytokines (IL-15, IL-7 and IL-21) and interferon-regulated molecules were associated with T cell infiltration and markers of activity. Finally, high density of regulatory T cells in pre-treatment TME associated with reduced axi-cel–related neurologic toxicity. These findings advance the understanding of LBCL TME characteristics associated with clinical responses to anti-CD19 CAR T cell therapy and could foster biomarker development and treatment optimization for patients with LBCL. Analysis of tumor biopsies from the pivotal phase 1/2 ZUMA-1 trial identifies pre-treatment T cell–related characteristics that are associated with clinical response and neurologic toxicity after anti-CD19 CAR T cell therapy in patients with large B cell lymphoma.">
    <meta name="prism.issn" content="1546-170X">
    <meta name="prism.publicationName" content="Nature Medicine">
    <meta name="prism.publicationDate" content="2022-08-29">
    <meta name="prism.volume" content="28">
    <meta name="prism.number" content="9">
    <meta name="prism.section" content="OriginalPaper">
    <meta name="prism.startingPage" content="1872">
    <meta name="prism.endingPage" content="1882">
    <meta name="prism.copyright" content="2022 The Author(s)">
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="prism.url" content="https://www.nature.com/articles/s41591-022-01916-x">
    <meta name="prism.doi" content="doi:10.1038/s41591-022-01916-x">
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41591-022-01916-x.pdf">
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41591-022-01916-x">
    <meta name="citation_journal_title" content="Nature Medicine">
    <meta name="citation_journal_abbrev" content="Nat Med">
    <meta name="citation_publisher" content="Nature Publishing Group">
    <meta name="citation_issn" content="1546-170X">
    <meta name="citation_title" content="Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma">
    <meta name="citation_volume" content="28">
    <meta name="citation_issue" content="9">
    <meta name="citation_publication_date" content="2022/09">
    <meta name="citation_online_date" content="2022/08/29">
    <meta name="citation_firstpage" content="1872">
    <meta name="citation_lastpage" content="1882">
    <meta name="citation_article_type" content="Article">
    <meta name="citation_fulltext_world_readable" content="">
    <meta name="citation_language" content="en">
    <meta name="dc.identifier" content="doi:10.1038/s41591-022-01916-x">
    <meta name="DOI" content="10.1038/s41591-022-01916-x">
    <meta name="size" content="249039">
    <meta name="citation_doi" content="10.1038/s41591-022-01916-x">
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41591-022-01916-x&amp;api_key=">
    <meta name="description" content="Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment with similar efficacy across conventional LBCL subtypes. Toward patient stratification, we assessed whether tumor immune contexture influenced clinical outcomes after axi-cel. We evaluated the tumor microenvironment (TME) of 135 pre-treatment and post-treatment tumor biopsies taken from 51 patients in the ZUMA-1 phase 2 trial. We uncovered dynamic patterns that occurred within 2 weeks after axi-cel. The biological associations among Immunoscore (quantification of tumor-infiltrating T cell density), Immunosign 21 (expression of pre-defined immune gene panel) and cell subsets were validated in three independent LBCL datasets. In the ZUMA-1 trial samples, clinical response and overall survival were associated with pre-treatment immune contexture as characterized by Immunoscore and Immunosign 21. Circulating CAR T cell levels were associated with post-treatment TME T cell exhaustion. TME enriched for chemokines (CCL5 and CCL22), γ-chain receptor cytokines (IL-15, IL-7 and IL-21) and interferon-regulated molecules were associated with T cell infiltration and markers of activity. Finally, high density of regulatory T cells in pre-treatment TME associated with reduced axi-cel–related neurologic toxicity. These findings advance the understanding of LBCL TME characteristics associated with clinical responses to anti-CD19 CAR T cell therapy and could foster biomarker development and treatment optimization for patients with LBCL. Analysis of tumor biopsies from the pivotal phase 1/2 ZUMA-1 trial identifies pre-treatment T cell–related characteristics that are associated with clinical response and neurologic toxicity after anti-CD19 CAR T cell therapy in patients with large B cell lymphoma.">
    <meta name="dc.creator" content="Scholler, Nathalie">
    <meta name="dc.creator" content="Perbost, Regis">
    <meta name="dc.creator" content="Locke, Frederick L.">
    <meta name="dc.creator" content="Jain, Michael D.">
    <meta name="dc.creator" content="Turcan, Sarah">
    <meta name="dc.creator" content="Danan, Corinne">
    <meta name="dc.creator" content="Chang, Edmund C.">
    <meta name="dc.creator" content="Neelapu, Sattva S.">
    <meta name="dc.creator" content="Miklos, David B.">
    <meta name="dc.creator" content="Jacobson, Caron A.">
    <meta name="dc.creator" content="Lekakis, Lazaros J.">
    <meta name="dc.creator" content="Lin, Yi">
    <meta name="dc.creator" content="Ghobadi, Armin">
    <meta name="dc.creator" content="Kim, Jenny J.">
    <meta name="dc.creator" content="Chou, Justin">
    <meta name="dc.creator" content="Plaks, Vicki">
    <meta name="dc.creator" content="Wang, Zixing">
    <meta name="dc.creator" content="Xue, Allen">
    <meta name="dc.creator" content="Mattie, Mike">
    <meta name="dc.creator" content="Rossi, John M.">
    <meta name="dc.creator" content="Bot, Adrian">
    <meta name="dc.creator" content="Galon, Jérôme">
    <meta name="dc.subject" content="Cancer microenvironment">
    <meta name="dc.subject" content="Immunotherapy">
    <meta name="dc.subject" content="Translational research">
    <meta name="dc.subject" content="Tumour immunology">
    <meta name="citation_reference" content="citation_journal_title=Immunol. Rev.; citation_title=Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells; citation_author=MC Jensen, SR Riddell; citation_volume=257; citation_publication_date=2014; citation_pages=127-144; citation_doi=10.1111/imr.12139; citation_id=CR1">
    <meta name="citation_reference" content="citation_journal_title=Adv. Immunol.; citation_title=Adoptive T-cell therapy for cancer; citation_author=JC Yang, SA Rosenberg; citation_volume=130; citation_publication_date=2016; citation_pages=279-294; citation_doi=10.1016/bs.ai.2015.12.006; citation_id=CR2">
    <meta name="citation_reference" content="Dunbar, C.E. et al. Gene therapy comes of age. Science 359, eaan4672 (2018).">
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=CAR T cell immunotherapy for human cancer; citation_author=CH June, RS O’Connor, OU Kawalekar, S Ghassemi, MC Milone; citation_volume=359; citation_publication_date=2018; citation_pages=1361-1365; citation_doi=10.1126/science.aar6711; citation_id=CR4">
    <meta name="citation_reference" content="citation_journal_title=Lancet Oncol.; citation_title=Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial; citation_author=FL Locke; citation_volume=20; citation_publication_date=2019; citation_pages=31-42; citation_doi=10.1016/S1470-2045(18)30864-7; citation_id=CR5">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma; citation_author=K Fu; citation_volume=26; citation_publication_date=2008; citation_pages=4587-4594; citation_doi=10.1200/JCO.2007.15.9277; citation_id=CR6">
    <meta name="citation_reference" content="citation_journal_title=Ann. Hematol.; citation_title=Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy; citation_author=A Carbone, A Gloghini, YL Kwong, A Younes; citation_volume=93; citation_publication_date=2014; citation_pages=1263-1277; citation_doi=10.1007/s00277-014-2116-y; citation_id=CR7">
    <meta name="citation_reference" content="citation_journal_title=Mol. Ther.; citation_title=Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma; citation_author=FL Locke; citation_volume=25; citation_publication_date=2017; citation_pages=285-295; citation_doi=10.1016/j.ymthe.2016.10.020; citation_id=CR8">
    <meta name="citation_reference" content="citation_journal_title=Cancer Res.; citation_title=The adaptive immunologic microenvironment in colorectal cancer: a novel perspective; citation_author=J Galon, WH Fridman, F Pages; citation_volume=67; citation_publication_date=2007; citation_pages=1883-1886; citation_doi=10.1158/0008-5472.CAN-06-4806; citation_id=CR9">
    <meta name="citation_reference" content="citation_journal_title=J. Transl. Med.; citation_title=Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015; citation_author=J Galon; citation_volume=14; citation_publication_date=2016; citation_doi=10.1186/s12967-016-1029-z; citation_id=CR10">
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Cancer; citation_title=Impact of oncogenic pathways on evasion of antitumour immune responses; citation_author=S Spranger, TF Gajewski; citation_volume=18; citation_publication_date=2018; citation_pages=139-147; citation_doi=10.1038/nrc.2017.117; citation_id=CR11">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Evolution of metastases in space and time under immune selection; citation_author=M Angelova; citation_volume=175; citation_publication_date=2018; citation_pages=751-765; citation_doi=10.1016/j.cell.2018.09.018; citation_id=CR12">
    <meta name="citation_reference" content="citation_journal_title=J. Immunother. Cancer; citation_title=Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop; citation_author=D Bedognetti; citation_volume=7; citation_publication_date=2019; citation_pages=131; citation_doi=10.1186/s40425-019-0602-4; citation_id=CR13">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Immune evasion before tumour invasion in early lung squamous carcinogenesis; citation_author=C Mascaux; citation_volume=571; citation_publication_date=2019; citation_pages=570-575; citation_doi=10.1038/s41586-019-1330-0; citation_id=CR14">
    <meta name="citation_reference" content="citation_journal_title=Immunity; citation_title=Tumor immunology and tumor evolution: intertwined histories; citation_author=J Galon, D Bruni; citation_volume=52; citation_publication_date=2020; citation_pages=55-81; citation_doi=10.1016/j.immuni.2019.12.018; citation_id=CR15">
    <meta name="citation_reference" content="citation_journal_title=Oncoimmunology; citation_title=The immune landscape of human tumors: implications for cancer immunotherapy; citation_author=G Bindea, B Mlecnik, HK Angell, J Galon; citation_volume=3; citation_publication_date=2014; citation_pages=e27456; citation_doi=10.4161/onci.27456; citation_id=CR16">
    <meta name="citation_reference" content="citation_journal_title=Int. Immunol.; citation_title=Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients; citation_author=A Kirilovsky; citation_volume=28; citation_publication_date=2016; citation_pages=373-382; citation_doi=10.1093/intimm/dxw021; citation_id=CR17">
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study; citation_author=F Pages; citation_volume=391; citation_publication_date=2018; citation_pages=2128-2139; citation_doi=10.1016/S0140-6736(18)30789-X; citation_id=CR18">
    <meta name="citation_reference" content="citation_journal_title=Cancer Cell; citation_title=The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients; citation_author=M Eynde; citation_volume=34; citation_publication_date=2018; citation_pages=1012-1026; citation_doi=10.1016/j.ccell.2018.11.003; citation_id=CR19">
    <meta name="citation_reference" content="Angell, H. K., Bruni, D., Barrett, J. C., Herbst, R. &amp; Galon, J. The Immunoscore: colon cancer and beyond. Clin. Cancer Res. 26, 332–339 (2019).">
    <meta name="citation_reference" content="citation_journal_title=Ann. Surg. Oncol.; citation_title=The Immunoscore is a superior prognostic tool in stages II and III colorectal cancer and is significantly correlated with programmed death-ligand 1 (PD-L1) expression on tumor-infiltrating mononuclear cells; citation_author=T Yomoda; citation_volume=26; citation_publication_date=2019; citation_pages=415-424; citation_doi=10.1245/s10434-018-07110-z; citation_id=CR21">
    <meta name="citation_reference" content="Bruni, D., Angell, H. K. &amp; Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662–680 (2020).">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=The next decade of immune checkpoint therapy; citation_author=P Sharma; citation_volume=11; citation_publication_date=2021; citation_pages=838-857; citation_doi=10.1158/2159-8290.CD-20-1680; citation_id=CR23">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma; citation_author=SS Neelapu; citation_volume=377; citation_publication_date=2017; citation_pages=2531-2544; citation_doi=10.1056/NEJMoa1707447; citation_id=CR24">
    <meta name="citation_reference" content="Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640–654 (2021).">
    <meta name="citation_reference" content="Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells associate with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621–2633 (2021).">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients’ blood cells: implications for cancer chemoimmunotherapy; citation_author=F Moschella; citation_volume=19; citation_publication_date=2013; citation_pages=4249-4261; citation_doi=10.1158/1078-0432.CCR-12-3666; citation_id=CR27">
    <meta name="citation_reference" content="citation_journal_title=J. Exp. Med.; citation_title=The B cell antigen CD75 is a cell surface sialytransferase; citation_author=I Stamenkovic; citation_volume=172; citation_publication_date=1990; citation_pages=641-643; citation_doi=10.1084/jem.172.2.641; citation_id=CR28">
    <meta name="citation_reference" content="citation_journal_title=PLoS Genet.; citation_title=PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia; citation_author=K Okuyama; citation_volume=15; citation_publication_date=2019; citation_pages=e1008280; citation_doi=10.1371/journal.pgen.1008280; citation_id=CR29">
    <meta name="citation_reference" content="citation_journal_title=Oncotarget; citation_title=Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma; citation_author=HY Park; citation_volume=7; citation_publication_date=2016; citation_pages=86433-86445; citation_doi=10.18632/oncotarget.13239; citation_id=CR30">
    <meta name="citation_reference" content="citation_journal_title=Annu. Rev. Pharmacol. Toxicol.; citation_title=Cause and consequence of cancer/testis antigen activation in cancer; citation_author=AW Whitehurst; citation_volume=54; citation_publication_date=2014; citation_pages=251-272; citation_doi=10.1146/annurev-pharmtox-011112-140326; citation_id=CR31">
    <meta name="citation_reference" content="citation_journal_title=Haematologica; citation_title=Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma; citation_author=M Autio; citation_volume=106; citation_publication_date=2021; citation_pages=718-729; citation_doi=10.3324/haematol.2019.243626; citation_id=CR32">
    <meta name="citation_reference" content="citation_journal_title=Curr. Opin. Immunol.; citation_title=From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer; citation_author=H Angell, J Galon; citation_volume=25; citation_publication_date=2013; citation_pages=261-267; citation_doi=10.1016/j.coi.2013.03.004; citation_id=CR33">
    <meta name="citation_reference" content="citation_journal_title=Blood Adv.; citation_title=Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma; citation_author=FL Locke; citation_volume=4; citation_publication_date=2020; citation_pages=4898-4911; citation_doi=10.1182/bloodadvances.2020002394; citation_id=CR34">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Stromal gene signatures in large-B-cell lymphomas; citation_author=G Lenz; citation_volume=359; citation_publication_date=2008; citation_pages=2313-2323; citation_doi=10.1056/NEJMoa0802885; citation_id=CR35">
    <meta name="citation_reference" content="citation_journal_title=Am. J. Hematol.; citation_title=Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment; citation_author=Y Liu, SK Barta; citation_volume=94; citation_publication_date=2019; citation_pages=604-616; citation_doi=10.1002/ajh.25460; citation_id=CR36">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Characterization of anti-CD19 chimeric antigen receptor (CAR) T-cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19); citation_author=J Galon; citation_volume=35; citation_publication_date=2017; citation_pages=3025; citation_doi=10.1200/JCO.2017.35.15_suppl.3025; citation_id=CR37">
    <meta name="citation_reference" content="citation_journal_title=Proc. Natl Acad. Sci. USA; citation_title=Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans; citation_author=D Sugiyama; citation_volume=110; citation_publication_date=2013; citation_pages=17945-17950; citation_doi=10.1073/pnas.1316796110; citation_id=CR38">
    <meta name="citation_reference" content="citation_journal_title=Int. J. Cancer; citation_title=CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T-cells in gastric cancer; citation_author=Y Mizukami; citation_volume=122; citation_publication_date=2008; citation_pages=2286-2293; citation_doi=10.1002/ijc.23392; citation_id=CR39">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels; citation_author=JN Kochenderfer; citation_volume=35; citation_publication_date=2017; citation_pages=1803-1813; citation_doi=10.1200/JCO.2016.71.3024; citation_id=CR40">
    <meta name="citation_reference" content="citation_journal_title=J. Interferon Cytokine Res.; citation_title=Cytokines in the treatment of cancer; citation_author=KC Conlon, MD Miljkovic, TA Waldmann; citation_volume=39; citation_publication_date=2019; citation_pages=6-21; citation_doi=10.1089/jir.2018.0019; citation_id=CR41">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy; citation_author=KM Cappell; citation_volume=38; citation_publication_date=2020; citation_pages=3805-3815; citation_doi=10.1200/JCO.20.01467; citation_id=CR42">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=A distinct function of regulatory T cells in tissue protection; citation_author=N Arpaia; citation_volume=162; citation_publication_date=2015; citation_pages=1078-1089; citation_doi=10.1016/j.cell.2015.08.021; citation_id=CR43">
    <meta name="citation_reference" content="citation_journal_title=Cell Metab.; citation_title=Roles of regulatory T cells in tissue pathophysiology and metabolism; citation_author=C Campbell, A Rudensky; citation_volume=31; citation_publication_date=2020; citation_pages=18-25; citation_doi=10.1016/j.cmet.2019.09.010; citation_id=CR44">
    <meta name="citation_reference" content="citation_journal_title=Front. Immunol.; citation_title=The pivotal role of regulatory T cells in the regulation of innate immune cells; citation_author=EB Okeke, JE Uzonna; citation_volume=10; citation_publication_date=2019; citation_pages=680; citation_doi=10.3389/fimmu.2019.00680; citation_id=CR45">
    <meta name="citation_reference" content="citation_journal_title=Immunity; citation_title=The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures; citation_author=J Galon, HK Angell, D Bedognetti, FM Marincola; citation_volume=39; citation_publication_date=2013; citation_pages=11-26; citation_doi=10.1016/j.immuni.2013.07.008; citation_id=CR46">
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Drug Discov.; citation_title=Approaches to treat immune hot, altered and cold tumours with combination immunotherapies; citation_author=J Galon, D Bruni; citation_volume=18; citation_publication_date=2019; citation_pages=197-218; citation_doi=10.1038/s41573-018-0007-y; citation_id=CR47">
    <meta name="citation_reference" content="Chen, P. H. et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight 5, e134612 (2020).">
    <meta name="citation_reference" content="citation_journal_title=Haematologica; citation_title=Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP; citation_author=R Coutinho; citation_volume=100; citation_publication_date=2015; citation_pages=363-369; citation_doi=10.3324/haematol.2014.110189; citation_id=CR49">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel; citation_author=R Faramand; citation_volume=26; citation_publication_date=2020; citation_pages=4823-4831; citation_doi=10.1158/1078-0432.CCR-20-1434; citation_id=CR50">
    <meta name="citation_reference" content="citation_journal_title=Expert Opin. Biol. Ther.; citation_title=Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy; citation_author=CK Chou, CJ Turtle; citation_volume=20; citation_publication_date=2020; citation_pages=653-664; citation_doi=10.1080/14712598.2020.1729735; citation_id=CR51">
    <meta name="citation_reference" content="citation_journal_title=Cancer Cell; citation_title=Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies; citation_author=KG Anderson, IM Stromnes, PD Greenberg; citation_volume=31; citation_publication_date=2017; citation_pages=311-325; citation_doi=10.1016/j.ccell.2017.02.008; citation_id=CR52">
    <meta name="citation_reference" content="citation_journal_title=Curr. Opin. Biotechnol.; citation_title=All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy; citation_author=E Lanitis, G Coukos, M Irving; citation_volume=65; citation_publication_date=2020; citation_pages=75-87; citation_doi=10.1016/j.copbio.2020.01.009; citation_id=CR53">
    <meta name="citation_reference" content="citation_journal_title=J. Transl. Med.; citation_title=Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma; citation_author=T Hudolin; citation_volume=11; citation_publication_date=2013; citation_doi=10.1186/1479-5876-11-123; citation_id=CR54">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis; citation_author=M Teater; citation_volume=9; citation_publication_date=2018; citation_doi=10.1038/s41467-017-02595-w; citation_id=CR55">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion; citation_author=O Khan; citation_volume=571; citation_publication_date=2019; citation_pages=211-218; citation_doi=10.1038/s41586-019-1325-x; citation_id=CR56">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Safety and feasibility of anti-CD19 CAR T-cells with fully human binding domains in patients with B-cell lymphoma; citation_author=JN Brudno; citation_volume=26; citation_publication_date=2020; citation_pages=270-280; citation_doi=10.1038/s41591-019-0737-3; citation_id=CR57">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction; citation_author=N Singh; citation_volume=10; citation_publication_date=2020; citation_pages=552-567; citation_doi=10.1158/2159-8290.CD-19-0813; citation_id=CR58">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy; citation_author=R Upadhyay; citation_volume=11; citation_publication_date=2021; citation_pages=599-613; citation_doi=10.1158/2159-8290.CD-20-0756; citation_id=CR59">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel; citation_author=V Plaks; citation_volume=138; citation_publication_date=2021; citation_pages=1081-1085; citation_doi=10.1182/blood.2021010930; citation_id=CR60">
    <meta name="citation_reference" content="Marliot, F. et al. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. J. Immunother. Cancer 8, e000272 (2020).">
    <meta name="citation_reference" content="citation_journal_title=J. Natl Cancer Inst.; citation_title=Immune activation and benefit from avelumab in EBV-positive gastric cancer; citation_author=A Panda; citation_volume=110; citation_publication_date=2018; citation_pages=316-320; citation_doi=10.1093/jnci/djx213; citation_id=CR62">
    <meta name="citation_reference" content="Agocs, G. R. et al. LAG-3 expression predicts outcome in stage II colon cancer. J. Pers. Med. 11, 749 (2021).">
    <meta name="citation_reference" content="citation_journal_title=Oncotarget; citation_title=Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment; citation_author=AS Syed Khaja; citation_volume=8; citation_publication_date=2017; citation_pages=33159-33171; citation_doi=10.18632/oncotarget.16565; citation_id=CR64">
    <meta name="citation_reference" content="citation_journal_title=PLoS ONE; citation_title=High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations; citation_author=L Maestre; citation_volume=15; citation_publication_date=2020; citation_pages=e0229743; citation_doi=10.1371/journal.pone.0229743; citation_id=CR65">
    <meta name="citation_reference" content="citation_journal_title=Exp. Ther. Med.; citation_title=Prognostic value of MTA1, SOX4 and EZH2 expression in esophageal squamous cell carcinoma; citation_author=W Liu; citation_volume=22; citation_publication_date=2021; citation_pages=722; citation_doi=10.3892/etm.2021.10154; citation_id=CR66">
    <meta name="citation_reference" content="citation_journal_title=Cancer Cell Int.; citation_title=Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients; citation_author=J Yuan; citation_volume=19; citation_publication_date=2019; citation_doi=10.1186/s12935-019-0957-0; citation_id=CR67">
    <meta name="citation_reference" content="citation_journal_title=Cell Death Dis.; citation_title=SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells; citation_author=S Xia; citation_volume=12; citation_publication_date=2021; citation_doi=10.1038/s41419-021-03853-y; citation_id=CR68">
    <meta name="citation_reference" content="citation_journal_title=Hum. Pathol.; citation_title=CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169− monocyte-derived cells in diffuse large B-cell lymphomas; citation_author=B Marmey; citation_volume=37; citation_publication_date=2006; citation_pages=68-77; citation_doi=10.1016/j.humpath.2005.09.016; citation_id=CR69">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Upregulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer; citation_author=A Hashimoto; citation_volume=27; citation_publication_date=2021; citation_pages=5961-5978; citation_doi=10.1158/1078-0432.CCR-21-0986; citation_id=CR70">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue; citation_author=DW Scott; citation_volume=123; citation_publication_date=2014; citation_pages=1214-1217; citation_doi=10.1182/blood-2013-11-536433; citation_id=CR71">
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Type, density, and location of immune cells within human colorectal tumors predict clinical outcome; citation_author=J Galon; citation_volume=313; citation_publication_date=2006; citation_pages=1960-1964; citation_doi=10.1126/science.1129139; citation_id=CR72">
    <meta name="citation_author" content="Scholler, Nathalie">
    <meta name="citation_author_institution" content="Kite, a Gilead company, Santa Monica, USA">
    <meta name="citation_author_institution" content="Gilead Sciences, Foster City, USA">
    <meta name="citation_author" content="Perbost, Regis">
    <meta name="citation_author_institution" content="Veracyte SAS, Marseille, France">
    <meta name="citation_author" content="Locke, Frederick L.">
    <meta name="citation_author_institution" content="Moffitt Cancer Center, Tampa, USA">
    <meta name="citation_author" content="Jain, Michael D.">
    <meta name="citation_author_institution" content="Moffitt Cancer Center, Tampa, USA">
    <meta name="citation_author" content="Turcan, Sarah">
    <meta name="citation_author_institution" content="Veracyte SAS, Marseille, France">
    <meta name="citation_author" content="Danan, Corinne">
    <meta name="citation_author_institution" content="Veracyte SAS, Marseille, France">
    <meta name="citation_author" content="Chang, Edmund C.">
    <meta name="citation_author_institution" content="Kite, a Gilead company, Santa Monica, USA">
    <meta name="citation_author" content="Neelapu, Sattva S.">
    <meta name="citation_author_institution" content="The University of Texas MD Anderson Cancer Center, Houston, USA">
    <meta name="citation_author" content="Miklos, David B.">
    <meta name="citation_author_institution" content="Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Jacobson, Caron A.">
    <meta name="citation_author_institution" content="Dana-Farber Cancer Institute, Boston, USA">
    <meta name="citation_author" content="Lekakis, Lazaros J.">
    <meta name="citation_author_institution" content="University of Miami Health System, Sylvester Comprehensive Cancer Center, Miami, USA">
    <meta name="citation_author" content="Lin, Yi">
    <meta name="citation_author_institution" content="Mayo Clinic, Rochester, USA">
    <meta name="citation_author" content="Ghobadi, Armin">
    <meta name="citation_author_institution" content="Washington University School of Medicine, St. Louis, USA">
    <meta name="citation_author" content="Kim, Jenny J.">
    <meta name="citation_author_institution" content="Kite, a Gilead company, Santa Monica, USA">
    <meta name="citation_author" content="Chou, Justin">
    <meta name="citation_author_institution" content="Kite, a Gilead company, Santa Monica, USA">
    <meta name="citation_author" content="Plaks, Vicki">
    <meta name="citation_author_institution" content="Kite, a Gilead company, Santa Monica, USA">
    <meta name="citation_author" content="Wang, Zixing">
    <meta name="citation_author_institution" content="Kite, a Gilead company, Santa Monica, USA">
    <meta name="citation_author" content="Xue, Allen">
    <meta name="citation_author_institution" content="Kite, a Gilead company, Santa Monica, USA">
    <meta name="citation_author" content="Mattie, Mike">
    <meta name="citation_author_institution" content="Kite, a Gilead company, Santa Monica, USA">
    <meta name="citation_author" content="Rossi, John M.">
    <meta name="citation_author_institution" content="Kite, a Gilead company, Santa Monica, USA">
    <meta name="citation_author" content="Bot, Adrian">
    <meta name="citation_author_institution" content="Kite, a Gilead company, Santa Monica, USA">
    <meta name="citation_author_institution" content="Capstan Therapeutics, San Diego, USA">
    <meta name="citation_author" content="Galon, Jérôme">
    <meta name="citation_author_institution" content="Veracyte SAS, Marseille, France">
    <meta name="citation_author_institution" content="INSERM, Sorbonne Université, Université Paris Cité, Centre de Recherche des Cordeliers, Equipe Labellisée Ligue Contre le Cancer, Laboratory of Integrative Cancer Immunology, Paris, France">
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access">
    <meta name="twitter:site" content="@naturemedicine">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:image:alt" content="Content cover image">
    <meta name="twitter:title" content="Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma">
    <meta name="twitter:description" content="Nature Medicine - Analysis of tumor biopsies from the pivotal phase 1/2 ZUMA-1 trial identifies pre-treatment T cell–related characteristics that are associated with clinical response and...">
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig1_HTML.png">
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41591-022-01916-x">
    <meta property="og:type" content="article">
    <meta property="og:site_name" content="Nature">
    <meta property="og:title" content="Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma - Nature Medicine">
    <meta property="og:description" content="Analysis of tumor biopsies from the pivotal phase 1/2 ZUMA-1 trial identifies pre-treatment T cell–related characteristics that are associated with clinical response and neurologic toxicity after anti-CD19 CAR T cell therapy in patients with large B cell lymphoma.">
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig1_HTML.png">
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
<style type="text/css">.cc-banner{background-color:#01324b;border:none!important;bottom:0;box-sizing:border-box;color:#fff!important;left:0;line-height:1.3;margin:auto 0 0;max-width:100%;outline:0;overflow:visible;padding:0;position:fixed;right:0;width:100%;z-index:99999}.cc-banner::backdrop{background-color:#0000004d}.cc-banner *{color:inherit!important}.cc-banner:focus{box-shadow:none;outline:0}.cc-banner a{color:#fff!important;text-decoration:underline}.cc-banner a:active,.cc-banner a:focus,.cc-banner a:hover{color:inherit;text-decoration:none}.cc-banner a:focus{outline:3px solid #08c!important}.cc-banner h2,.cc-banner h3,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-banner .cc-h2,.cc-banner h2{font-size:18px}.cc-banner .cc-h3,.cc-banner h3{font-size:16px}.cc-banner .cc-h4,.cc-banner .cc-h5,.cc-banner .cc-h6,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-size:14px}.cc-banner .cc-button{font-size:16px}.cc-banner__content{background-color:#01324b;display:flex;flex-direction:column;margin:0 auto;max-height:90vh;max-width:100%;padding:16px;position:relative}.cc-banner__content:focus{outline:0}@media (min-width:680px){.cc-banner__content{padding:12px}}@media (min-width:980px){.cc-banner__content{max-height:60vh;padding-bottom:20px;padding-top:20px}}@media (min-width:1320px){.cc-banner__content{padding-bottom:40px;padding-top:40px}}.cc-banner__container{display:flex;flex-direction:column;margin:auto;max-width:1320px;overflow:auto}.cc-banner__title{background:none!important;border:0;flex-shrink:0;font-size:18px!important;font-size:22px!important;font-weight:700!important;letter-spacing:normal;margin:0 0 12px!important;padding:0}@media (min-width:680px){.cc-banner__title{font-size:24px!important;margin:0 0 16px!important}}@media (min-width:1320px){.cc-banner__title{font-size:26px!important;margin:0 0 24px!important}}.cc-banner__body{display:flex;flex-direction:column;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif!important;overflow-x:hidden;overflow-y:auto;padding:3px 3px 16px}@media (min-width:980px){.cc-banner__body{flex-direction:row}}.cc-banner__policy p{font-size:16px!important;margin:0;max-width:none;padding:0}.cc-banner__policy p:not(:last-child){margin:0 0 16px}@media (min-width:980px){.cc-banner__policy p:not(:last-child){margin:0 0 24px}}.cc-banner__policy p a{font-size:16px!important;font-weight:700}.cc-banner__footer{box-shadow:none;flex-shrink:0;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif !important!important;margin:0;padding:12px 0 3px 3px;position:relative}@media (min-width:380px){.cc-banner__footer{align-items:stretch;display:flex;flex-wrap:wrap}}@media (min-width:680px){.cc-banner__footer{box-shadow:none;flex-wrap:nowrap;width:40%}}.cc-banner__footer .cc-banner__button{flex:1 1 auto;font-weight:700;overflow:hidden;padding:.5em 1em;width:100%}@media (min-width:680px){.cc-banner__footer .cc-banner__button{max-width:275px}}.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:12px}@media (min-width:680px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:0;margin-right:16px}}@media (min-width:980px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-right:24px}}@media (min-width:680px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:16px!important;margin-right:0!important}}@media (min-width:980px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:24px!important;margin-right:0!important}}.cc-banner__button-preferences{padding-left:0;padding-right:0}@media (min-width:380px){.cc-banner__button-preferences{flex:0 0 auto;margin:auto}}@media (min-width:680px){.cc-banner__button-preferences{margin:0}}@media (min-width:380px) and (max-width:680px){.cc-banner__button-break{display:block}}@media (min-width:680px){.cc-banner--is-tcf .cc-banner__footer{width:auto}}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__footer{padding-right:48px;width:66%}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px!important}.cc-banner--is-tcf .cc-banner__stacks{margin:16px 0 0}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__stacks{display:flex;flex:0 0 33%;flex-direction:column;margin:0 0 0 48px;overflow:auto}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px;margin:0 0 12px}.cc-banner--is-tcf .cc-banner__stacks-details{padding:0 3px}.cc-banner--is-tcf .cc-banner .cc-details{border-color:#fff3!important}.cc-box{border-radius:10px;padding:12px}.cc-box--info{background-color:#eff6fb}.cc-box--light{background-color:#faf9f6}.cc-button{border:2px solid #0000;border-radius:32px!important;color:inherit;cursor:pointer;font-size:14px;font-weight:700!important;left:auto;line-height:1.2;margin:0;padding:.5em 1em;right:auto;text-transform:none!important;transition:all .2s}@media (min-width:680px){.cc-button{font-size:14px;padding:.75em 1em}}.cc-button--sm{font-size:12px;padding:2px 8px!important}.cc-button--primary{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--primary:focus{outline:3px solid #08c}.cc-button--primary:focus,.cc-button--primary:hover,.cc-button--secondary{background-color:#fff!important;border-color:#025e8d!important;color:#025e8d!important}.cc-button--secondary:focus{background-color:#025e8d!important;border-color:#fff!important;color:#fff!important;outline:3px solid #08c!important}.cc-button--secondary:hover{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--secondary:active{border:2px solid #01324b!important}.cc-button--secondary.cc-button--contrast{border-color:#fff!important}.cc-button--secondary.cc-button--contrast:hover{background-color:initial!important;color:#fff!important}.cc-button--tertiary{background-color:#f0f7fc!important;background-image:none;border:2px solid #f0f7fc;color:#025e8d!important;text-decoration:underline!important;text-underline-offset:.25em}.cc-button--tertiary:focus{outline:3px solid #08c!important}.cc-button--tertiary:hover{text-decoration-thickness:.25em}.cc-button--tertiary:active{color:#013c5b}.cc-button--link{background-color:initial!important;border-color:#0000!important;border-radius:0!important;color:inherit!important;padding:0!important;text-decoration:underline!important;width:inherit!important}.cc-button--link:focus{outline:3px solid #08c}.cc-button--link:hover{background-color:initial!important;box-shadow:none;text-decoration:none}.cc-button--text{border-radius:0;padding:0}.cc-button--details{padding-right:24px!important;position:relative;width:auto}.cc-button--details:after,.cc-button--details:before{background-color:currentColor;content:"";position:absolute;transition:transform .25s ease-out}.cc-button--details:before{height:10px;margin-top:-5px;right:12px;top:50%;width:2px}.cc-button--details:after{height:2px;margin-top:-1px;right:8px;top:50%;width:10px}.cc-button--details.cc-active:before{transform:rotate(90deg);transform-origin:center}.cc-button--details.cc-active:after{display:none}.cc-details{border-bottom:1px solid #0000001a;padding:12px 0;position:relative;width:100%}.cc-details__summary{align-items:center;display:flex;font-size:14px;font-weight:700;list-style-type:none}.cc-details__summary:focus,.cc-details__summary:focus-visible{outline:3px solid #08c!important;will-change:auto}.cc-details__title{align-items:baseline;display:flex}.cc-details__title h2,.cc-details__title h3,.cc-details__title h4,.cc-details__title h5{line-height:1.4;margin:0!important;padding:0!important}.cc-details__title svg{flex-shrink:0;height:auto;margin-right:8px;position:relative;top:-1px;transition:all .2s;width:auto}.cc-details[open] .cc-details__title svg{top:2px;transform:rotate(90deg)}.cc-details__switch{margin-left:auto}.cc-details__section{padding:16px 0 0 18px}.cc-details__section p{margin:0}.cc-details__section p:not(:last-child){margin-bottom:12px}details summary::-webkit-details-marker{display:none}.cc-radio{align-items:center;display:flex;position:relative}.cc-radio *{cursor:pointer}.cc-radio__input{height:22px;left:0;position:absolute;top:0;width:22px}.cc-radio__input:focus{outline:none}.cc-radio__label{color:inherit;font-size:14px;font-weight:700;line-height:23px;margin:0;padding-left:28px}.cc-radio__label:after,.cc-radio__label:before{background-color:#fff;content:"";display:block;position:absolute;transition:transform .25s ease-out}.cc-radio__label:before{border:1px solid #777;border-radius:50%;height:22px;left:0;top:0;width:22px}.cc-radio__label:after{border:7px solid #025e8d;border-radius:50%;height:0;left:4px;opacity:0;top:4px;width:0}.cc-radio__input:focus+.cc-radio__label:before{box-shadow:0 0 0 2px #08c;outline:none}.cc-radio__label--hidden{display:none}.cc-radio__input:checked+.cc-radio__label:after{opacity:1}.cc-radio__input:disabled{cursor:default}.cc-radio__input:disabled+.cc-radio__label{cursor:default;opacity:.5}.cc-switch *{cursor:pointer}.cc-switch{align-items:center;display:flex;line-height:1}.cc-switch__label{cursor:pointer;display:inline-block;font-size:14px;font-weight:700;margin:0;-webkit-user-select:none;user-select:none}.cc-switch__input[type=checkbox]{-webkit-appearance:none;appearance:none;background-color:#fff!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='rgba(0, 0, 0, 0.25)'/%3E%3C/svg%3E")!important;background-position:0!important;background-repeat:no-repeat!important;border:1px solid #777!important;border-radius:16px!important;height:18px!important;margin:0 8px 0 0!important;transition:background-position .2s ease-in-out!important;width:32px!important}.cc-switch__input[type=checkbox]:focus{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%2380b3cc'/%3E%3C/svg%3E")!important}.cc-switch__input[type=checkbox]:checked{background-color:#025e8d!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%23fff'/%3E%3C/svg%3E")!important;background-position:100%!important}.cc-switch__input[type=checkbox]:checked~.cc-switch__label>.cc-switch__text-off,.cc-switch__input[type=checkbox]:not(:checked)~.cc-switch__label>.cc-switch__text-on{display:none}.cc-switch__input[type=checkbox]:hover{cursor:pointer;outline:none}.cc-switch__input[type=checkbox]:focus-visible{cursor:pointer;outline:3px solid #fc0}.cc-switch__input[type=checkbox]:checked:before{background-color:none!important;color:#0000!important}html[dir=rtl] .cc-switch__input[type=checkbox]{margin-left:8px!important;margin-right:0!important}.cc-list>ul,ul.cc-list{list-style-type:disc;margin-left:0;padding-left:0}.cc-list>ul>li,ul.cc-list>li{margin-left:1em}.cc-list>ul>li:not(:last-child),ul.cc-list>li:not(:last-child){margin-bottom:4px}.cc-list__title{margin-bottom:8px!important}.cc-list--inline>ul,ul.cc-list--inline{display:flex;flex-wrap:wrap;list-style-type:none}.cc-list--inline>ul>li,ul.cc-list--inline>li{margin:0 .5em .5em 0}.cc-overlay{background-color:#0000004d;z-index:99998}.cc-overlay,.cc-preferences{bottom:0;left:0;position:fixed;right:0;top:0}.cc-preferences{background-color:#050a14f2!important;border:0;box-sizing:border-box;color:#111;font-family:sans-serif!important;line-height:1.4;margin:auto;max-height:100vh;overflow:auto;padding:0;z-index:100000}.cc-preferences:focus{outline:none}.cc-preferences *,.cc-preferences :after,.cc-preferences :before{box-sizing:inherit!important}.cc-preferences h2,.cc-preferences h3,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-preferences .cc-h2,.cc-preferences h2{font-size:18px}.cc-preferences .cc-h3,.cc-preferences h3{font-size:16px}.cc-preferences .cc-h4,.cc-preferences .cc-h5,.cc-preferences .cc-h6,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-size:14px}.cc-preferences a{color:#025e8d;text-decoration:underline}.cc-preferences a:hover{color:inherit;text-decoration:none}.cc-preferences h3{background:none;color:#111;padding:0;text-transform:none}dialog.cc-preferences{background-color:initial}dialog.cc-preferences::backdrop{background-color:#000000e6}.cc-preferences__dialog{display:flex;flex-direction:column;margin:auto;max-height:100vh;max-width:860px;padding:12px;position:relative}.cc-preferences__dialog>:last-child{border-bottom-left-radius:10px;border-bottom-right-radius:10px}@media (min-width:980px){.cc-preferences__dialog{padding:16px}}.cc-preferences__close{background:#0000!important;border:1px solid #ececec;border-radius:50%;color:#111!important;cursor:pointer;font-family:Times New Roman,serif;font-size:40px;height:40px;left:auto;line-height:1;margin-top:-20px;padding:0!important;position:absolute;right:20px;top:50%;width:40px}.cc-preferences__close:focus{outline:3px solid #08c}.cc-preferences__close-label{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__header{background:#fff!important;border-bottom:1px solid #0000001a;border-top-left-radius:10px;border-top-right-radius:10px;padding:16px;position:relative;text-align:center}.cc-preferences__title{background:none!important;color:#111!important;font-family:sans-serif!important;font-size:18px!important;font-weight:700!important;margin:0!important;padding:0 16px 0 0!important}@media (min-width:480px){.cc-preferences__title{padding-right:0!important}}@media (min-width:980px){.cc-preferences__title{font-size:22px!important}}.cc-preferences__body{background:#fff!important;flex:1 1 auto;min-height:200px;overflow-x:hidden;overflow-y:auto;padding:16px}.cc-preferences__footer{background:#fff!important;border-top:1px solid #d0d0d0;box-shadow:0 0 5px 0 #0003;margin-bottom:0;padding:12px;position:relative}@media (min-width:480px){.cc-preferences__footer{align-items:stretch;display:flex}}.cc-preferences__footer>.cc-button{display:block;width:100%}@media (min-width:480px){.cc-preferences__footer>.cc-button{flex:1 1 auto}}@media (min-width:980px){.cc-preferences__footer>.cc-button{flex-basis:auto}}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:first-child){margin-left:12px}}.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:8px}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:0}}.cc-preferences__categories{list-style:none;margin:0;padding:0}.cc-preferences__category:not(:last-child){border-bottom:1px solid #0000001a;margin-bottom:12px;padding-bottom:12px}.cc-preferences__category-description{font-size:14px;margin:0 0 8px;padding:0}.cc-preferences__category-footer{align-items:center;display:flex;justify-content:space-between}.cc-preferences__status{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__controls{display:flex;margin:0}.cc-preferences__controls>:not(:last-child){margin-right:12px}.cc-preferences__always-on{font-size:14px;font-weight:700;padding-left:26px;position:relative}.cc-preferences__always-on:before{background:#0000!important;border:solid;border-top-color:#0000;border-width:0 0 4px 4px;content:"";display:block;height:10px;left:0;position:absolute;top:2px;transform:rotate(-45deg);width:18px}.cc-preferences__details{background-color:#eff6fb!important;border-radius:10px;font-size:14px;margin:12px 0 0;padding:12px}.cc-preferences__cookie-list,.cc-preferences__provider-list{list-style:none;margin:0;padding:0}.cc-preferences__provider-list{columns:170px}.cc-preferences__cookie-title{font-size:1em;font-style:normal;font-weight:400;margin:0}.cc-preferences__cookie-description{font-size:1em;margin:0 0 8px}.cc-preferences__cookie-domain,.cc-preferences__cookie-lifespan{border-left:1px solid #999;color:#666;margin-left:8px;padding-left:4px}body.cc-has-preferences-open{overflow:hidden;position:relative}.cc-table{border-collapse:collapse;width:100%}.cc-table tbody tr{border-top:1px solid #0000001a}.cc-table td,.cc-table th{font-size:14px;padding:4px 8px;vertical-align:top}.cc-table+.cc-table{margin-top:8px}.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:70%}@media (min-width:680px){.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:80%}}.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{padding-left:8px;width:40%}@media (min-width:680px){.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{width:30%}}.cc-tabs,.cc-tabs>ul{background-color:#faf9f6;display:flex;list-style:none;margin:0;padding:0}.cc-tabs__panel{border-top:1px solid #ececec;margin-top:-1px}.cc-tabs__button{background-color:initial;border:0;border-left:1px solid #0000;border-right:1px solid #0000;color:#111;font-size:16px;font-weight:700;margin:0;padding:15px 16px 12px;position:relative}.cc-tabs__button:before{background-color:initial;content:"";display:block;height:3px;left:0;position:absolute;top:0;width:100%}.cc-tabs__button.cc-active{background-color:#fff;border-color:#025e8d #ececec #ececec;color:#111}.cc-tabs__button.cc-active:before{background-color:#025e8d}.cc-tabs__content{background-color:#fff;display:none;font-size:14px;padding:16px}.cc-tabs__section:not(:first-child){padding-top:24px}.cc-tcf{font-size:14px;margin-top:16px}.cc-tcf__list{list-style:none;margin:0;padding:0}.cc-vendor-count{color:#666;font-size:16px;margin:0 0 8px}.cc-hide{display:none!important}.cc-show{display:block!important}.cc-external-link{background-color:#ececec;background-image:url("data:image/svg+xml;base64,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");background-position:right 8px center;background-repeat:no-repeat;background-size:10px auto;border-radius:3px;box-shadow:0 1px 0 #0003;color:#111!important;display:inline-block;font-size:12px;padding:4px 26px 4px 8px;text-decoration:none!important}.cc-external-link:hover{text-decoration:underline!important}.cc-m-0{margin:0!important}.cc-grey{color:#666}</style><script async="" type="text/javascript" src="https://injections.readcube.com/nature/inject.fa744f3f.js"></script></head>
<body class="article-page"><dialog class="cc-banner" data-cc-banner="" data-nosnippet="" aria-labelledby="cc-banner-label" open="">
		<div class="cc-banner__content" autofocus="" tabindex="-1">
			<div class="cc-banner__container">
				<div class="cc-banner__header">
					<h2 class="cc-banner__title" id="cc-banner-label">Your privacy, your choice</h2>
				</div>
				<div class="cc-banner__body">
					<div class="cc-banner__policy">
						<p>We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.</p><p>By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.</p><p>See our <a href="https://www.nature.com/info/privacy" data-cc-action="privacy">privacy policy</a> for more information on the use of your personal data.</p><p><button type="button" data-cc-action="preferences" class="cc-button cc-button--link cc-button--text">Manage preferences</button> for further information and to change your choices.</p>
					</div>
					
				</div>
				<div class="cc-banner__footer">
					
			<button data-cc-action="accept" class="cc-button cc-button--secondary cc-button--contrast cc-banner__button cc-banner__button-accept">Accept all cookies</button>
			
		
				</div>
			</div>
		</div>
	</dialog>

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>



<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    

    
    
        <div class="u-hide u-show-following-ad"></div>

    <aside class="c-ad c-ad--728x90" style="display: none !important;">
        <div class="c-ad__inner" data-container-type="banner-advert">
            <p class="c-ad__label">Advertisement</p>
            
        
            
    <div id="div-gpt-ad-top-1" class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide" data-ad-type="top" data-test="top-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="728x90" data-gpt-targeting="type=article;pos=top;artid=s41591-022-01916-x;doi=10.1038/s41591-022-01916-x;subjmeta=250,251,308,327,575,580,631,67,692;kwrd=Cancer+microenvironment,Immunotherapy,Translational+research,Tumour+immunology">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=1378764626&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-022-01916-x%26doi%3D10.1038/s41591-022-01916-x%26subjmeta%3D250,251,308,327,575,580,631,67,692%26kwrd%3DCancer+microenvironment,Immunotherapy,Translational+research,Tumour+immunology">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=1378764626&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-022-01916-x%26doi%3D10.1038/s41591-022-01916-x%26subjmeta%3D250,251,308,327,575,580,631,67,692%26kwrd%3DCancer+microenvironment,Immunotherapy,Translational+research,Tumour+immunology"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
        </div>
    </aside>


    <header class="c-header" id="header" data-header="" data-track-component="nature-150-split-header" style="border-color:#e40428">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/nm" data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" height="32" alt="Nature Medicine">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link" data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search" href="javascript:;" data-header-expander="" data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"></path></svg><span>Search</span>
                            </a><div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width has-tethered u-js-hide" data-track-component="nature-150-split-header" hidden="">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected="">All journals</option>
                                    <option value="nm">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced" data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a class="c-header__link eds-c-header__link" id="identity-account-widget" data-track="click_login" data-track-context="header" href="https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-022-01916-x"><span class="eds-c-header__widget-fragment-title">Log in</span></a>
                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--explore" data-track="click" data-track-action="open explore expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span><span class="c-header__show-text">Explore</span> content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header" hidden="">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-articles" data-track="click" data-track-action="research articles" data-track-label="link" data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-and-analysis" data-track="click" data-track-action="reviews &amp; analysis" data-track-label="link" data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/news-and-comment" data-track="click" data-track-action="news &amp; comment" data-track-label="link" data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/podcast" data-track="click" data-track-action="podcasts" data-track-label="link" data-test="explore-nav-item">
                                    Podcasts
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/current-issue" data-track="click" data-track-action="current issue" data-track-label="link" data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/collections" data-track="click" data-track-action="collections" data-track-label="link" data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://www.facebook.com/Nature-Medicine-193691346949/" data-track="click" data-track-action="facebook" data-track-label="link">Follow us on Facebook
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://twitter.com/naturemedicine" data-track="click" data-track-action="twitter" data-track-label="link">Follow us on Twitter
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id=5" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-external="" data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"></path></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--about-the-journal" data-track="click" data-track-action="open about the journal expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/aims" data-track="click" data-track-action="aims &amp; scope" data-track-label="link">
                                    Aims &amp; Scope
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-information" data-track="click" data-track-action="journal information" data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-impact" data-track="click" data-track-action="journal metrics" data-track-label="link">
                                    Journal Metrics
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editors" data-track="click" data-track-action="about the editors" data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-cross-journal-editorial-team" data-track="click" data-track-action="research cross-journal editorial team" data-track-label="link">
                                    Research Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-cross-journal-editorial-team" data-track="click" data-track-action="reviews cross-journal editorial team" data-track-label="link">
                                    Reviews Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/statistics-advisory-panel" data-track="click" data-track-action="statistical advisory panel" data-track-label="link">
                                    Statistical Advisory Panel
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/our-publishing-models" data-track="click" data-track-action="our publishing models" data-track-label="link">
                                    Our publishing models
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-values-statement" data-track="click" data-track-action="editorial values statement" data-track-label="link">
                                    Editorial Values Statement
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-policies" data-track="click" data-track-action="editorial policies" data-track-label="link">
                                    Editorial Policies
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/content" data-track="click" data-track-action="content types" data-track-label="link">
                                    Content Types
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/web-feeds" data-track="click" data-track-action="web feeds" data-track-label="link">
                                    Web Feeds
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/contact" data-track="click" data-track-action="contact" data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="javascript:;" class="c-header__link c-header__link--dropdown-menu" data-header-expander="" data-test="menu-button--publish" data-track="click" data-track-action="open publish with us expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                        </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/submission-guidelines" data-track="click" data-track-action="submission guidelines" data-track-label="link">
                                    Submission Guidelines
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/for-reviewers" data-track="click" data-track-action="for reviewers" data-track-label="link">
                                    For Reviewers
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" data-test="nature-author-services" data-track="nav_language_services" data-track-context="header publish with us dropdown menu" data-track-action="manuscript author services" data-track-label="link manuscript author services" href="https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&amp;utm_medium=Website_Nature&amp;utm_campaign=Platform+Experimentation+2022&amp;utm_id=PE2022">
                                    Language editing services
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/open-access-funding" data-test="funding-eligibility-link" data-track="click_explore_funding" data-track-context="header publish with us" data-track-action="funding eligibility">Open access funding</a>
                            </li>
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link" href="https://mts-nmed.nature.com/cgi-bin/main.plex" data-track="click_submit_manuscript" data-track-context="submit link in Nature header dropdown menu" data-track-action="submit manuscript" data-track-label="link (publish with us dropdown menu)" data-track-external="" data-gtm-criteo="submit-manuscript">Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"></path></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item" data-test="alert-link">
                                    <a class="c-header__link" href="https://journal-alerts.springernature.com/subscribe?journal_id=41591" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-label="link (desktop site header)" data-track-external="">
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"></path></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope="" itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature medicine"><span itemprop="name">nature medicine</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm/articles?type=article" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:articles"><span itemprop="name">articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container" data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            
                <div class="c-context-bar u-hide" id="js-enable-context-bar" data-test="context-bar" data-context-bar="" aria-hidden="true">
                    <div class="c-context-bar__container u-container" data-track-context="sticky banner">
                        <div class="c-context-bar__title">
                            Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
                        </div>
                        
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01916-x.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                    </div>
                </div>
            
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-16 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container" data-track-context="article body">
                        
                            
                                
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01916-x.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                            
                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Article</li>
    
        <li class="c-article-identifiers__item">
            <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a>
        </li>
    
    

                        <li class="c-article-identifiers__item">Published: <time datetime="2022-08-29">29 August 2022</time></li>
                    </ul>

                    <h1 class="c-article-title" data-test="article-title" data-article-title="">Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma</h1>
                    <ul class="c-article-author-list c-article-author-list--short js-no-scroll" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Nathalie-Scholler-Aff1-Aff2" data-author-popup="auth-Nathalie-Scholler-Aff1-Aff2" data-author-search="Scholler, Nathalie" data-track-context="researcher popup with no profile" data-track-index="1_22">Nathalie Scholler</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Regis-Perbost-Aff3" data-author-popup="auth-Regis-Perbost-Aff3" data-author-search="Perbost, Regis" data-track-context="researcher popup with no profile" data-track-index="2_22">Regis Perbost</a><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Frederick_L_-Locke-Aff4" data-author-popup="auth-Frederick_L_-Locke-Aff4" data-author-search="Locke, Frederick L." data-track-context="researcher popup with no profile" data-track-index="3_22">Frederick L. Locke</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-9063-6691"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-9063-6691</a></span><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Michael_D_-Jain-Aff4" data-author-popup="auth-Michael_D_-Jain-Aff4" data-author-search="Jain, Michael D." data-track-context="researcher popup with no profile" data-track-index="4_22">Michael D. Jain</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-7789-1257"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-7789-1257</a></span><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Sarah-Turcan-Aff3" data-author-popup="auth-Sarah-Turcan-Aff3" data-author-search="Turcan, Sarah" data-track-context="researcher popup with no profile" data-track-index="5_22">Sarah Turcan</a><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Corinne-Danan-Aff3" data-author-popup="auth-Corinne-Danan-Aff3" data-author-search="Danan, Corinne" data-track-context="researcher popup with no profile" data-track-index="6_22">Corinne Danan</a><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Edmund_C_-Chang-Aff1" data-author-popup="auth-Edmund_C_-Chang-Aff1" data-author-search="Chang, Edmund C." data-track-context="researcher popup with no profile" data-track-index="7_22">Edmund C. Chang</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Sattva_S_-Neelapu-Aff5" data-author-popup="auth-Sattva_S_-Neelapu-Aff5" data-author-search="Neelapu, Sattva S." data-track-context="researcher popup with no profile" data-track-index="8_22">Sattva S. Neelapu</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-1045-4914"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-1045-4914</a></span><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-David_B_-Miklos-Aff6" data-author-popup="auth-David_B_-Miklos-Aff6" data-author-search="Miklos, David B." data-track-context="researcher popup with no profile" data-track-index="9_22">David B. Miklos</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-0717-4305"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-0717-4305</a></span><sup class="u-js-hide"><a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Caron_A_-Jacobson-Aff7" data-author-popup="auth-Caron_A_-Jacobson-Aff7" data-author-search="Jacobson, Caron A." data-track-context="researcher popup with no profile" data-track-index="10_22">Caron A. Jacobson</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Lazaros_J_-Lekakis-Aff8" data-author-popup="auth-Lazaros_J_-Lekakis-Aff8" data-author-search="Lekakis, Lazaros J." data-track-context="researcher popup with no profile" data-track-index="11_22">Lazaros J. Lekakis</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Yi-Lin-Aff9" data-author-popup="auth-Yi-Lin-Aff9" data-author-search="Lin, Yi" data-track-context="researcher popup with no profile" data-track-index="12_22">Yi Lin</a><sup class="u-js-hide"><a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Armin-Ghobadi-Aff10" data-author-popup="auth-Armin-Ghobadi-Aff10" data-author-search="Ghobadi, Armin" data-track-context="researcher popup with no profile" data-track-index="13_22">Armin Ghobadi</a><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jenny_J_-Kim-Aff1" data-author-popup="auth-Jenny_J_-Kim-Aff1" data-author-search="Kim, Jenny J." data-track-context="researcher popup with no profile" data-track-index="14_22">Jenny J. Kim</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Justin-Chou-Aff1" data-author-popup="auth-Justin-Chou-Aff1" data-author-search="Chou, Justin" data-track-context="researcher popup with no profile" data-track-index="15_22">Justin Chou</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Vicki-Plaks-Aff1" data-author-popup="auth-Vicki-Plaks-Aff1" data-author-search="Plaks, Vicki" data-track-context="researcher popup with no profile" data-track-index="16_22">Vicki Plaks</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Zixing-Wang-Aff1" data-author-popup="auth-Zixing-Wang-Aff1" data-author-search="Wang, Zixing" data-track-context="researcher popup with no profile" data-track-index="17_22">Zixing Wang</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Allen-Xue-Aff1" data-author-popup="auth-Allen-Xue-Aff1" data-author-search="Xue, Allen" data-track-context="researcher popup with no profile" data-track-index="18_22">Allen Xue</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Mike-Mattie-Aff1" data-author-popup="auth-Mike-Mattie-Aff1" data-author-search="Mattie, Mike" data-track-context="researcher popup with no profile" data-track-index="19_22">Mike Mattie</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-John_M_-Rossi-Aff1" data-author-popup="auth-John_M_-Rossi-Aff1" data-author-search="Rossi, John M." data-track-context="researcher popup with no profile" data-track-index="20_22">John M. Rossi</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Adrian-Bot-Aff1-Aff11" data-author-popup="auth-Adrian-Bot-Aff1-Aff11" data-author-search="Bot, Adrian" data-track-context="researcher popup with no profile" data-track-index="21_22">Adrian Bot</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff11" tabindex="-1">11</a></sup> &amp; </li><li class="c-article-author-list__show-more" aria-label="Show all 22 authors for this article" title="Show all 22 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-J_r_me-Galon-Aff3-Aff12" data-author-popup="auth-J_r_me-Galon-Aff3-Aff12" data-author-search="Galon, Jérôme" data-corresp-id="c1" data-track-context="researcher popup with no profile" data-track-index="22_22">Jérôme Galon<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-9635-1339"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-9635-1339</a></span><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a>,<a href="#Aff12" tabindex="-1">12</a></sup>&nbsp;</li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/nm" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Nature Medicine</i></a>

                        <b data-test="journal-volume"><span class="u-visually-hidden">volume</span>&nbsp;28</b>,&nbsp;<span class="u-visually-hidden">pages </span>1872–1882 (<span data-test="article-publication-year">2022</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item" data-test="access-count">
                        <p class="c-article-metrics-bar__count">32k <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                    <li class="c-article-metrics-bar__item" data-test="citation-count">
                        <p class="c-article-metrics-bar__count">122 <span class="c-article-metrics-bar__label">Citations</span></p>
                    </li>
                
                
                    
                        <li class="c-article-metrics-bar__item" data-test="altmetric-score">
                            <p class="c-article-metrics-bar__count">60 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                <li class="c-article-metrics-bar__item">
                    <p class="c-article-metrics-bar__details"><a href="/articles/s41591-022-01916-x/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                </li>
            </ul>
        </div>
    
                    
                </header>

                
    

                
    
    

    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment with similar efficacy across conventional LBCL subtypes. Toward patient stratification, we assessed whether tumor immune contexture influenced clinical outcomes after axi-cel. We evaluated the tumor microenvironment (TME) of 135 pre-treatment and post-treatment tumor biopsies taken from 51 patients in the ZUMA-1 phase 2 trial. We uncovered dynamic patterns that occurred within 2 weeks after axi-cel. The biological associations among Immunoscore (quantification of tumor-infiltrating T cell density), Immunosign 21 (expression of pre-defined immune gene panel) and cell subsets were validated in three independent LBCL datasets. In the ZUMA-1 trial samples, clinical response and overall survival were associated with pre-treatment immune contexture as characterized by Immunoscore and Immunosign 21. Circulating CAR T cell levels were associated with post-treatment TME T cell exhaustion. TME enriched for chemokines (CCL5 and CCL22), γ-chain receptor cytokines (IL-15, IL-7 and IL-21) and interferon-regulated molecules were associated with T cell infiltration and markers of activity. Finally, high density of regulatory T cells in pre-treatment TME associated with reduced axi-cel–related neurologic toxicity. These findings advance the understanding of LBCL TME characteristics associated with clinical responses to anti-CD19 CAR T cell therapy and could foster biomarker development and treatment optimization for patients with LBCL.</p></div></div></section>

            
                
            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41591-023-02754-1/MediaObjects/41591_2023_2754_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41591-023-02754-1?fromPaywallRec=false" data-track="select_recommendations_1" data-track-context="inline recommendations" data-track-action="click recommendations inline - 1" data-track-label="10.1038/s41591-023-02754-1">Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">17 January 2024</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41591-022-01960-7/MediaObjects/41591_2022_1960_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41591-022-01960-7?fromPaywallRec=false" data-track="select_recommendations_2" data-track-context="inline recommendations" data-track-action="click recommendations inline - 2" data-track-label="10.1038/s41591-022-01960-7">Post-infusion CAR T<sub>Reg</sub> cells identify patients resistant to CD19-CAR therapy
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                        
                                         <span class="c-article-meta-recommendations__date">12 September 2022</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs43018-024-00763-8/MediaObjects/43018_2024_763_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s43018-024-00763-8?fromPaywallRec=false" data-track="select_recommendations_3" data-track-context="inline recommendations" data-track-action="click recommendations inline - 3" data-track-label="10.1038/s43018-024-00763-8">Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                        
                                         <span class="c-article-meta-recommendations__date">19 April 2024</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'semantic',
                        model: 'specter',
                        policy_id: 'NA',
                        timestamp: 1749514047,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    
                        <section data-title="Main"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Main</h2><div class="c-article-section__content" id="Sec1-content"><p>Immunotherapies have revolutionized cancer treatment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Jensen, M. C. &amp; Riddell, S. R. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol. Rev. 257, 127–144 (2014)." href="#ref-CR1" id="ref-link-section-d59023944e794">1</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Yang, J. C. &amp; Rosenberg, S. A. Adoptive T-cell therapy for cancer. Adv. Immunol. 130, 279–294 (2016)." href="#ref-CR2" id="ref-link-section-d59023944e794_1">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Dunbar, C.E. et al. Gene therapy comes of age. Science 359, eaan4672 (2018)." href="#ref-CR3" id="ref-link-section-d59023944e794_2">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. &amp; Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361–1365 (2018)." href="/articles/s41591-022-01916-x#ref-CR4" id="ref-link-section-d59023944e797">4</a></sup>. Axicabtagene ciloleucel (axi-cel) is a first-in-class anti-CD19 CAR T cell therapy approved for the treatment of relapsed/refractory (r/r) LBCL. In the pivotal ZUMA-1 study (<a href="https://clinicaltrials.gov/ct2/show/NCT02348216">NCT02348216</a>), the objective response (OR) rate was 83% (58% complete response (CR) rate); 39% of patients had ongoing responses (median of 27.1 months of follow-up); and grade ≥3 neurologic events (NEs) were reported in 32% of patients<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31–42 (2019)." href="/articles/s41591-022-01916-x#ref-CR5" id="ref-link-section-d59023944e808">5</a></sup>. Unlike other therapies, such as rituximab<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Fu, K. et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J. Clin. Oncol. 26, 4587–4594 (2008)." href="/articles/s41591-022-01916-x#ref-CR6" id="ref-link-section-d59023944e812">6</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Carbone, A., Gloghini, A., Kwong, Y. L. &amp; Younes, A. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann. Hematol. 93, 1263–1277 (2014)." href="/articles/s41591-022-01916-x#ref-CR7" id="ref-link-section-d59023944e815">7</a></sup>, axi-cel has similar efficacy across LBCL subtypes defined through conventional histological, cytogenetic and molecular prognostic markers<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Carbone, A., Gloghini, A., Kwong, Y. L. &amp; Younes, A. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann. Hematol. 93, 1263–1277 (2014)." href="/articles/s41591-022-01916-x#ref-CR7" id="ref-link-section-d59023944e819">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Locke, F. L. et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25, 285–295 (2017)." href="/articles/s41591-022-01916-x#ref-CR8" id="ref-link-section-d59023944e822">8</a></sup>. However, ~60% of patients showed primary treatment resistance (~15%) or relapse (~45%) within the first year<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31–42 (2019)." href="/articles/s41591-022-01916-x#ref-CR5" id="ref-link-section-d59023944e827">5</a></sup>, warranting efforts to understand mechanisms and markers underlying response.</p><p>Although the prognostic and predictive roles of the TME<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Galon, J., Fridman, W. H. &amp; Pages, F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 67, 1883–1886 (2007)." href="#ref-CR9" id="ref-link-section-d59023944e834">9</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Galon, J. et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J. Transl. Med. 14, 273 (2016)." href="#ref-CR10" id="ref-link-section-d59023944e834_1">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Spranger, S. &amp; Gajewski, T. F. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat. Rev. Cancer 18, 139–147 (2018)." href="#ref-CR11" id="ref-link-section-d59023944e834_2">11</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Angelova, M. et al. Evolution of metastases in space and time under immune selection. Cell 175, 751–765 (2018)." href="#ref-CR12" id="ref-link-section-d59023944e834_3">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bedognetti, D. et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J. Immunother. Cancer 7, 131 (2019)." href="#ref-CR13" id="ref-link-section-d59023944e834_4">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Mascaux, C. et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature 571, 570–575 (2019)." href="#ref-CR14" id="ref-link-section-d59023944e834_5">14</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Galon, J. &amp; Bruni, D. Tumor immunology and tumor evolution: intertwined histories. Immunity 52, 55–81 (2020)." href="/articles/s41591-022-01916-x#ref-CR15" id="ref-link-section-d59023944e837">15</a></sup> have been described for solid tumors, including for checkpoint inhibitors<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bindea, G., Mlecnik, B., Angell, H. K. &amp; Galon, J. The immune landscape of human tumors: implications for cancer immunotherapy. Oncoimmunology 3, e27456 (2014)." href="#ref-CR16" id="ref-link-section-d59023944e841">16</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Kirilovsky, A. et al. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int. Immunol. 28, 373–382 (2016)." href="#ref-CR17" id="ref-link-section-d59023944e841_1">17</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Pages, F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391, 2128–2139 (2018)." href="#ref-CR18" id="ref-link-section-d59023944e841_2">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Van den Eynde, M. et al. The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients. Cancer Cell 34, 1012–1026 (2018)." href="#ref-CR19" id="ref-link-section-d59023944e841_3">19</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Angell, H. K., Bruni, D., Barrett, J. C., Herbst, R. &amp; Galon, J. The Immunoscore: colon cancer and beyond. Clin. Cancer Res. 26, 332–339 (2019)." href="#ref-CR20" id="ref-link-section-d59023944e841_4">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Yomoda, T. et al. The Immunoscore is a superior prognostic tool in stages II and III colorectal cancer and is significantly correlated with programmed death-ligand 1 (PD-L1) expression on tumor-infiltrating mononuclear cells. Ann. Surg. Oncol. 26, 415–424 (2019)." href="#ref-CR21" id="ref-link-section-d59023944e841_5">21</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bruni, D., Angell, H. K. &amp; Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662–680 (2020)." href="#ref-CR22" id="ref-link-section-d59023944e841_6">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838–857 (2021)." href="/articles/s41591-022-01916-x#ref-CR23" id="ref-link-section-d59023944e844">23</a></sup>, the importance of TME for CAR T cell therapy has not been established. Taking into account the immune mechanistic nature of the CAR T cell intervention and its proven activity in patients with diffuse LBCL (DLBCL) with poor or favorable conventional tumor-related prognostic markers, such as bcl-2, bcl-6 and c-Myc status, we first hypothesized that dynamic patterns developing rapidly in the post-treatment TME distinguish responders and non-responders and, second, that certain characteristics of the tumor immune contexture, pre-treatment, may associate with CAR T cell treatment outcome. Specifically, features of tumor immune contexture, such as presence of activated or exhausted T cells, infiltration with immune regulatory myeloid cells or other categories of immune cells, along with gene expression programs that may influence the recruitment, expansion and activity of T cells, may, in fact, provide a global integrative perspective on whether the given status of the tumoral process and immune system in a given patient are favorable or detrimental with respect to benefitting from this treatment modality.</p><p>In this study, we systematically investigated a broad range of immune programs in pre-treatment and post-treatment biopsy specimens from the ZUMA-1 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31–42 (2019)." href="/articles/s41591-022-01916-x#ref-CR5" id="ref-link-section-d59023944e851">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)." href="/articles/s41591-022-01916-x#ref-CR24" id="ref-link-section-d59023944e854">24</a></sup>) pivotal study (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">1</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig7">1</a>) and uncovered key TME immune features that associate with clinical outcomes. When possible, we validated our findings in three independent datasets—namely, treatment-naive biopsy specimens and pre-treatment specimens from patients enrolled in an ongoing, second-line CAR T cell interventional study<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640–654 (2021)." href="/articles/s41591-022-01916-x#ref-CR25" id="ref-link-section-d59023944e864">25</a></sup> (ZUMA-7; <a href="https://clinicaltrials.gov/ct2/show/NCT03391466">NCT03391466</a>) and from patients treated with commercial axi-cel at Moffitt Cancer Center<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells associate with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621–2633 (2021)." href="/articles/s41591-022-01916-x#ref-CR26" id="ref-link-section-d59023944e876">26</a></sup> (Supplementary Tables <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">2</a> and <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">3</a>). These findings advance understanding of the effect of CAR T cell therapy on the TME and the association with clinical response; they also foster biomarker development and treatment optimization.</p></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Results</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">TME rapid evolution was a hallmark of clinical response</h3><p>Best responses to CAR T cell therapy include rapid CAR expansion within 7–14 days after infusion and anti-tumor activity typically evaluated by positron emission tomography–computed tomography (PET–CT) 30 days after infusion. However, the lack of robust predictive biomarkers for patient stratification and monitoring remains a major challenge in the field of cellular immunotherapy. To investigate mechanisms and markers underlying response to axi-cel, we analyzed and compared pre-treatment TME patterns that may distinguish responders from non-responders by transcriptomics (Supplementary Tables <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">4</a> and <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">5</a>) and assessed whether axi-cel triggered changes of the tumor immune contexture detectable before the first evaluation of clinical response, which is typically evaluated 1 month after axi-cel infusion by PET–CT imaging. Figure <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig1">1</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig8">2</a> highlight the significant transcriptomics changes in tumor biopsies from pre-treatment to 2 weeks after axi-cel in function of the therapeutic response. Supplementary Tables <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">6</a>–<a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">8</a> provide the differential expression of all the genes assessed before and after axi-cel infusion per therapeutic response type. In responders, the post-treatment evolution of TME gene expression patterns strikingly differed from those of non-responders; results were consistent across fresh-frozen (FF; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig1">1a,b</a>) and formalin-fixed paraffin-embedded (FFPE) sample sets (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig8">2</a>) and were independent of pre-treatment tumor burden (TB; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig8">2a</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Evolution of TME after axi-cel infusion associated with clinical outcomes in ZUMA-1."><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1: Evolution of TME after axi-cel infusion associated with clinical outcomes in ZUMA-1.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01916-x/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="604"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p><b>a</b>, Heat map of gene expression measured by PanCancer Immune Profiling panel (NanoString) in FF tumor biopsy specimens from patients in ZUMA-1 at baseline (before conditioning and axi-cel infusion, subset 1, <i>n</i> = 23) and 2–4 weeks after axi-cel infusion (subset 2, <i>n</i> = 13). Among the genes with significant differential expression between pre-treatment and post-treatment (two-sided <i>t</i>-test without adjustment, <i>P</i> &lt; 0.05), shown genes were selected according to their belonging to a specific TME-related signature. Patients with CR (<i>n</i> = 18 (12 pre-treatment; six within 2 weeks post-treatment)), PR (<i>n</i> = 7, as noted by asterisks (five pre-treatment, two within 2 weeks post-treatment)) and SD/PD (<i>n</i> = 11 (six pre-treatment, four within 2 weeks post-treatment and one with SD within 4 weeks post-treatment) are shown. The color range is set to log-transform scaled values. Scaled values are calculated by dividing by the standard deviation. <b>b</b>,<b>c</b>, Expression of T cell–related genes (<b>b</b>) and B cell lineage genes (<b>c</b>) measured by PanCancer Immune Profiling panel in paired FF biopsy specimens. Values and two-sided <i>t</i>-test without adjustment in embedded tables. DC, dendritic cell; FOXP3, forkhead box P3; GZMA, granzyme A; IL, interleukin; PAX5, paired box protein 5; PD, progressive disease; PD-1, programmed cell death protein 1; PR, partial response; SD, stable disease.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01916-x/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Differences spanned all major categories of TME genes, including innate and adaptive immunity and tumor-related and stroma-related genes with well-described immune activity or yet-to-be-determined functionality (Supplementary Tables <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">6</a>–<a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">8</a>). Responders showed early and rapid elevation of cytotoxic T cell–related genes (CD8α and granzyme A) and key T cell growth factor (IL-15) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig1">1a,b</a>) as well as interferon (IFN)-γ–regulated immune checkpoint (IC) encoding genes (CD274, CD276 and CTLA-4), myeloid-related genes and chemokines (CD14, CD68 and CCL2) (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig8">2b,c</a>). The evolution of TME gene expression patterns was vastly different in non-responders, where no increase in immune-related genes was observed, except for a positive trend in two pro-inflammatory chemokines (CXCL10 and CXCL11) that was consistent across FF and FFPE sample sets (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig8">2d,e</a>) and likely modulated by chemo-conditioning<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Moschella, F. et al. Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients’ blood cells: implications for cancer chemoimmunotherapy. Clin. Cancer Res. 19, 4249–4261 (2013)." href="/articles/s41591-022-01916-x#ref-CR27" id="ref-link-section-d59023944e1005">27</a></sup>.</p><p>Gene expression across all B cell lineage markers decreased markedly in the TME from responders, including CD19, CD20 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Stamenkovic, I. et al. The B cell antigen CD75 is a cell surface sialytransferase. J. Exp. Med. 172, 641–643 (1990)." href="/articles/s41591-022-01916-x#ref-CR28" id="ref-link-section-d59023944e1012">28</a></sup>), B cell transcriptional master switch PAX5 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Okuyama, K. et al. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia. PLoS Genet. 15, e1008280 (2019)." href="/articles/s41591-022-01916-x#ref-CR29" id="ref-link-section-d59023944e1016">29</a></sup>) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig1">1c</a>), ST6GAL1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Stamenkovic, I. et al. The B cell antigen CD75 is a cell surface sialytransferase. J. Exp. Med. 172, 641–643 (1990)." href="/articles/s41591-022-01916-x#ref-CR28" id="ref-link-section-d59023944e1023">28</a></sup>), CD22 and transcriptional coactivator POU2AF1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Park, H. Y. et al. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma. Oncotarget 7, 86433–86445 (2016)." href="/articles/s41591-022-01916-x#ref-CR30" id="ref-link-section-d59023944e1027">30</a></sup>) (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig8">2f,h</a>). These changes likely reflected axi-cel–mediated tumor cell clearance given that patients in ZUMA-1 were largely B cell aplastic at enrollment due to prior rituximab treatment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)." href="/articles/s41591-022-01916-x#ref-CR24" id="ref-link-section-d59023944e1035">24</a></sup>. In addition, the rapid decrease in gene expression of cancer testis antigens (CTAs<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Whitehurst, A. W. Cause and consequence of cancer/testis antigen activation in cancer. Annu. Rev. Pharmacol. Toxicol. 54, 251–272 (2014)." href="/articles/s41591-022-01916-x#ref-CR31" id="ref-link-section-d59023944e1039">31</a></sup>) was more marked in responders (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig8">2g</a>), further supporting a rapid evolution toward a reduced tumor-related signature consistent with the negative correlation in DLBCL between tumor-infiltrating immune cell signature and B cell signature (for example, CD19, MS4A1, CD79A and CD79B)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Autio, M. et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica 106, 718–729 (2021)." href="/articles/s41591-022-01916-x#ref-CR32" id="ref-link-section-d59023944e1046">32</a></sup>. Finally, these changes were similar across strata defined by classical prognostic markers<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)." href="/articles/s41591-022-01916-x#ref-CR24" id="ref-link-section-d59023944e1050">24</a></sup>, and, whereas many immune contexture genes were strongly upregulated, other immune genes specific for other immune cell types, including TLR9, HMGB1, ILF3, CSF2, IL3RA and ICAM4, were not increased post-treatment. Altogether, rapid and broad changes across adaptive and innate immune programs and B cell lineage markers in post-treatment TME distinguished responders from non-responders.</p><h3 class="c-article__sub-heading" id="Sec4">T cell density in TME associated with CR</h3><p>To validate these findings at the cellular and protein level, we performed multiplex spatial tissue analyses that combine multiplexed immunohistochemistry (IHC) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig2">2a</a> and Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig9">3</a>–<a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig11">5</a>), advanced image analysis and computerized algorithm<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Angell, H. &amp; Galon, J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr. Opin. Immunol. 25, 261–267 (2013)." href="/articles/s41591-022-01916-x#ref-CR33" id="ref-link-section-d59023944e1071">33</a></sup>. This methodology was initially developed to create the Immunoscore index<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Angell, H. K., Bruni, D., Barrett, J. C., Herbst, R. &amp; Galon, J. The Immunoscore: colon cancer and beyond. Clin. Cancer Res. 26, 332–339 (2019)." href="/articles/s41591-022-01916-x#ref-CR20" id="ref-link-section-d59023944e1075">20</a></sup> to quantify tumor T cell infiltrate and better predict the prognosis of patients with colorectal cancer than AJCC/UICC TNM staging. Tumor immune contexture<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Bruni, D., Angell, H. K. &amp; Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662–680 (2020)." href="/articles/s41591-022-01916-x#ref-CR22" id="ref-link-section-d59023944e1080">22</a></sup> characterizes the spatial organization and density of tumor-infiltrating immune cells and predicts prognosis and response to IC inhibitors in various solid tumors. To adapt the approach to r/r LBCL and to evaluate additional immune cell subsets and exhaustion markers, we developed three panels in addition to Immunoscore T lymphocytes (TLs): Immunoscore T cell exhaustion (TCE) and TCE<sup>+</sup> (with TOX marker) panels and Immunoscore suppressive cells (SCs) panel (Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig9">3</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig10">4</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">9</a>). We demonstrated excellent consistency in quantification of CD3<sup>+</sup> and CD8<sup>+</sup> T cell densities between Immunoscore TL and Immunoscore TCE (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig11">5a,b</a>) and between Immunoscore TCE and Immunoscore TCE<sup>+</sup> (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig11">5c</a>). Lastly, the Immunoscore index significantly correlated with tumor infiltration of T cell subsets, including CD3, CD4, CD8 and regulatory T cells (Tregs), but not with myeloid cell subsets in pre-treatment ZUMA-1 biopsies (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig11">5d</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Evolution of T cell subset densities in the TME after axi-cel infusion."><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2: Evolution of T cell subset densities in the TME after axi-cel infusion.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01916-x/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig2_HTML.png?as=webp"><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="464"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p><b>a</b>, Representative T cell subset densities measured by Immunoscore TCE/TCE<sup>+</sup> in patients with ongoing CR versus PR with relapse before and after axi-cel infusion (FFPE biopsy specimens, one staining per sample per marker). <b>b</b>, Evolution of T cell subset densities in the TME as a function of clinical response and TB. Analysis by Immunoscore TCE/TCE<sup>+</sup> of FFPE biopsy specimens from ten patients in ZUMA-1 with high (&gt;3,000 mm<sup>2</sup>; <i>n</i> = 5) or low (&lt;3,000 mm<sup>2</sup>; <i>n</i> = 5) TB. Seven of the paired samples belonged to subsets 1 and 2, and three belonged to subsets 1 and 3. Six patients had CR; two patients had PR; and two patients had SD/PD. In the Th panel, the blue square indicates five patients with CR with low TB and high Th cell density within the TME pre-infusion and post-infusion (50% of tested patients, two-sided exact Fisher test, <i>P</i> = 0.10). One patient relapsed &gt;6 months after initial CR (circle with black center). The purple arrows in the Tc/PD-1<sup>+</sup> and Th/PD-1<sup>+</sup> panels indicate a patient with CR despite high TB and with increased PD-1<sup>+</sup> tumor-infiltrating T cells in post-treatment TME (10% of tested patients). The black square in the Th/PD-1<sup>+</sup> panel indicates non-CR patients with high TB and low CD4<sup>+</sup> T cell density pre-treatment and post-treatment (20% of tested patients, Fisher test, <i>P</i> = 0.09). Data are also shown for two patients (one with PR and one with SD/PD) with high TB and intermediary/high tumor-infiltrating T cell density post-infusion who both relapsed (20% of tested patients, Fisher test, <i>P</i> = 0.10). FOXP3, forkhead box P3; PD, progressive disease; PD-1, programmed cell death protein 1; PR, partial response; SD, stable disease.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01916-x/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Using these panels, we first investigated whether T cell density in pre-treatment and/or post-treatment TME associated with clinical outcomes and TB. Immunoscore TCE was measured in ten paired samples from the ZUMA-1 subset 1 (pre-treatment) and subset 2 (early post-treatment) biopsies. Figure <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig2">2b</a> shows that all patients with low TB and higher helper T (Th) cell density achieved CR (pink circles in blue squares), and their TME presented a higher T cell density both pre-therapy and post-therapy to compare with the TME from patients with high TB (orange symbols). Conversely, four of five patients with pre-treatment high TB and low T cell density did not achieve CR. However, one patient with high TB achieved CR. This patient (orange circle) presented a pre-treatment intermediary T cell density with post-treatment evolution of TME to higher density of T cells with activated phenotype (PD1<sup>+</sup>LAG-3<sup>−</sup>TIM3<sup>−</sup>) (purple arrow). The results of this small dataset suggest that post-treatment TME T cell density reflected pre-treatment density and supported CR association with low TB and high cell density before the first clinical response evaluation.</p><h3 class="c-article__sub-heading" id="Sec5">Lower CAR T levels associated with TME exhausted T cells</h3><p>Early studies showed that axi-cel efficacy associates with rapid CAR T cell expansion in blood<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31–42 (2019)." href="/articles/s41591-022-01916-x#ref-CR5" id="ref-link-section-d59023944e1191">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)." href="/articles/s41591-022-01916-x#ref-CR24" id="ref-link-section-d59023944e1194">24</a></sup> and that the ratio of early CAR T cell expansion to pre-treatment TB associates with durable response<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898–4911 (2020)." href="/articles/s41591-022-01916-x#ref-CR34" id="ref-link-section-d59023944e1198">34</a></sup>. We hypothesized that tumor immune contexture pre-treatment and early post-treatment could better predict LBCL response to axi-cel than classical prognostic markers (described in ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)." href="/articles/s41591-022-01916-x#ref-CR24" id="ref-link-section-d59023944e1202">24</a></sup>; Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">3a</a>), including the activated B cell–like (ABC) cell-of-origin (COO) subtype that predicts a lower overall survival after standard chemotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313–2323 (2008)." href="/articles/s41591-022-01916-x#ref-CR35" id="ref-link-section-d59023944e1209">35</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36" title="Liu, Y. &amp; Barta, S. K. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am. J. Hematol. 94, 604–616 (2019)." href="/articles/s41591-022-01916-x#ref-CR36" id="ref-link-section-d59023944e1212">36</a></sup> than germinal center B cell–like (GCB) or unclassified subtypes of DLBCL.</p><p>We, thus, investigated whether there was an association between circulating CAR T cell levels and pre-treatment and post-treatment tumor immune contexture to compare with COO. Tumor immune contexture was evaluated with Immunoscore TL, TCE<sup>+</sup> and Immunosign 21 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Galon, J. et al. Characterization of anti-CD19 chimeric antigen receptor (CAR) T-cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19). J. Clin. Oncol. 35, 3025 (2017)." href="/articles/s41591-022-01916-x#ref-CR37" id="ref-link-section-d59023944e1221">37</a></sup>). Immunosign 21 profiles the expression of a pre-defined set of genes associated with T cell and innate immune programs, effector T cells, ICs, chemokines and IFN-related molecules (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">5</a>). Immunosign 21 score captured immune contexture-related features in all (three) independent datasets analyzed (<i>n</i> = 341 patients; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig12">6</a>) and was highly correlated with Immunoscore both in the ZUMA-1 subset and therapy-naive DLBCL from commercial origin (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">1a,b</a>). Immunoscore trended positively with axi-cel response (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">1d–j</a>). In agreement with previous findings showing similar axi-cel efficacy across disease subtypes and stages<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Fu, K. et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J. Clin. Oncol. 26, 4587–4594 (2008)." href="#ref-CR6" id="ref-link-section-d59023944e1241">6</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Carbone, A., Gloghini, A., Kwong, Y. L. &amp; Younes, A. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann. Hematol. 93, 1263–1277 (2014)." href="#ref-CR7" id="ref-link-section-d59023944e1241_1">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Locke, F. L. et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25, 285–295 (2017)." href="/articles/s41591-022-01916-x#ref-CR8" id="ref-link-section-d59023944e1244">8</a></sup>, we found no association between peak CAR T cell levels and COO (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig3">3a,b</a>). However, Immunoscore TL index and Immunosign 21 score were significantly lower in the ABC COO subtype (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig3">3c,d</a>), suggesting that TME-independent features may contribute to therapeutic response and compensate for TME detrimental characteristics. In fact, circulating peak CAR levels associated positively with post-treatment TME density of Th cells lacking expression of ICs or of TOX, a known marker of T cell exhaustion<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Stamenkovic, I. et al. The B cell antigen CD75 is a cell surface sialytransferase. J. Exp. Med. 172, 641–643 (1990)." href="/articles/s41591-022-01916-x#ref-CR28" id="ref-link-section-d59023944e1254">28</a></sup>, before (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig3">3e</a>, right panel) and after normalization to TB (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig13">7</a>). Consistent with this observation, the density of cytotoxic T (Tc) cells expressing all four ICs or TOX<sup>+</sup> in combination with any checkpoint associated negatively with circulating CAR T cell levels in post-treatment TME (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig3">3e</a>, left panel). These results revealed an association between poor CAR T cell expansion in blood and post-treatment TME infiltration with exhausted Tc cells. The results may indicate that systemic T cell exhaustion, including of tumor-infiltrating lymphocytes and circulating CAR T cells, associates with a lack of durable response to cell therapy.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Correlations between circulating CAR T cell levels and tumor immune contexture."><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3: Correlations between circulating CAR T cell levels and tumor immune contexture.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01916-x/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="742"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p><b>a</b>–<b>d</b>, COO subtypes were determined by independent transcriptomics analyses in ZUMA-1 samples (<i>n</i> = 51) (<b>a</b>,<b>b</b>) and commercially available DLBCL biopsies (<b>c</b>,<b>d</b>) at diagnosis (<i>n</i> = 50, 16/20/14 for ABC/GCB/UN, respectively). COO subtypes were correlated to peak CAR T cell levels (two-sided <i>t</i>-test without adjustment <i>P</i> values as shown) absolute (<b>a</b>) or normalized (<b>b</b>) to TB and to Immunoscore TL (<b>c</b>) and Immunosign 21 (<b>d</b>). <b>e</b>, Peak CAR T cell levels were also correlated to cell densities of tumor-infiltrating Tc or Th measured with Immunoscore TCE<sup>+</sup> panel in ZUMA-1 patient biopsies, 7–14 days after axi-cel infusion (subset 2, <i>n</i> = 18). Tc and Th phenotypes were classified by checkpoint expression (PD-1<sup>+/–</sup>, LAG-3<sup>+/–</sup>, TIM-3<sup>+/–</sup> and TOX<sup>+/–</sup>). The gray ribbons represent the 95% confidence interval of the regression line. Statistical significance of the Spearman coefficient level (two-sided <i>P</i> value) was calculated, and significant <i>P</i> values (&lt;0.05) are shown in red squares. From top to bottom: all phenotypes (any checkpoint), 0 IC (no checkpoint), 1 IC (any one checkpoint: PD-1 or LAG-3 or TIM-3 or TOX), 2 IC (any two checkpoints: PD-1<sup>+</sup>LAG-3<sup>+</sup> or PD-1<sup>+</sup>TIM-3<sup>+</sup> or PD-1<sup>+</sup>TOX<sup>+</sup> or LAG-3<sup>+</sup>TIM-3<sup>+</sup> or LAG-3<sup>+</sup>/TOX<sup>+</sup> or TIM-3<sup>+</sup>TOX<sup>+</sup>), 3 IC (any three checkpoints: PD-1<sup>+</sup>LAG-3<sup>+</sup>TIM-3<sup>+</sup> or PD-1<sup>+</sup>LAG-3<sup>+</sup>TOX<sup>+</sup> or LAG-3<sup>+</sup>TIM-3<sup>+</sup>TOX<sup>+</sup>), 4 IC (all four checkpoints: PD-1<sup>+</sup>LAG-3<sup>+</sup>TIM-3<sup>+</sup>TOX<sup>+</sup>), TOX<sup>+</sup> (TOX<sup>+</sup> in combination with any checkpoint(s): TOX<sup>+</sup>PD-1<sup>+/–</sup>LAG-3<sup>+/–</sup>TIM-3<sup>+/–</sup>) and TOX<sup>–</sup> (any combination of checkpoint(s) without TOX: TOX<sup>–</sup>PD-1<sup>+/–</sup>LAG-3<sup>+/–</sup>TIM-3<sup>+/–</sup>). LAG-3, lymphocyte activation gene 3; PD-1, programmed cell death protein 1; TIM-3, T cell immunoglobulin and mucin domain 3; TOX, thymocyte selection–associated high mobility group box.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01916-x/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec6">Evolution of tumor immune contexture at relapse</h3><p>We interrogated TME dynamic changes of axi-cel–treated patients developing secondary treatment resistance after 6 months<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31–42 (2019)." href="/articles/s41591-022-01916-x#ref-CR5" id="ref-link-section-d59023944e1442">5</a></sup>. As our dataset of patients who relapsed after achieving a clinical response to axi-cel was limited, analyses were performed in matched FF and FFPE biopsies and in paired samples (<i>n</i> = 7, all patients with longitudinal samples and three patients with both FF and FFPE biopsies). The TME at relapse evolved toward a global reduction in expression of T cell–related and IC genes, cytokine and IFN-related genes and major histocompatibility complex (MHC) class I–related genes compared to early post-treatment TME (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig14">8a–c</a>). The results were consistent across FF (upper rows), FFPE (middle rows) and paired (lower rows) biopsies (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig14">8a,b</a>). Concurrently, an increase in immune counter-regulatory and tumor-associated markers was observed at relapse, including genes involved in immune suppression, CTLA-4, CCR4 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Sugiyama, D. et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl Acad. Sci. USA 110, 17945–17950 (2013)." href="/articles/s41591-022-01916-x#ref-CR38" id="ref-link-section-d59023944e1455">38</a></sup>) and CCL22 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Mizukami, Y. et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T-cells in gastric cancer. Int. J. Cancer 122, 2286–2293 (2008)." href="/articles/s41591-022-01916-x#ref-CR39" id="ref-link-section-d59023944e1460">39</a></sup>) (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig14">8d</a>; upper row, FFPE biopsies, and lower row, FF biopsies). TME composition at relapse significantly associated with an increase of CTLA4 gene counts normalized to tumor-infiltrating CD3 gene counts (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig14">8e,f</a>) but not of FoxP3 gene (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig14">8g,i</a>). Consistent with these findings, CCL22 gene counts correlated with Treg cell density (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig14">8j</a>) and with CCR4 gene counts in subset 1 (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig14">8k</a>). Unsurprisingly, B cell lineage and CTA gene expression also significantly increased at relapse (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig15">9</a>).</p><h3 class="c-article__sub-heading" id="Sec7">Pre-treatment immune contexture associated with survival</h3><p>We next addressed whether pre-treatment T cell infiltration in the TME correlated with efficacy and survival of patients in ZUMA-1. Although T cell–related genes and T cell densities only modestly trended with axi-cel response (Tc density, <i>P</i> = 0.12, and Th density, <i>P</i> = 0.29; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig4">4a,b</a>), the pre-defined Immunoscore index and Immunosign 21 significantly correlated with overall survival (Immunoscore<i>, P</i> = 0.045, and Immunosign 21, <i>P</i> = 0.008; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig4">4c,d</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-4" data-title="Pre-treatment tumor immune contexture associated with survival probability of patients in ZUMA-1."><figure><figcaption><b id="Fig4" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 4: Pre-treatment tumor immune contexture associated with survival probability of patients in ZUMA-1.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01916-x/figures/4" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig4_HTML.png?as=webp"><img aria-describedby="Fig4" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig4_HTML.png" alt="figure 4" loading="lazy" width="685" height="513"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-4-desc"><p><b>a</b>–<b>d</b>, Overall survival of patients in ZUMA-1 as a function of Tc (<b>a</b>) or Th (<b>b</b>) cell infiltration in pre-treatment TME, Immunoscore index (<b>c</b>) or Immunosign 21 score (<b>d</b>). The <i>P</i> values were generated by using an unweighted log-rank test with survminer package in R. <b>e</b>,<b>f</b>, Survival hazard ratios from multivariate analyses of ZUMA-1 patient clinical characteristics and pre-treatment tumor biopsies analyzed for Immunoscore (<i>n</i> = 29) (<b>e</b>) and Immunosign 21 (<i>n</i> = 27 (<b>f</b>). TB analysis was performed as continuous variable. Cox multivariate regression was used to calculate hazard ratio statistical significance. <i>P</i> values are two-sided. CI, confidence interval; HR, hazard ratio; Inf, infinity; N/A, no available molecular data to determine subtype; PD, progressive disease; PR, partial response; SD, stable disease; SPD, sum of the products of diameters.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01916-x/figures/4" data-track-dest="link:Figure4 Full size image" aria-label="Full size image figure 4" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Multivariate analyses with clinical and molecular features further confirmed that survival hazard ratios significantly associated with Immunoscore and Immunosign 21 (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig4">4e,f</a>; <i>P</i> = 0.020) as well as TB (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig4">4e,f</a>; <i>P</i> = 0.018/0.03), consistent with previously published data<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898–4911 (2020)." href="/articles/s41591-022-01916-x#ref-CR34" id="ref-link-section-d59023944e1589">34</a></sup>. These results emphasized the reliability of Immunoscore and Immunosign 21 scoring of T cell tumor infiltration across datasets, but we cannot exclude some inter-dependency between these two covariates, which will need further exploration using larger datasets.</p><p>We next interrogated TME gene expression of chemokines, cytokines and their receptors for possible association with T cell genes and T cell density. We analyzed the association between T cell subsets and chemokine and cytokine expression in pre-treatment TME across four independent datasets. Available transcriptomics data from an ongoing, second-line DLBCL, CAR T cell interventional study<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640–654 (2021)." href="/articles/s41591-022-01916-x#ref-CR25" id="ref-link-section-d59023944e1596">25</a></sup>, as well as published results from commercial patients treated at Moffitt Cancer Center<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells associate with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621–2633 (2021)." href="/articles/s41591-022-01916-x#ref-CR26" id="ref-link-section-d59023944e1600">26</a></sup>, were added to ZUMA-1 and treatment-naive DLBCL datasets already described. The dataset from the ongoing, second-line DLBLC clinical trial could not be used to validate associations with clinical outcomes. Chemokines secreted only by myeloid cells (CXCL9 and CXCL14) or by both myeloid and T cells (CCL5 and its receptor CCR5), as well as STAT1 gene expression, were directly associated with T cell density in all four datasets (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig5">5</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig16">10</a>). T cell genes (CD3δ, CD8 and CD4) also correlated with genes encoding cytokines important for T cell expansion, stemness, viability and differentiation, such as IL-21 Th cells or IL-7, IL-18 and IL-15 produced by stromal or myeloid cells<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Kochenderfer, J. N. et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J. Clin. Oncol. 35, 1803–1813 (2017)." href="/articles/s41591-022-01916-x#ref-CR40" id="ref-link-section-d59023944e1610">40</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Conlon, K. C., Miljkovic, M. D. &amp; Waldmann, T. A. Cytokines in the treatment of cancer. J. Interferon Cytokine Res. 39, 6–21 (2019)." href="/articles/s41591-022-01916-x#ref-CR41" id="ref-link-section-d59023944e1613">41</a></sup> (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">10</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-5" data-title="T cell subsets in pre-treatment tumor biopsies associated with myeloid-secreted chemokines."><figure><figcaption><b id="Fig5" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 5: T cell subsets in pre-treatment tumor biopsies associated with myeloid-secreted chemokines.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01916-x/figures/5" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig5_HTML.png?as=webp"><img aria-describedby="Fig5" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig5_HTML.png" alt="figure 5" loading="lazy" width="685" height="812"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-5-desc"><p><b>a</b>–<b>c</b>, Correlation between CXCL9 gene expression in pre-treatment tumor biopsies and CD8<sup>+</sup> T cell tumor infiltrate measured by Immunoscore TCE panel (<b>a</b>) or CD8A gene expression (<b>b</b>,<b>c</b>) in patients in ZUMA-1 (subset 1; <i>n</i> = 19) (<b>a</b>), second-line patients with DLBCL (<i>n</i> = 252) (<b>b</b>) and treatment-naive patients with DLBCL (<i>n</i> = 67) (<b>c</b>). Gene expression was measured by PanCancer Immune panel for <b>a</b> and <b>c</b> and Immuno-Oncology 360 panel for <b>b</b>. <b>d</b>–<b>f</b>, Correlation matrix for myeloid-secreted and/or T cell–produced cytokines and chemokines (horizontal axis) with T cell subset–related genes (vertical axis) in pre-treatment tumor biopsies from ZUMA-1 (<b>d</b>), second-line (<b>e</b>) and treatment-naive patients with DLBCL (<b>f</b>). The scale bar (−1 to 1) represents the <i>R</i> value. The gray ribbons represent the 95% confidence interval of the regression line. Statistical significance of the Spearman coefficient level (two-sided <i>P</i> value as shown) was calculated. CCL, chemokine ligand; CXCL, chemokine C-X-C motif ligand; FoxP3, forkhead box P3; GNLY, granulysin; GZMA, granzyme A; IL, interleukin; IRF1, interferon regulatory factor 1; PD, progressive disease; PR, partial response; SD, stable disease; STAT, signal transducer and activator of transcription; NFRSF14, tumour necrosis factor receptor superfamily member 14.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01916-x/figures/5" data-track-dest="link:Figure5 Full size image" aria-label="Full size image figure 5" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>We next sought to validate biological associations seen in the ZUMA-1 cohort using other patient independent datasets extracted from a second-line DLBCL clinical trial<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640–654 (2021)." href="/articles/s41591-022-01916-x#ref-CR25" id="ref-link-section-d59023944e1711">25</a></sup> and a commercial axi-cel dataset. In second-line DLBCL, IL-15 and IL-18 correlated with CD3ε gene expression (Spearman <i>P</i> &lt; 1 × 10<sup>−16</sup> and <i>P</i> = 6.6 × 10<sup>−16</sup>, respectively). These results were also confirmed in 33 commercial patients. Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig16">10a,b</a> shows a robust correlation between activated T cell markers (GZMA and GNLY) and chemokines (CCL5)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells associate with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621–2633 (2021)." href="/articles/s41591-022-01916-x#ref-CR26" id="ref-link-section-d59023944e1729">26</a></sup> in the commercial axi-cel datasets. Finally, the analysis of the main immune pathways associated with CR compared to non-CR in two independent datasets (ZUMA-1 and commercial axi-cel patients) revealed that, in each patient group, lymphocyte co-stimulation and leukocyte cell–cell adhesion were associated with increased fold change, whereas antigen processing and presentation of peptide antigen genes related to M2 macrophages and myeloid activation (CD206, CD36, CD74, HLA-DM, HLA-DQ, HLA-DRA, HLA-E and TREM2) were associated with a decrease in fold change (CR versus non-CR; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig16">10c,d</a>).</p><p>Altogether, these data linked key pre-treatment tumor immune characteristics, including chemokines and γ-chain receptor cytokine expression, to a T cell–involved immune contexture and may indicate actionable functional pathways to sensitize the TME to CAR T cell therapy.</p><h3 class="c-article__sub-heading" id="Sec8">Pre-treatment TME T cell subsets associated with survival</h3><p>To identify the cell subsets associated with axi-cel outcomes in the patients in ZUMA-1, we measured the T cell density in pre-treatment TME with Immunoscore TCE and the expression levels of B cell lineage genes. The density of CD8<sup>+</sup> T cells with activated phenotype (PD-1<sup>+</sup> checkpoint and LAG3<sup>+/−</sup>TIM3<sup>−</sup>) was most significantly associated with OR, contrasting with other CD8<sup>+</sup> T cell subsets, including non-activated (no checkpoint expression) or exhausted (three checkpoints (PD-1<sup>+</sup>LAG-3<sup>+</sup>TIM-3<sup>+</sup>)) T cells (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig6">6a</a>). But the expression levels of B cell lineage genes, including CD19 (CAR target), CD79b, CD22 and PAX5, were similar across outcome groups (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig15">9c</a>), whereas the expression of some CTA genes (PRAME and MAGE-B2 family members) was more elevated in non-responders (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig15">9d</a>). The cell density of various myeloid subsets, including CD11b<sup>+</sup>CD15<sup>−</sup>CD14<sup>+</sup> monocytes and CD68<sup>+</sup> macrophages, was greater than the T cell density in pre-treatment TME (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">11</a>), but the overall myeloid subset density was not significantly associated with clinical outcomes (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">2</a>)</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-6" data-title="Cell density of T cell subsets in pre-treatment tumor biopsies associated with axi-cel efficacy, NEs and CAR T cell expansion."><figure><figcaption><b id="Fig6" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 6: Cell density of T cell subsets in pre-treatment tumor biopsies associated with axi-cel efficacy, NEs and CAR T cell expansion.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01916-x/figures/6" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig6_HTML.png?as=webp"><img aria-describedby="Fig6" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig6_HTML.png" alt="figure 6" loading="lazy" width="685" height="568"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-6-desc"><p>T cell subset densities were measured by Immunoscore TCE panel in ZUMA-1 tumor biopsies (<i>n</i> = 27) and plotted as a function of clinical response to axi-cel (CR/PR versus SD/PD; 19 CR, four PR and four SD/PD) or NE grade (grades 0–2, <i>n</i> = 22, versus grade ≥3, <i>n</i> = 5) and IC expression (PD-1, LAG-3 and TIM3). <b>a</b>, Tc density versus clinical response and IC expression. <b>b</b>, Treg density versus NE grade and IC expression. N/A = not applicable, regardless of PD-1, LAG3, TIM-3 expression (<b>a</b>,<b>b</b>). <b>c</b>, Correlation of clinical outcomes and NE grades with densities of tumor-infiltrating Tc and Treg cells. Two-sided exact Fisher test <i>P</i> value of responders with NE grade ≥3 and low Treg density (purple box) versus all other patients = 5.698 × 10<sup>−5</sup>; two-sided exact Fisher test <i>P</i> value of complete responders with NE grades 0–2 and high Treg density (blue box) versus all other patients = 0.02. <b>d</b>,<b>e</b>, Correlations of non-activated Th density measured by Immunoscore TCE panel and peak CAR T cells without (<i>n</i> = 23) (<b>d</b>) or with (<i>n</i> = 19) (<b>e</b>) normalization to pre-treatment TB. <b>f</b>,<b>g</b>, Correlations of Immunoscore and peak CAR T cells without (<i>n</i> = 29) (<b>f</b>) or with (<i>n</i> = 27) (<b>g</b>) normalization to pre-treatment TB. The gray ribbons (<b>d</b>–<b>g</b>) represent the 95% confidence interval of the regression line. Statistical significance of the Spearman coefficient level (two-sided <i>P</i> value) as shown was calculated. LAG-3, lymphocyte activation gene 3; PD, progressive disease; PD-1, programmed cell death protein 1; PR, partial response; SD, stable disease; TIM-3, T cell immunoglobulin and mucin domain 3.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01916-x/figures/6" data-track-dest="link:Figure6 Full size image" aria-label="Full size image figure 6" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>In contrast, Treg density (CD3<sup>+</sup>CD8<sup>−</sup>FoxP3<sup>+</sup>) was markedly reduced in patients who developed high-grade (grade ≥3) NEs after axi-cel, independently of checkpoint expression (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig6">6b</a>; <i>P</i> &lt; 0.0001; Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">3a</a>). Unexpectedly, Treg density associated positively with TME features favoring axi-cel clinical response, including high CD8<sup>+</sup>PD-1<sup>+</sup> T cell density (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">3b</a>). Patients with high density of CD8<sup>+</sup>PD-1<sup>+</sup> T cells and intermediary/high density of PD-1<sup>+</sup> Tregs (≈1/4 of all tested patients) achieved CR without serious NEs after axi-cel. Most patients (<i>n</i> = 4/5) with low density of Tregs yet measurable CD8<sup>+</sup>PD-1<sup>+</sup> T cells in pre-treatment TME developed grade ≥3 NEs after axi-cel (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig6">6c</a>, purple box; Fisher <i>P</i> = 5.7 × 10<sup>−5</sup>). Furthermore, pre-treatment tumor-infiltrating non-activated Th cells positively associated with peak CAR T cell levels, with or without normalization to TB (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig6">6de</a>), and pre-treatment Immunoscore significantly associated with normalized peak CAR T cell levels (<i>P</i> = 0.028; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig6">6g</a>). These data suggest that pre-treatment subsets of tumor-infiltrating lymphocytes, such as activated CD8<sup>+</sup> T cells and Treg cells, associate differentially with efficacy and neurotoxicity after axi-cel.</p></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec9-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec9">Discussion</h2><div class="c-article-section__content" id="Sec9-content"><p>Recent findings suggest that CAR T cell therapy may have curative potential in select patients with non-Hodgkin’s lymphoma<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Cappell, K. M. et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 38, 3805–3815 (2020)." href="/articles/s41591-022-01916-x#ref-CR42" id="ref-link-section-d59023944e1960">42</a></sup>, but existing prognostic subgroups do not predict response to axi-cel<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Locke, F. L. et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25, 285–295 (2017)." href="/articles/s41591-022-01916-x#ref-CR8" id="ref-link-section-d59023944e1964">8</a></sup>. As preclinical models typically fail to mimic accurately the complex mechanisms of action of immunotherapy, reverse translational studies were undertaken to identify tumor-related features associated with outcomes to CAR T cell intervention. We performed comprehensive gene expression analyses on more than 400 patients with LBCL treated with axi-cel (ZUMA-1, third-line, r/r LBCL; third-line, relapse LBCL commercial axi-cel patients; patients with DLBCL enrolled in an ongoing, second-line, CAR T cell study;<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640–654 (2021)." href="/articles/s41591-022-01916-x#ref-CR25" id="ref-link-section-d59023944e1968">25</a></sup> and treatment-naive patients with DLBCL) as well as multiplex spatial tissue analysis on 118 ZUMA-1 and treatment-naive patients with DLBCL. Clinical outcome data were available only for the ZUMA-1 patient datasets; the second-line and treatment-naive patient datasets served as validation for biological associations. We discovered that tumor immune contexture was associated with, and potentially a major determinant of, axi-cel clinical efficacy in patients in ZUMA-1. The key findings of this study are: (1) rapid change of immune TME features after axi-cel; (2) CR to CAR T cell treatment associated with pre-treatment TME rich in cytokines and chemokines that favors T cell involvement; (3) high density of PD-1<sup>+</sup>LAG-3<sup>+/–</sup> T cells in pre-treatment TME associated with OR; (4) low density of Tregs in pre-treatment TME associated with grade ≥3 neurotoxicity; (5) overall survival associated with high Immunoscore and Immunosign 21 in pre-treatment TME; and (6) the higher the T cell exhaustion in post-treatment TME, the lower the circulating CAR T cell levels, a key correlate of durable response<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898–4911 (2020)." href="/articles/s41591-022-01916-x#ref-CR34" id="ref-link-section-d59023944e1977">34</a></sup>.</p><p>This study demonstrated that TME gene signature evolution occurs quickly after axi-cel treatment, whereby responders show rapid upregulation of the T cell–related signature and downregulation of B cell tumor-related markers, defining a dynamic pattern that separates responders from non-responders within 2 weeks post-treatment. The early TME gene expression changes that were observed may serve as a pharmacodynamic marker of response. Patients with low pre-treatment TB and high T cell involvement showed higher likelihood of achieving CR, but, when response was achieved, the TME evolved similarly in small versus large TB. The pre-specified Immunoscore and Immunosign 21 indexes—pertaining to T cell activity and related immune programs—were associated with overall survival, with clinical follow-up exceeding 1 year. The density of activated CD8<sup>+</sup>PD-1<sup>+</sup>LAG-3<sup>+/−</sup>TIM-3<sup>−</sup> T cells was the TME feature most associated with clinical efficacy. In addition, pre-treatment TME density of CD3<sup>+</sup>CD8<sup>−</sup>FoxP3<sup>+</sup> Tregs and related features associated with lower-grade axi-cel–related neurotoxicity without a notable association with efficacy, suggesting overall better T cell infiltration and/or a beneficial effect of TME-infiltrating Tregs on the therapeutic index in this setting possibly related to the essential role of Tregs in normal tissue protection<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Arpaia, N. et al. A distinct function of regulatory T cells in tissue protection. Cell 162, 1078–1089 (2015)." href="/articles/s41591-022-01916-x#ref-CR43" id="ref-link-section-d59023944e1999">43</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Campbell, C. &amp; Rudensky, A. Roles of regulatory T cells in tissue pathophysiology and metabolism. Cell Metab. 31, 18–25 (2020)." href="/articles/s41591-022-01916-x#ref-CR44" id="ref-link-section-d59023944e2002">44</a></sup>. At relapse, the TME acquired an immune-detrimental contexture with decreased T cell–related signature and increased tumor-associated and immune counter-regulatory markers<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="Okeke, E. B. &amp; Uzonna, J. E. The pivotal role of regulatory T cells in the regulation of innate immune cells. Front. Immunol. 10, 680 (2019)." href="/articles/s41591-022-01916-x#ref-CR45" id="ref-link-section-d59023944e2006">45</a></sup>, including CCR4 and CCL22. Finally, pre-treatment tumor immune contexture associated with T cell presence and activity in TME through chemokines (for example, CXCL9 and CXCL14) and cytokines (for example, IL-15, IL-7, IL-18 and IL-21) produced locally (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig5">5</a>, Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig16">10</a>, Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">4</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">10</a>), which supports the hypothesis that stromal production of T cell–attractive chemokines and γ-chain receptor cytokines may promote a T cell–involved TME generally favorable for CAR T cell activity.</p><p>The positive association between high density of CD8<sup>+</sup>PD-1<sup>+</sup> T cells in pre-treatment TME and axi-cel response mirrors previous findings in solid tumors describing response to IC blockade<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Galon, J. et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J. Transl. Med. 14, 273 (2016)." href="/articles/s41591-022-01916-x#ref-CR10" id="ref-link-section-d59023944e2030">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Galon, J. &amp; Bruni, D. Tumor immunology and tumor evolution: intertwined histories. Immunity 52, 55–81 (2020)." href="/articles/s41591-022-01916-x#ref-CR15" id="ref-link-section-d59023944e2033">15</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Bruni, D., Angell, H. K. &amp; Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662–680 (2020)." href="/articles/s41591-022-01916-x#ref-CR22" id="ref-link-section-d59023944e2036">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Galon, J., Angell, H. K., Bedognetti, D. &amp; Marincola, F. M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39, 11–26 (2013)." href="/articles/s41591-022-01916-x#ref-CR46" id="ref-link-section-d59023944e2039">46</a></sup> and expands the paradigm that immunotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Galon, J. &amp; Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197–218 (2019)." href="/articles/s41591-022-01916-x#ref-CR47" id="ref-link-section-d59023944e2043">47</a></sup>, including CAR T cell therapy, is favored by an immune-involved TME<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Chen, P. H. et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight 5, e134612 (2020)." href="/articles/s41591-022-01916-x#ref-CR48" id="ref-link-section-d59023944e2047">48</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49" title="Coutinho, R. et al. Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. Haematologica 100, 363–369 (2015)." href="/articles/s41591-022-01916-x#ref-CR49" id="ref-link-section-d59023944e2050">49</a></sup>. Overall survival also was positively correlated with high Immunoscore index and Immunosign 21 score. The immune contexture, as measured by the pre-specified gene expression panel Immunosign 21, has been linked to prediction of response to multiple immunotherapies in multiple cancer types<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Bruni, D., Angell, H. K. &amp; Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662–680 (2020)." href="/articles/s41591-022-01916-x#ref-CR22" id="ref-link-section-d59023944e2055">22</a></sup>. It would, thus, be of interest to also evaluate pre-treatment Immunosign 21 before CAR T cell therapy for solid tumors.</p><p>Furthermore, axi-cel expansion relative to TB, a known robust correlate of durable efficacy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31–42 (2019)." href="/articles/s41591-022-01916-x#ref-CR5" id="ref-link-section-d59023944e2062">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898–4911 (2020)." href="/articles/s41591-022-01916-x#ref-CR34" id="ref-link-section-d59023944e2065">34</a></sup>, was positively associated with a T cell–involved TME at baseline and negatively associated with exhausted (TOX<sup>+</sup>) tumor-infiltrating T-cells after axi-cel, providing a key rationale to link pre-treatment and post-treatment tumor immune contexture and axi-cel performance. In brief, patients with lower pre-treatment TB, higher density of activated CD8<sup>+</sup> T cells and measurable Tregs within the TME may have a more favorable clinical evolution in terms of efficacy and toxicity after axi-cel, and these parameters could be included in the design of future clinical trials.</p><p>This analysis—directed at comparing patients by best response to axi-cel—has not identified a clear association between pre-treatment myeloid cell signature in the TME and clinical outcomes or between COO classification and the response rate to axi-cel in patients with r/r LBCL. Other studies recently identified a link between specific myeloid cell signatures and CAR T cell treatment-related toxicities<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 50" title="Faramand, R. et al. Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. Clin. Cancer Res. 26, 4823–4831 (2020)." href="/articles/s41591-022-01916-x#ref-CR50" id="ref-link-section-d59023944e2077">50</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 51" title="Chou, C. K. &amp; Turtle, C. J. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opin. Biol. Ther. 20, 653–664 (2020)." href="/articles/s41591-022-01916-x#ref-CR51" id="ref-link-section-d59023944e2080">51</a></sup> and durable response, respectively<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells associate with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621–2633 (2021)." href="/articles/s41591-022-01916-x#ref-CR26" id="ref-link-section-d59023944e2084">26</a></sup>. The study by Jain et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells associate with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621–2633 (2021)." href="/articles/s41591-022-01916-x#ref-CR26" id="ref-link-section-d59023944e2088">26</a></sup> investigated a distinct question—namely, the effect of myeloid cells (M-MDSCs) and associated IFN signalling on the process of relapse in patients who responded to axi-cel, indicating that a dysregulated myeloid signature may be mechanistically involved in the process. Immunoscore index and Immunosign 21 were identified as significant predictors of overall survival after CAR T cell treatment (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig4">4</a>), and the latter was correlated with T cell subset densities (<i>P</i> &lt; 0.005) but not with macrophages or mononuclear subsets (<i>P</i> = 0.69 and <i>P</i> = 0.27, respectively; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig12">6b</a>) in patients in ZUMA-1. Interestingly, in treatment-naive and second-line patients with DLBCL, Immunosign 21 did correlate with myeloid subsets (macrophage density, <i>P</i> = 0.0077, and CD68 gene expression, <i>P</i> = 5.5 × 10<sup>−15</sup>, respectively; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig12">6c,d</a>), in addition to CD8 T cells. Furthermore, lower Immunoscore and Immunosign 21 associated with ABC subtype in treatment-naive patients, but COO did not correlate with the overall survival of the patients in ZUMA-1 reported in this manuscript (Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig3">3</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig4">4</a>). These observations suggest that molecular attributes of DLBCL subtypes initially influence the TME composition but are not associated with CAR T cell response. In contrast, the immune infiltrate, as well as TB, was associated with response to CAR T cells, and multiple lines of chemotherapy may later modify the composition of the immune infiltrate.</p><p>In addition to yielding predictive markers, these findings suggest strategies to overcome treatment resistance in patients with immune-detrimental TME through local or systemic provision of T cell chemokines, γ-chain receptor cytokines or IFN program-stimulating factors, using T cell engineering or combinatorial approaches<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells associate with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621–2633 (2021)." href="/articles/s41591-022-01916-x#ref-CR26" id="ref-link-section-d59023944e2129">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Galon, J. &amp; Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197–218 (2019)." href="/articles/s41591-022-01916-x#ref-CR47" id="ref-link-section-d59023944e2132">47</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 52" title="Anderson, K. G., Stromnes, I. M. &amp; Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31, 311–325 (2017)." href="/articles/s41591-022-01916-x#ref-CR52" id="ref-link-section-d59023944e2135">52</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 53" title="Lanitis, E., Coukos, G. &amp; Irving, M. All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy. Curr. Opin. Biotechnol. 65, 75–87 (2020)." href="/articles/s41591-022-01916-x#ref-CR53" id="ref-link-section-d59023944e2138">53</a></sup>. These approaches may include epigenetic modulators aimed at restoring dysregulated gene expression manifesting through elevated CTAs<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Stamenkovic, I. et al. The B cell antigen CD75 is a cell surface sialytransferase. J. Exp. Med. 172, 641–643 (1990)." href="/articles/s41591-022-01916-x#ref-CR28" id="ref-link-section-d59023944e2142">28</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 54" title="Hudolin, T. et al. Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma. J. Transl. Med. 11, 123 (2013)." href="/articles/s41591-022-01916-x#ref-CR54" id="ref-link-section-d59023944e2145">54</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 55" title="Teater, M. et al. AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nat. Commun. 9, 222 (2018)." href="/articles/s41591-022-01916-x#ref-CR55" id="ref-link-section-d59023944e2148">55</a></sup> or TOX, the central regulator of exhausted CD88<sup>+</sup> T cells<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 56" title="Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211–218 (2019)." href="/articles/s41591-022-01916-x#ref-CR56" id="ref-link-section-d59023944e2154">56</a></sup>, which were found to be negatively associated with clinical response to axi-cel. Supporting the latter, current CAR T cell generation has a propensity for premature antigen-induced cell exhaustion and death owing to supraphysiological signaling<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 57" title="Brudno, J. N. et al. Safety and feasibility of anti-CD19 CAR T-cells with fully human binding domains in patients with B-cell lymphoma. Nat. Med. 26, 270–280 (2020)." href="/articles/s41591-022-01916-x#ref-CR57" id="ref-link-section-d59023944e2158">57</a></sup>.</p><p>Our study has several limitations. The only sample dataset with linked clinical outcomes was the ZUMA-1 patient dataset, and the sample size for relapse and paired subsets was small. Also, CAR T cell probes were not included in the study because CAR levels in the TME were unexpectedly low in biopsies performed 2 weeks after axi-cel. Earlier immunohistochemical and in situ data have shown that CAR T cells make up only a very small percentage of intratumoral T cells 5 days or more after axi-cel infusion<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Chen, P. H. et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight 5, e134612 (2020)." href="/articles/s41591-022-01916-x#ref-CR48" id="ref-link-section-d59023944e2165">48</a></sup>. In addition, in two prior studies of tumoral transcriptomics predicting clinical outcomes to CAR T therapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 58" title="Singh, N. et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 10, 552–567 (2020)." href="/articles/s41591-022-01916-x#ref-CR58" id="ref-link-section-d59023944e2169">58</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 59" title="Upadhyay, R. et al. A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov. 11, 599–613 (2021)." href="/articles/s41591-022-01916-x#ref-CR59" id="ref-link-section-d59023944e2172">59</a></sup>, clinical benefit was associated with tumor expression of death receptors, but the content of the transcriptomics panels employed in this study did not allow us to investigate other possible tumor cell intrinsic factors, such expression of death receptors. In two prior studies of tumoral transcriptomics predicting clinical outcomes to CAR T therapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 58" title="Singh, N. et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 10, 552–567 (2020)." href="/articles/s41591-022-01916-x#ref-CR58" id="ref-link-section-d59023944e2176">58</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 59" title="Upadhyay, R. et al. A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov. 11, 599–613 (2021)." href="/articles/s41591-022-01916-x#ref-CR59" id="ref-link-section-d59023944e2179">59</a></sup>, both showed the benefit of tumoral expression of death receptors. Finally, the broad deployment of immune responses after CAR T infusion contrasts with the unexpected low frequency of detectable autologous CAR T cells in the TME. Reduced CAR expression on the membrane surface after antigen stimulation could occur through several mechanisms, hampering detection by IHC-based and RNA-based methods. Alternative approaches to detection of CAR T cells in the TME are warranted before translating the results of this study to other cell therapy modalities.</p><p>In conclusion, this study advances understanding of axi-cel mechanism of action, linking its performance (that is, CAR T cell efficacy, toxicity and patient survival) to tumor immune contexture pre-treatment and post-treatment (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">4</a>). This study also highlights a third mechanism of resistance to axi-cel in third-line DLBCL, in addition to product T cell fitness<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898–4911 (2020)." href="/articles/s41591-022-01916-x#ref-CR34" id="ref-link-section-d59023944e2189">34</a></sup> and target-related evasion<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 60" title="Plaks, V. et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood 138, 1081–1085 (2021)." href="/articles/s41591-022-01916-x#ref-CR60" id="ref-link-section-d59023944e2193">60</a></sup>, that is related to the tumor immune microenvironment. Although our sample size was limited, these results, pending validation, suggest that immune-based therapies with curative potential, such as axi-cel, should be considered in earlier lines of therapy where a larger percentage of patients have more favorable TME features and lower TB, to potentially maximize clinical benefit and curative potential. Given the practical implications, further TME signature optimization and validation in larger studies is warranted in LBCL and in other tumor types for which T cell therapies are being developed.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec10-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec10">Methods</h2><div class="c-article-section__content" id="Sec10-content"><h3 class="c-article__sub-heading" id="Sec11">Patient sample collection and preparation</h3><p>The study protocol for the single-arm, multicenter, registrational ZUMA-1 study of axi-cel in patients with relapsed LBCL was previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31–42 (2019)." href="/articles/s41591-022-01916-x#ref-CR5" id="ref-link-section-d59023944e2209">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)." href="/articles/s41591-022-01916-x#ref-CR24" id="ref-link-section-d59023944e2212">24</a></sup>. Each study site’s institutional review board reviewed and approved the study protocol and amendments, and all patients provided written informed consent. The study was done according to the International Conference on Harmonisation Good Clinical Practice guidelines. Patients in the ZUMA-1 study did not receive compensation for their participation. Eligible patients had histologically confirmed LBCL and refractory disease, defined as progressive or stable disease as best response to most recent chemotherapy regimen or disease progression or relapse within 12 months after autologous stem cell transplantation<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31–42 (2019)." href="/articles/s41591-022-01916-x#ref-CR5" id="ref-link-section-d59023944e2216">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)." href="/articles/s41591-022-01916-x#ref-CR24" id="ref-link-section-d59023944e2219">24</a></sup>. Patients received axi-cel at a target dose of 2.0 × 10<sup>6</sup> CAR T cells per kilogram<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31–42 (2019)." href="/articles/s41591-022-01916-x#ref-CR5" id="ref-link-section-d59023944e2225">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)." href="/articles/s41591-022-01916-x#ref-CR24" id="ref-link-section-d59023944e2228">24</a></sup>. Tumor biopsy specimens from patients in ZUMA-1 (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig7">1</a>) were collected at baseline (before conditioning chemotherapy (pre-lymphodepletion)) and after axi-cel infusion. The largest group of samples (40%) was from lymph nodes, but no significant differences in the TME composition between tumor originating from lymph nodes versus other origins were found by principal component analysis (PCA) of all gene expression for FFPE baseline samples (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig7">1b</a>). Patients with samples collected before axi-cel infusion are referred to throughout the manuscript as subset 1, early after CAR T cell infusion (days 7–14) as subset 2 and later at relapse as subset 3 (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig7">1c</a>). Of note, not all patient samples are on all figures. Inclusion of samples was based on the following. (1) In addition to the informed consent statement for trial participation and primary analysis, consent for exploratory analysis was required, which reduces the amount from the total number of patients enrolled in the ZUMA-1 phase 2 pivotal trial. (2) Remaining sample available for testing. (3) Samples that passed quality control (QC) for any given platform, as described below. After sample quality was controlled for, a total of 135 baseline and post-treatment biopsy specimens from 51 patients in ZUMA-1 with LBCL were analyzed for this study. The patient characteristics and clinical outcomes analyzed in this study were compared to those of the overall ZUMA-1 population. No significant differences were found (<i>t</i>-test <i>P</i> values for age = 1; <i>P</i> value for sex = 0.318; <i>P</i> value for best response = 0.175; <i>P</i> value for disease type comparison = 0.664; <i>P</i> value for International Prognostic Index (IPI) = 0.846; <i>P</i> value for more than three prior lines of therapy = 0.664; <i>P</i> value for CAR T cell levels = 0.854). All post-treatment biopsy specimens were acquired between days 7 and 14, except for a specimen collected at week 4 from a patient with stable disease. Subset 1 (baseline) includes 46 patients, with nine patients with FF biopsies, 19 patients with FFPE biopsies and 18 patients with both types of biopsies. Subset 2 (post-treatment) includes 28 patients, with nine patients with FF biopsies, ten patients with FFPE biopsies and nine patients with both. Subset 3 (relapse) includes seven patients, with one patient with FF biopsies, four patients with FFPE biopsies and two patients with both (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig7">1d</a>). The patient characteristics and clinical outcomes described in this study were consistent with those observed in the overall ZUMA-1 cohort (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">1</a>). Best response was evaluated within 2 years of axi-cel infusion for patients enrolled in ZUMA-1 phases 1 and 2 (cohorts 1 and 2) and within 6 months of axi-cel infusion for patients enrolled in ZUMA-1 phase 2 (cohort 3). NEs in ZUMA-1 were graded according to Common Terminology Criteria for Adverse Events, version 4 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31–42 (2019)." href="/articles/s41591-022-01916-x#ref-CR5" id="ref-link-section-d59023944e2274">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)." href="/articles/s41591-022-01916-x#ref-CR24" id="ref-link-section-d59023944e2277">24</a></sup>).</p><p>Three independent datasets were also included in this study (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">3</a>)—namely, 67 biopsy specimens from treatment-naive patients with DLBCL (collected at time of diagnosis), 252 biopsy specimens from patients with r/r DLBCL in an ongoing open-label, second-line, interventional study (<a href="https://clinicaltrials.gov/ct2/show/NCT03391466">NCT03391466</a>; study is still blinded to outcomes) and 33 biopsy specimens from axi-cel commercial patients treated at Moffitt Cancer Center<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells associate with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621–2633 (2021)." href="/articles/s41591-022-01916-x#ref-CR26" id="ref-link-section-d59023944e2294">26</a></sup>. Baseline tumor samples were analyzed by targeted transcriptomics (Immuno-Oncology 360) for the 252 second-line patients and 33 axi-cel commercial patients treated at Moffitt Cancer Center.</p><h3 class="c-article__sub-heading" id="Sec12">Gene expression profiling</h3><p>Gene expression profiling was performed using three gene panels (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">4</a>) on 89 biopsy specimens from ZUMA-1 patient subsets 1, 2 and 3. Twenty-four patients had longitudinal biopsy specimens (baseline/post-infusion, <i>n</i> = 17; baseline/post-infusion/relapse, <i>n</i> = 6; baseline/relapse, <i>n</i> = 1). Clinical research tests, including Immunoscore TL (consensus Immunoscore assay CD3 and CD8), Immunoscore TCE (CD3, CD8, FoxP3, PD-1, LAG-3 and TIM-3), Immunoscore TCE<sup>+</sup> (CD3, CD8, FoxP3, PD-1, LAG-3, TIM-3, TOX ND and EZH2), Immunoscore SC (CD11b, CD14, CD15, CD68, S100A9 and LOX-1) and Immunosign 21 (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">4</a>), were performed in a Clinical Laboratory Improvement Amendments–certified laboratory (HalioDx). For ZUMA-1 pre/post–axi-cel comparisons, biopsy specimens were analyzed using the PanCancer Immune Profiling Panel. For pre-treatment (baseline) analyses, biopsy specimens were analyzed using the PanCancer Immune + Immunosign Gene Panel. Slide sets were prepared from each FFPE block by cutting ten consecutive 4-µm sections, which were further immobilized on Superfrost Plus slides. One slide was used for hematoxylin and eosin (H&amp;E) staining; two consecutive slides were used for Immunoscore TL (automatic staining CD3/CD8, BenchMark XT); and four or five consecutive slides were used for RNA extraction and NanoString profiling. Slides were de-identified and tracked using a unique number for each pre-analytical step, and two workflows per patient were performed</p><h3 class="c-article__sub-heading" id="Sec13">Sample QC</h3><p>QC at various steps was implemented to remove samples or data that failed to meet requirements. Incoming FFPE blocks were visually inspected to assess block quality or to determine whether sufficient material remained. Tissue sections were assessed for defects in section quality. H&amp;E stains were assessed for image quality and necrosis by a pathologist. Slides with more than 95% necrotic tissues were not stained. Because most DLBCL biopsy specimens lacked an identifiable invasive margin, the percentage of tumor content was not part of the initial tissue selection for staining. After multiplex IHC panels, technical criteria—including tissue staining QC of tissue sections, image QC for blurry areas or artifacts and digital pathology QC (specificity, intensity, detection sensitivity and detection of tumor areas)—were used to select study samples. For RNA sequencing, samples that did not meet input requirements or had extensive degradation were eliminated. Suitable samples were then assessed for library preparation metrics, sequencing QC (Q30 &gt; 70%) and analysis QC (10 million assigned reads obtained). For NanoString analyses, samples that did not have sufficient input and any samples flagged as failing raw data QC or normalization QC by NCounter software during analysis were removed. The starting number of samples and final number of samples that passed all QC metrics and were, therefore, included in the various analyses are stated below for the respective assays.</p><h3 class="c-article__sub-heading" id="Sec14">Antibody validation</h3><p>The CD3 (HDX1) and CD8 (HDX2) primary antibody performances have been established and validated for the Immunoscore colon cancer test (CLIA and CE-IVD marked test) and are produced by Veracyte. Commercial antibody characteristics are listed in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">12</a> and include CD3 (1 μg ml<sup>−1</sup>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 61" title="Marliot, F. et al. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. J. Immunother. Cancer 8, e000272 (2020)." href="/articles/s41591-022-01916-x#ref-CR61" id="ref-link-section-d59023944e2345">61</a></sup>, CD8 (1 μg ml<sup>−1</sup>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 61" title="Marliot, F. et al. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. J. Immunother. Cancer 8, e000272 (2020)." href="/articles/s41591-022-01916-x#ref-CR61" id="ref-link-section-d59023944e2351">61</a></sup>, PD1 (1/8,000, 0.125 μg ml<sup>−1</sup>; <a href="https://cdn.origene.com/datasheet/um800091.pdf">https://cdn.origene.com/datasheet/um800091.pdf</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 62" title="Panda, A. et al. Immune activation and benefit from avelumab in EBV-positive gastric cancer. J. Natl Cancer Inst. 110, 316–320 (2018)." href="/articles/s41591-022-01916-x#ref-CR62" id="ref-link-section-d59023944e2365">62</a></sup>, LAG3 (1/400, 1.95 μg ml<sup>−1</sup>; <a href="https://www.cellsignal.com/products/primary-antibodies/lag3-d2g4o-xp-rabbit-mab/15372">https://www.cellsignal.com/products/primary-antibodies/lag3-d2g4o-xp-rabbit-mab/15372</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 63" title="Agocs, G. R. et al. LAG-3 expression predicts outcome in stage II colon cancer. J. Pers. Med. 11, 749 (2021)." href="/articles/s41591-022-01916-x#ref-CR63" id="ref-link-section-d59023944e2378">63</a></sup>, TIM3 (1/400, 0.04 μg ml<sup>−1</sup>; <a href="https://www.cellsignal.com/products/primary-antibodies/tim-3-d5d5r-xp-rabbit-mab/45208">https://www.cellsignal.com/products/primary-antibodies/tim-3-d5d5r-xp-rabbit-mab/45208</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Autio, M. et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica 106, 718–729 (2021)." href="/articles/s41591-022-01916-x#ref-CR32" id="ref-link-section-d59023944e2392">32</a></sup>, FoxP3 (1/100, 5 μg ml<sup>−1</sup>; <a href="https://www.thermofisher.com/antibody/product/FOXP3-Antibody-clone-236A-E7-Monoclonal/14-4777-82">https://www.thermofisher.com/antibody/product/FOXP3-Antibody-clone-236A-E7-Monoclonal/14-4777-82</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 64" title="Syed Khaja, A. S. et al. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. Oncotarget 8, 33159–33171 (2017)." href="/articles/s41591-022-01916-x#ref-CR64" id="ref-link-section-d59023944e2405">64</a></sup>, TOX (1/100, 10 μg ml<sup>−1</sup>; <a href="https://www.abcam.com/tox-antibody-nan448b-ab237009.html">https://www.abcam.com/tox-antibody-nan448b-ab237009.html</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 65" title="Maestre, L. et al. High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations. PLoS ONE 15, e0229743 (2020)." href="/articles/s41591-022-01916-x#ref-CR65" id="ref-link-section-d59023944e2419">65</a></sup>, EZH2 (1/800, 0.53 μg ml<sup>−1</sup>; <a href="https://www.cellsignal.com/products/primary-antibodies/ezh2-d2c9-xp-rabbit-mab/5246">https://www.cellsignal.com/products/primary-antibodies/ezh2-d2c9-xp-rabbit-mab/5246</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 66" title="Liu, W. et al. Prognostic value of MTA1, SOX4 and EZH2 expression in esophageal squamous cell carcinoma. Exp. Ther. Med. 22, 722 (2021)." href="/articles/s41591-022-01916-x#ref-CR66" id="ref-link-section-d59023944e2432">66</a></sup>, LOX1 (1/800, 1.25 μg ml<sup>−1</sup>; <a href="https://www.merckmillipore.com/FR/fr/product/Anti-LOX-1-clone-9E12.1,MM_NF-MABS186">https://www.merckmillipore.com/FR/fr/product/Anti-LOX-1-clone-9E12.1,MM_NF-MABS186</a>), CD68 (1/1,000, 0.7 μg ml<sup>−1</sup>; <a href="https://www.abcam.com/cd68-antibody-epr20545-ab213363.html">https://www.abcam.com/cd68-antibody-epr20545-ab213363.html</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 67" title="Yuan, J. et al. Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients. Cancer Cell Int. 19, 238 (2019)." href="/articles/s41591-022-01916-x#ref-CR67" id="ref-link-section-d59023944e2455">67</a></sup>, CD11b (1/200, 0.5 μg ml<sup>−1</sup>; <a href="https://www.cellsignal.com/products/primary-antibodies/cd11b-itgam-d6x1n-rabbit-mab/49420">https://www.cellsignal.com/products/primary-antibodies/cd11b-itgam-d6x1n-rabbit-mab/49420</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 68" title="Xia, S. et al. SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. Cell Death Dis. 12, 570 (2021)." href="/articles/s41591-022-01916-x#ref-CR68" id="ref-link-section-d59023944e2469">68</a></sup>, CD14 (1/50, 0.07 μg ml<sup>−1</sup>; <a href="https://www.cellmarque.com/antibodies/CM/2066/CD14_EPR3653">https://www.cellmarque.com/antibodies/CM/2066/CD14_EPR3653</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 69" title="Marmey, B. et al. CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169− monocyte-derived cells in diffuse large B-cell lymphomas. Hum. Pathol. 37, 68–77 (2006)." href="/articles/s41591-022-01916-x#ref-CR69" id="ref-link-section-d59023944e2482">69</a></sup>, CD15 (1/100, 5 μg ml<sup>−1</sup>; <a href="https://www.bdbiosciences.com/en-us/search-results?searchKey=555400">https://www.bdbiosciences.com/en-us/search-results?searchKey=555400</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 70" title="Hashimoto, A. et al. Upregulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer. Clin. Cancer Res. 27, 5961–5978 (2021)." href="/articles/s41591-022-01916-x#ref-CR70" id="ref-link-section-d59023944e2496">70</a></sup> and S100A9 (1/16,666, 0.06 μg ml<sup>−1</sup>; <a href="https://cdn.origene.com/datasheet/um800066.pdf">https://cdn.origene.com/datasheet/um800066.pdf</a>). The primary antibodies were selected to cross-react on human tissues and were recommended by the suppliers for IHC on FFPE tissues. Supporting literature regarding antibody specificity is found in the suppliers’ documentation. For Immunoscore testing, the specificity of the selected primary antibodies was verified using human tonsil as positive tissue for targeted immune biomarkers. Simplex IHC protocol was further optimized for each biomarker using DLBCL FFPE samples before the multiplex IHC.</p><h3 class="c-article__sub-heading" id="Sec15">Targeted transcriptomics analysis and Immunosign scores</h3><p>RNA was extracted from frozen or fixed biopsy specimens using a QIAGEN RNeasy kit or QIAGEN RNeasy FFPE extraction kit, respectively. Annotations from the pathologist performing the H&amp;E staining were used to guide removal of normal tissue from the slides by microdissection before RNA extraction, which occurred after tissue deparaffinization and lysis. Each RNA extraction was independently quantified (NanoDrop) and qualified (Agilent Bioanalyzer). Degradation assessment was quantified as the percentage of RNA fragments smaller than 300 base pairs (Agilent Bioanalyzer, RNA 6000 Nano Kit). The qualification assessments (RNA quantity or quality) were informative but not used as acceptance criteria, except for samples that did not meet the minimum RNA input requirements. When needed, overdiluted RNA was concentrated using the clean-up approach from QIAGEN RNeasy kit protocols. Good sample quality was defined as &lt;50% of RNA fragments of 50–300 base pairs in size. All the extracted RNA was tested independent of the concentration or the degradation rate. One RNA QC sample was included in each testing run as a positive control for extraction.</p><p>RNA expression profiling was performed using one standard panel (PanCancer human Immuno-Oncology 360 Panel) and two custom NanoString panels (Supplementary Tables <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">4</a> and <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">5</a>). After data normalization and analysis, a high or low Immunosign score cutoff was arbitrarily defined as the 25th percentile of the observed scores among samples, and gene expression levels for 21 pre-specified genes were compositely scored as Immunosign 21 (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig12">6a</a>). High scores indicated expression of immune-related genes that were potentially associated with tumor response. Univariate and multivariate analyses were performed to determine whether pre-treatment tumor or immune features influence clinical responses.</p><p>The determination of the COO subtypes of DLBCL was performed following transcriptomic<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 71" title="Scott, D. W. et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123, 1214–1217 (2014)." href="/articles/s41591-022-01916-x#ref-CR71" id="ref-link-section-d59023944e2533">71</a></sup> (lymph2Cx) or proteomic (Hans algorithm) methods in place in patient care centers.</p><h3 class="c-article__sub-heading" id="Sec16">IHC, Immunoscore TL, Immunoscore TCE, Immunoscore TCE<sup>+</sup> and Immunoscore SC</h3><p>H&amp;E staining allowed preliminary tissue evaluation for FFPE block QC. Slides were scanned with the NanoZoomer-XR to generate digital images (×20). A pathologist identified the tumor area and provided qualitative and semi-quantitative assessments. CD19 IHC staining (LE-CD19) was scored by composite H-score (0–5 = ‘No’; 6–300 = ‘Yes’).</p><p>Results of the Immunoscore TL assay, which measures the density of CD8<sup>+</sup> Tc cells and CD3<sup>+</sup> T cells in resected or biopsied cancer samples, are expressed as a score determined by a percentile approach<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 72" title="Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006)." href="/articles/s41591-022-01916-x#ref-CR72" id="ref-link-section-d59023944e2555">72</a></sup>. Consecutive FFPE slices (4 µm) were immunostained using a qualified BenchMark XT in accordance with the following workflow and reagents: antigen retrieval; staining with primary antibody CD3, HDX2 or CD8, HDX1 or HalioDx/Veracyte SAS; detection with a secondary antibody using an ultraView Universal DAB Detection Kit (Roche, 760-500); and counterstaining using the hematoxylin and bluing reagent Hematoxylin II (Roche, 790-2208). Control slides were systematically included in each staining run to permit QC of the obtained measurements. After coverslipping, slides were scanned with the NanoZoomer-XR to generate digital images (×20) and were analyzed in parallel by two independent, qualified operators. CD3 and CD8 IHC staining (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig9">3ab</a>) was scored and converted into an Immunoscore using the HalioDx/Veracyte algorithm.</p><p>The Immunoscore TCE (CD3, CD8, FoxP3, PD-1, LAG-3 and TIM-3; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig9">3c</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">9</a>) and SC (CD11b, CD14, CD15, CD68, S100A9 and LOX-1; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig9">3d</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">9</a>) sequential IHC panels were performed to measure 14 myeloid and T cell subsets using FFPE biopsy specimens. The Immunoscore TCE<sup>+</sup> sequential IHC panel (CD3, CD8, FoxP3, PD-1, LAG-3, TIM-3, TOX and EZH2; Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig9">3</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig10">4</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">9</a>) was performed to measure 37 T cell subsets (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">9</a>). Phenotype consistency between TCE and TCE<sup>+</sup> stainings was demonstrated using eight samples that overlapped between the TCE and TCE<sup>+</sup> panels (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01916-x#Fig11">5c</a>). Successive stainings were performed on the same slide using a Leica Bond RX and the antibodies listed in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">13</a>. For the TCE and TCE<sup>+</sup> panels, signal detection was performed using MACH 2 rabbit universal horseradish peroxidase polymer or MACH 2 mouse universal horseradish peroxidase polymer as secondary antibody and ImmPACT AMEC Red substrate detection. Counterstaining of cellular nuclei using hematoxylin was performed at the end of each staining workflow. One control slide was systematically included in each run to permit QC of the obtained measurements using qualitative acceptance criteria (specificity, staining location (nucleus/membrane), cell type and lack of background or unspecific staining). After each individual staining, coverslipping was performed automatically by the workstation CTM6 with aqueous mounting. Slides were scanned with the NanoZoomer-XR (×20), and a visual QC permitted qualification. Coverslips were carefully removed from slides using a warm water bath; slides were AMEC-destained by ethanol; and antibodies were stripped with denaturing solution. Each sample was analyzed using a HalioDx Digital Pathology Platform. Images were aligned with Brightplex-fuse (in-house software). Tumor areas were identified using annotation tools; subsequently, positively stained cells were detected and quantified in the selected regions of interest using HALO software (Indica Labs). Phenotypes of stained cells were visually verified according to expected staining and analyzed with Brightplex MultiplexR (in-house software).</p><h3 class="c-article__sub-heading" id="Sec17">Statistics and reproducibility</h3><p>No valid data were excluded from the analyses.</p><p>All statistical analysis and graphics were performed using R (version 4.0.3) and R Studio (version 1.3.1093) software. <i>t</i>-tests, exact Fisher tests, Wilcoxon tests, Kruskal–Wallis tests and Spearman correlation tests were evaluated using R built-in stats library. Heat maps were performed using the library ComplexHeatmap (version 2.4.3); box plots and scatter plots were performed using the library ggpubr (version 0.4.0); Cox proportional hazards regression was performed using the library survival (version 3.2.7); and Kaplan–Meier plots were performed using the library survminer (version 0.4.8). For each box plot, the lower bond, center and higher bond of the box are 25th (Q1), 50th (median) and 75th (Q3) percentiles, respectively. The boundaries of the whiskers are found within the 1.5 interquartile range (IQR) value (where IQR = Q3 − Q1). From above the upper quartile (Q3), a distance of 1.5 times the IQR is measured out, and a whisker (max.whisker) is drawn up to the largest observed data point from the dataset that falls within this distance. Similarly, a distance of 1.5 times the IQR is measured out below the lower quartile (Q1), and a whisker (min.whisker) is drawn down to the lowest observed data point from the dataset that falls within this distance. The box plot statistics are shown in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">14</a>.</p><h3 class="c-article__sub-heading" id="Sec18">Reporting summary</h3><p>Further information on research design is available in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM2">Nature Research Reporting Summary</a> linked to this article.</p></div></div></section>
                    
                </div>
            

            <div class="u-mt-32">
                <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content">
              
              <p>Clinical response data and demographics/patient characteristics for ZUMA-1 are available in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">1</a>, and demographics/patient characteristics for ZUMA-7 are available in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">2</a>. Patient-related data not included in the paper were generated as part of clinical trials and may be subject to patient confidentiality. Any data and materials that can be shared will be released via a material transfer agreement. Correlations between pre-treatment gene expression of cytokines and cytokine-responsive transcription factors and T cell markers in ZUMA-1 patients who achieved CR are available in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">6</a>. Correlations between pre-treatment gene expression of cytokines and cytokine-responsive transcription factors and T cell markers in ZUMA-1 patients who achieved OR are available in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">7</a>. Correlations between pre-treatment gene expression of cytokines and cytokine-responsive transcription factors and T cell markers in ZUMA-1 patients who did not achieve CR or OR are available in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">8</a>. Differential gene expression by pathway in pre-treatment tumor biopsies of axi-cel responders versus non-responders are available in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01916-x#MOESM1">12</a>. The NanoString data from ZUMA-1 patients discussed in this publication have been deposited in the National Center of Biotechnology Information Gene Expression Omnibus (GEO) and are accessible through GEO Series with the following accession number and access code: <a href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE197977">GSE197977</a> and chuhmyuidlwrdiv.</p>
            </div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Jensen, M. C. &amp; Riddell, S. R. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. <i>Immunol. Rev.</i> <b>257</b>, 127–144 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1111/imr.12139" data-track-item_id="10.1111/imr.12139" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1111%2Fimr.12139" aria-label="Article reference 1" data-doi="10.1111/imr.12139">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXhvFequrjE" aria-label="CAS reference 1">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24329794" aria-label="PubMed reference 1">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991306" aria-label="PubMed Central reference 1">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=Design%20and%20implementation%20of%20adoptive%20therapy%20with%20chimeric%20antigen%20receptor-modified%20T%20cells&amp;journal=Immunol.%20Rev.&amp;doi=10.1111%2Fimr.12139&amp;volume=257&amp;pages=127-144&amp;publication_year=2014&amp;author=Jensen%2CMC&amp;author=Riddell%2CSR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Yang, J. C. &amp; Rosenberg, S. A. Adoptive T-cell therapy for cancer. <i>Adv. Immunol.</i> <b>130</b>, 279–294 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/bs.ai.2015.12.006" data-track-item_id="10.1016/bs.ai.2015.12.006" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fbs.ai.2015.12.006" aria-label="Article reference 2" data-doi="10.1016/bs.ai.2015.12.006">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXotVGqsLY%3D" aria-label="CAS reference 2">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26923004" aria-label="PubMed reference 2">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293459" aria-label="PubMed Central reference 2">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=Adoptive%20T-cell%20therapy%20for%20cancer&amp;journal=Adv.%20Immunol.&amp;doi=10.1016%2Fbs.ai.2015.12.006&amp;volume=130&amp;pages=279-294&amp;publication_year=2016&amp;author=Yang%2CJC&amp;author=Rosenberg%2CSA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">Dunbar, C.E. et al. Gene therapy comes of age. <i>Science</i> <b>359</b>, eaan4672 (2018).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. &amp; Milone, M. C. CAR T cell immunotherapy for human cancer. <i>Science</i> <b>359</b>, 1361–1365 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/science.aar6711" data-track-item_id="10.1126/science.aar6711" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.aar6711" aria-label="Article reference 4" data-doi="10.1126/science.aar6711">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXltFehtb4%3D" aria-label="CAS reference 4">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29567707" aria-label="PubMed reference 4">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=CAR%20T%20cell%20immunotherapy%20for%20human%20cancer&amp;journal=Science&amp;doi=10.1126%2Fscience.aar6711&amp;volume=359&amp;pages=1361-1365&amp;publication_year=2018&amp;author=June%2CCH&amp;author=O%E2%80%99Connor%2CRS&amp;author=Kawalekar%2COU&amp;author=Ghassemi%2CS&amp;author=Milone%2CMC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. <i>Lancet Oncol.</i> <b>20</b>, 31–42 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(18)30864-7" data-track-item_id="10.1016/S1470-2045(18)30864-7" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2818%2930864-7" aria-label="Article reference 5" data-doi="10.1016/S1470-2045(18)30864-7">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXisVSgt7bE" aria-label="CAS reference 5">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30518502" aria-label="PubMed reference 5">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Long-term%20safety%20and%20activity%20of%20axicabtagene%20ciloleucel%20in%20refractory%20large%20B-cell%20lymphoma%20%28ZUMA-1%29%3A%20a%20single-arm%2C%20multicentre%2C%20phase%201-2%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2818%2930864-7&amp;volume=20&amp;pages=31-42&amp;publication_year=2019&amp;author=Locke%2CFL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Fu, K. et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. <i>J. Clin. Oncol.</i> <b>26</b>, 4587–4594 (2008).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2007.15.9277" data-track-item_id="10.1200/JCO.2007.15.9277" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2007.15.9277" aria-label="Article reference 6" data-doi="10.1200/JCO.2007.15.9277">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXht1KqtLfI" aria-label="CAS reference 6">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18662967" aria-label="PubMed reference 6">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Addition%20of%20rituximab%20to%20standard%20chemotherapy%20improves%20the%20survival%20of%20both%20the%20germinal%20center%20B-cell-like%20and%20non-germinal%20center%20B-cell-like%20subtypes%20of%20diffuse%20large%20B-cell%20lymphoma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2007.15.9277&amp;volume=26&amp;pages=4587-4594&amp;publication_year=2008&amp;author=Fu%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Carbone, A., Gloghini, A., Kwong, Y. L. &amp; Younes, A. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. <i>Ann. Hematol.</i> <b>93</b>, 1263–1277 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s00277-014-2116-y" data-track-item_id="10.1007/s00277-014-2116-y" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00277-014-2116-y" aria-label="Article reference 7" data-doi="10.1007/s00277-014-2116-y">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXoslCkurY%3D" aria-label="CAS reference 7">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24870942" aria-label="PubMed reference 7">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082139" aria-label="PubMed Central reference 7">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Diffuse%20large%20B%20cell%20lymphoma%3A%20using%20pathologic%20and%20molecular%20biomarkers%20to%20define%20subgroups%20for%20novel%20therapy&amp;journal=Ann.%20Hematol.&amp;doi=10.1007%2Fs00277-014-2116-y&amp;volume=93&amp;pages=1263-1277&amp;publication_year=2014&amp;author=Carbone%2CA&amp;author=Gloghini%2CA&amp;author=Kwong%2CYL&amp;author=Younes%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Locke, F. L. et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. <i>Mol. Ther.</i> <b>25</b>, 285–295 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ymthe.2016.10.020" data-track-item_id="10.1016/j.ymthe.2016.10.020" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ymthe.2016.10.020" aria-label="Article reference 8" data-doi="10.1016/j.ymthe.2016.10.020">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXmvFCmtbg%3D" aria-label="CAS reference 8">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28129122" aria-label="PubMed reference 8">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363293" aria-label="PubMed Central reference 8">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%201%20results%20of%20ZUMA-1%3A%20a%20multicenter%20study%20of%20KTE-C19%20anti-CD19%20CAR%20T%20cell%20therapy%20in%20refractory%20aggressive%20lymphoma&amp;journal=Mol.%20Ther.&amp;doi=10.1016%2Fj.ymthe.2016.10.020&amp;volume=25&amp;pages=285-295&amp;publication_year=2017&amp;author=Locke%2CFL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Galon, J., Fridman, W. H. &amp; Pages, F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. <i>Cancer Res.</i> <b>67</b>, 1883–1886 (2007).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/0008-5472.CAN-06-4806" data-track-item_id="10.1158/0008-5472.CAN-06-4806" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F0008-5472.CAN-06-4806" aria-label="Article reference 9" data-doi="10.1158/0008-5472.CAN-06-4806">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2sXit12qtbo%3D" aria-label="CAS reference 9">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17332313" aria-label="PubMed reference 9">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20adaptive%20immunologic%20microenvironment%20in%20colorectal%20cancer%3A%20a%20novel%20perspective&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-06-4806&amp;volume=67&amp;pages=1883-1886&amp;publication_year=2007&amp;author=Galon%2CJ&amp;author=Fridman%2CWH&amp;author=Pages%2CF">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Galon, J. et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. <i>J. Transl. Med.</i> <b>14</b>, 273 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s12967-016-1029-z" data-track-item_id="10.1186/s12967-016-1029-z" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s12967-016-1029-z" aria-label="Article reference 10" data-doi="10.1186/s12967-016-1029-z">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC2svis1Shuw%3D%3D" aria-label="CAS reference 10">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27650038" aria-label="PubMed reference 10">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029056" aria-label="PubMed Central reference 10">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=Immunoscore%20and%20Immunoprofiling%20in%20cancer%3A%20an%20update%20from%20the%20melanoma%20and%20immunotherapy%20bridge%202015&amp;journal=J.%20Transl.%20Med.&amp;doi=10.1186%2Fs12967-016-1029-z&amp;volume=14&amp;publication_year=2016&amp;author=Galon%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Spranger, S. &amp; Gajewski, T. F. Impact of oncogenic pathways on evasion of antitumour immune responses. <i>Nat. Rev. Cancer</i> <b>18</b>, 139–147 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nrc.2017.117" data-track-item_id="10.1038/nrc.2017.117" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnrc.2017.117" aria-label="Article reference 11" data-doi="10.1038/nrc.2017.117">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXnvVKgsw%3D%3D" aria-label="CAS reference 11">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29326431" aria-label="PubMed reference 11">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685071" aria-label="PubMed Central reference 11">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Impact%20of%20oncogenic%20pathways%20on%20evasion%20of%20antitumour%20immune%20responses&amp;journal=Nat.%20Rev.%20Cancer&amp;doi=10.1038%2Fnrc.2017.117&amp;volume=18&amp;pages=139-147&amp;publication_year=2018&amp;author=Spranger%2CS&amp;author=Gajewski%2CTF">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">Angelova, M. et al. Evolution of metastases in space and time under immune selection. <i>Cell</i> <b>175</b>, 751–765 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2018.09.018" data-track-item_id="10.1016/j.cell.2018.09.018" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2018.09.018" aria-label="Article reference 12" data-doi="10.1016/j.cell.2018.09.018">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvFSqsrvM" aria-label="CAS reference 12">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30318143" aria-label="PubMed reference 12">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=Evolution%20of%20metastases%20in%20space%20and%20time%20under%20immune%20selection&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2018.09.018&amp;volume=175&amp;pages=751-765&amp;publication_year=2018&amp;author=Angelova%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Bedognetti, D. et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. <i>J. Immunother. Cancer</i> <b>7</b>, 131 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s40425-019-0602-4" data-track-item_id="10.1186/s40425-019-0602-4" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s40425-019-0602-4" aria-label="Article reference 13" data-doi="10.1186/s40425-019-0602-4">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31113486" aria-label="PubMed reference 13">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529999" aria-label="PubMed Central reference 13">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=Toward%20a%20comprehensive%20view%20of%20cancer%20immune%20responsiveness%3A%20a%20synopsis%20from%20the%20SITC%20workshop&amp;journal=J.%20Immunother.%20Cancer&amp;doi=10.1186%2Fs40425-019-0602-4&amp;volume=7&amp;publication_year=2019&amp;author=Bedognetti%2CD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Mascaux, C. et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. <i>Nature</i> <b>571</b>, 570–575 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41586-019-1330-0" data-track-item_id="10.1038/s41586-019-1330-0" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41586-019-1330-0" aria-label="Article reference 14" data-doi="10.1038/s41586-019-1330-0">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXht1yktL7N" aria-label="CAS reference 14">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31243362" aria-label="PubMed reference 14">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Immune%20evasion%20before%20tumour%20invasion%20in%20early%20lung%20squamous%20carcinogenesis&amp;journal=Nature&amp;doi=10.1038%2Fs41586-019-1330-0&amp;volume=571&amp;pages=570-575&amp;publication_year=2019&amp;author=Mascaux%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Galon, J. &amp; Bruni, D. Tumor immunology and tumor evolution: intertwined histories. <i>Immunity</i> <b>52</b>, 55–81 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.immuni.2019.12.018" data-track-item_id="10.1016/j.immuni.2019.12.018" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.immuni.2019.12.018" aria-label="Article reference 15" data-doi="10.1016/j.immuni.2019.12.018">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXnslWksbY%3D" aria-label="CAS reference 15">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31940273" aria-label="PubMed reference 15">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20immunology%20and%20tumor%20evolution%3A%20intertwined%20histories&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2019.12.018&amp;volume=52&amp;pages=55-81&amp;publication_year=2020&amp;author=Galon%2CJ&amp;author=Bruni%2CD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Bindea, G., Mlecnik, B., Angell, H. K. &amp; Galon, J. The immune landscape of human tumors: implications for cancer immunotherapy. <i>Oncoimmunology</i> <b>3</b>, e27456 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4161/onci.27456" data-track-item_id="10.4161/onci.27456" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4161%2Fonci.27456" aria-label="Article reference 16" data-doi="10.4161/onci.27456">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24800163" aria-label="PubMed reference 16">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006852" aria-label="PubMed Central reference 16">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20immune%20landscape%20of%20human%20tumors%3A%20implications%20for%20cancer%20immunotherapy&amp;journal=Oncoimmunology&amp;doi=10.4161%2Fonci.27456&amp;volume=3&amp;publication_year=2014&amp;author=Bindea%2CG&amp;author=Mlecnik%2CB&amp;author=Angell%2CHK&amp;author=Galon%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Kirilovsky, A. et al. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. <i>Int. Immunol.</i> <b>28</b>, 373–382 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/intimm/dxw021" data-track-item_id="10.1093/intimm/dxw021" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fintimm%2Fdxw021" aria-label="Article reference 17" data-doi="10.1093/intimm/dxw021">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28Xhs1Ontr3E" aria-label="CAS reference 17">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27121213" aria-label="PubMed reference 17">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986234" aria-label="PubMed Central reference 17">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Rational%20bases%20for%20the%20use%20of%20the%20Immunoscore%20in%20routine%20clinical%20settings%20as%20a%20prognostic%20and%20predictive%20biomarker%20in%20cancer%20patients&amp;journal=Int.%20Immunol.&amp;doi=10.1093%2Fintimm%2Fdxw021&amp;volume=28&amp;pages=373-382&amp;publication_year=2016&amp;author=Kirilovsky%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Pages, F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet</i> <b>391</b>, 2128–2139 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(18)30789-X" data-track-item_id="10.1016/S0140-6736(18)30789-X" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2818%2930789-X" aria-label="Article reference 18" data-doi="10.1016/S0140-6736(18)30789-X">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29754777" aria-label="PubMed reference 18">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=International%20validation%20of%20the%20consensus%20Immunoscore%20for%20the%20classification%20of%20colon%20cancer%3A%20a%20prognostic%20and%20accuracy%20study&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2818%2930789-X&amp;volume=391&amp;pages=2128-2139&amp;publication_year=2018&amp;author=Pages%2CF">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Van den Eynde, M. et al. The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients. <i>Cancer Cell</i> <b>34</b>, 1012–1026 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ccell.2018.11.003" data-track-item_id="10.1016/j.ccell.2018.11.003" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ccell.2018.11.003" aria-label="Article reference 19" data-doi="10.1016/j.ccell.2018.11.003">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30537506" aria-label="PubMed reference 19">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20link%20between%20the%20multiverse%20of%20immune%20microenvironments%20in%20metastases%20and%20the%20survival%20of%20colorectal%20cancer%20patients&amp;journal=Cancer%20Cell&amp;doi=10.1016%2Fj.ccell.2018.11.003&amp;volume=34&amp;pages=1012-1026&amp;publication_year=2018&amp;author=Eynde%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Angell, H. K., Bruni, D., Barrett, J. C., Herbst, R. &amp; Galon, J. The Immunoscore: colon cancer and beyond. <i>Clin. Cancer Res.</i> <b>26</b>, 332–339 (2019).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Yomoda, T. et al. The Immunoscore is a superior prognostic tool in stages II and III colorectal cancer and is significantly correlated with programmed death-ligand 1 (PD-L1) expression on tumor-infiltrating mononuclear cells. <i>Ann. Surg. Oncol.</i> <b>26</b>, 415–424 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1245/s10434-018-07110-z" data-track-item_id="10.1245/s10434-018-07110-z" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1245%2Fs10434-018-07110-z" aria-label="Article reference 21" data-doi="10.1245/s10434-018-07110-z">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30569297" aria-label="PubMed reference 21">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20Immunoscore%20is%20a%20superior%20prognostic%20tool%20in%20stages%20II%20and%20III%20colorectal%20cancer%20and%20is%20significantly%20correlated%20with%20programmed%20death-ligand%201%20%28PD-L1%29%20expression%20on%20tumor-infiltrating%20mononuclear%20cells&amp;journal=Ann.%20Surg.%20Oncol.&amp;doi=10.1245%2Fs10434-018-07110-z&amp;volume=26&amp;pages=415-424&amp;publication_year=2019&amp;author=Yomoda%2CT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Bruni, D., Angell, H. K. &amp; Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. <i>Nat. Rev. Cancer</i> <b>20</b>, 662–680 (2020).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Sharma, P. et al. The next decade of immune checkpoint therapy. <i>Cancer Discov.</i> <b>11</b>, 838–857 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-20-1680" data-track-item_id="10.1158/2159-8290.CD-20-1680" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-20-1680" aria-label="Article reference 23" data-doi="10.1158/2159-8290.CD-20-1680">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtlKqurbN" aria-label="CAS reference 23">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33811120" aria-label="PubMed reference 23">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20next%20decade%20of%20immune%20checkpoint%20therapy&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-20-1680&amp;volume=11&amp;pages=838-857&amp;publication_year=2021&amp;author=Sharma%2CP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. <i>N. Engl. J. Med.</i> <b>377</b>, 2531–2544 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1707447" data-track-item_id="10.1056/NEJMoa1707447" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1707447" aria-label="Article reference 24" data-doi="10.1056/NEJMoa1707447">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVGjtbw%3D" aria-label="CAS reference 24">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29226797" aria-label="PubMed reference 24">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882485" aria-label="PubMed Central reference 24">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=Axicabtagene%20ciloleucel%20CAR%20T-cell%20therapy%20in%20refractory%20large%20B-cell%20lymphoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1707447&amp;volume=377&amp;pages=2531-2544&amp;publication_year=2017&amp;author=Neelapu%2CSS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. <i>N. Engl. J. Med.</i> <b>386</b>, 640–654 (2021).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells associate with CAR T-cell failure in large B-cell lymphoma. <i>Blood</i> <b>137</b>, 2621–2633 (2021).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Moschella, F. et al. Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients’ blood cells: implications for cancer chemoimmunotherapy. <i>Clin. Cancer Res.</i> <b>19</b>, 4249–4261 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-12-3666" data-track-item_id="10.1158/1078-0432.CCR-12-3666" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-12-3666" aria-label="Article reference 27" data-doi="10.1158/1078-0432.CCR-12-3666">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXht1amt7zO" aria-label="CAS reference 27">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23759676" aria-label="PubMed reference 27">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=Cyclophosphamide%20induces%20a%20type%20I%20interferon-associated%20sterile%20inflammatory%20response%20signature%20in%20cancer%20patients%E2%80%99%20blood%20cells%3A%20implications%20for%20cancer%20chemoimmunotherapy&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-12-3666&amp;volume=19&amp;pages=4249-4261&amp;publication_year=2013&amp;author=Moschella%2CF">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">Stamenkovic, I. et al. The B cell antigen CD75 is a cell surface sialytransferase. <i>J. Exp. Med.</i> <b>172</b>, 641–643 (1990).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1084/jem.172.2.641" data-track-item_id="10.1084/jem.172.2.641" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1084%2Fjem.172.2.641" aria-label="Article reference 28" data-doi="10.1084/jem.172.2.641">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK3cXmtV2ntL8%3D" aria-label="CAS reference 28">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=2373995" aria-label="PubMed reference 28">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20B%20cell%20antigen%20CD75%20is%20a%20cell%20surface%20sialytransferase&amp;journal=J.%20Exp.%20Med.&amp;doi=10.1084%2Fjem.172.2.641&amp;volume=172&amp;pages=641-643&amp;publication_year=1990&amp;author=Stamenkovic%2CI">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Okuyama, K. et al. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia. <i>PLoS Genet.</i> <b>15</b>, e1008280 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pgen.1008280" data-track-item_id="10.1371/journal.pgen.1008280" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pgen.1008280" aria-label="Article reference 29" data-doi="10.1371/journal.pgen.1008280">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtFKmtb0%3D" aria-label="CAS reference 29">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31381561" aria-label="PubMed reference 29">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695195" aria-label="PubMed Central reference 29">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=PAX5%20is%20part%20of%20a%20functional%20transcription%20factor%20network%20targeted%20in%20lymphoid%20leukemia&amp;journal=PLoS%20Genet.&amp;doi=10.1371%2Fjournal.pgen.1008280&amp;volume=15&amp;publication_year=2019&amp;author=Okuyama%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Park, H. Y. et al. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma. <i>Oncotarget</i> <b>7</b>, 86433–86445 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.18632/oncotarget.13239" data-track-item_id="10.18632/oncotarget.13239" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.18632%2Foncotarget.13239" aria-label="Article reference 30" data-doi="10.18632/oncotarget.13239">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27835906" aria-label="PubMed reference 30">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349924" aria-label="PubMed Central reference 30">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=Whole-exome%20and%20transcriptome%20sequencing%20of%20refractory%20diffuse%20large%20B-cell%20lymphoma&amp;journal=Oncotarget&amp;doi=10.18632%2Foncotarget.13239&amp;volume=7&amp;pages=86433-86445&amp;publication_year=2016&amp;author=Park%2CHY">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Whitehurst, A. W. Cause and consequence of cancer/testis antigen activation in cancer. <i>Annu. Rev. Pharmacol. Toxicol.</i> <b>54</b>, 251–272 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1146/annurev-pharmtox-011112-140326" data-track-item_id="10.1146/annurev-pharmtox-011112-140326" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1146%2Fannurev-pharmtox-011112-140326" aria-label="Article reference 31" data-doi="10.1146/annurev-pharmtox-011112-140326">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXjsVSqtrc%3D" aria-label="CAS reference 31">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24160706" aria-label="PubMed reference 31">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Cause%20and%20consequence%20of%20cancer%2Ftestis%20antigen%20activation%20in%20cancer&amp;journal=Annu.%20Rev.%20Pharmacol.%20Toxicol.&amp;doi=10.1146%2Fannurev-pharmtox-011112-140326&amp;volume=54&amp;pages=251-272&amp;publication_year=2014&amp;author=Whitehurst%2CAW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Autio, M. et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. <i>Haematologica</i> <b>106</b>, 718–729 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3324/haematol.2019.243626" data-track-item_id="10.3324/haematol.2019.243626" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3324%2Fhaematol.2019.243626" aria-label="Article reference 32" data-doi="10.3324/haematol.2019.243626">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXnslyntLo%3D" aria-label="CAS reference 32">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32079690" aria-label="PubMed reference 32">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=Immune%20cell%20constitution%20in%20the%20tumor%20microenvironment%20predicts%20the%20outcome%20in%20diffuse%20large%20B-cell%20lymphoma&amp;journal=Haematologica&amp;doi=10.3324%2Fhaematol.2019.243626&amp;volume=106&amp;pages=718-729&amp;publication_year=2021&amp;author=Autio%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Angell, H. &amp; Galon, J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. <i>Curr. Opin. Immunol.</i> <b>25</b>, 261–267 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.coi.2013.03.004" data-track-item_id="10.1016/j.coi.2013.03.004" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.coi.2013.03.004" aria-label="Article reference 33" data-doi="10.1016/j.coi.2013.03.004">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXls1SntL8%3D" aria-label="CAS reference 33">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23579076" aria-label="PubMed reference 33">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=From%20the%20immune%20contexture%20to%20the%20Immunoscore%3A%20the%20role%20of%20prognostic%20and%20predictive%20immune%20markers%20in%20cancer&amp;journal=Curr.%20Opin.%20Immunol.&amp;doi=10.1016%2Fj.coi.2013.03.004&amp;volume=25&amp;pages=261-267&amp;publication_year=2013&amp;author=Angell%2CH&amp;author=Galon%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Adv.</i> <b>4</b>, 4898–4911 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/bloodadvances.2020002394" data-track-item_id="10.1182/bloodadvances.2020002394" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fbloodadvances.2020002394" aria-label="Article reference 34" data-doi="10.1182/bloodadvances.2020002394">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXis12ktrnP" aria-label="CAS reference 34">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33035333" aria-label="PubMed reference 34">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556133" aria-label="PubMed Central reference 34">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20burden%2C%20inflammation%2C%20and%20product%20attributes%20determine%20outcomes%20of%20axicabtagene%20ciloleucel%20in%20large%20B-cell%20lymphoma&amp;journal=Blood%20Adv.&amp;doi=10.1182%2Fbloodadvances.2020002394&amp;volume=4&amp;pages=4898-4911&amp;publication_year=2020&amp;author=Locke%2CFL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. <i>N. Engl. J. Med.</i> <b>359</b>, 2313–2323 (2008).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa0802885" data-track-item_id="10.1056/NEJMoa0802885" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa0802885" aria-label="Article reference 35" data-doi="10.1056/NEJMoa0802885">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXhsVehtbvF" aria-label="CAS reference 35">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19038878" aria-label="PubMed reference 35">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103713" aria-label="PubMed Central reference 35">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=Stromal%20gene%20signatures%20in%20large-B-cell%20lymphomas&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa0802885&amp;volume=359&amp;pages=2313-2323&amp;publication_year=2008&amp;author=Lenz%2CG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Liu, Y. &amp; Barta, S. K. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. <i>Am. J. Hematol.</i> <b>94</b>, 604–616 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/ajh.25460" data-track-item_id="10.1002/ajh.25460" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fajh.25460" aria-label="Article reference 36" data-doi="10.1002/ajh.25460">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXntVCnsLc%3D" aria-label="CAS reference 36">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30859597" aria-label="PubMed reference 36">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=Diffuse%20large%20B-cell%20lymphoma%3A%202019%20update%20on%20diagnosis%2C%20risk%20stratification%2C%20and%20treatment&amp;journal=Am.%20J.%20Hematol.&amp;doi=10.1002%2Fajh.25460&amp;volume=94&amp;pages=604-616&amp;publication_year=2019&amp;author=Liu%2CY&amp;author=Barta%2CSK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Galon, J. et al. Characterization of anti-CD19 chimeric antigen receptor (CAR) T-cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19). <i>J. Clin. Oncol.</i> <b>35</b>, 3025 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2017.35.15_suppl.3025" data-track-item_id="10.1200/JCO.2017.35.15_suppl.3025" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2017.35.15_suppl.3025" aria-label="Article reference 37" data-doi="10.1200/JCO.2017.35.15_suppl.3025">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=Characterization%20of%20anti-CD19%20chimeric%20antigen%20receptor%20%28CAR%29%20T-cell-mediated%20tumor%20microenvironment%20immune%20gene%20profile%20in%20a%20multicenter%20trial%20%28ZUMA-1%29%20with%20axicabtagene%20ciloleucel%20%28axi-cel%2C%20KTE-C19%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2017.35.15_suppl.3025&amp;volume=35&amp;publication_year=2017&amp;author=Galon%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38">Sugiyama, D. et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3<sup>+</sup>CD4<sup>+</sup> regulatory T cells, evoking antitumor immune responses in humans. <i>Proc. Natl Acad. Sci. USA</i> <b>110</b>, 17945–17950 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1073/pnas.1316796110" data-track-item_id="10.1073/pnas.1316796110" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1073%2Fpnas.1316796110" aria-label="Article reference 38" data-doi="10.1073/pnas.1316796110">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXhvVWmurzL" aria-label="CAS reference 38">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24127572" aria-label="PubMed reference 38">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816454" aria-label="PubMed Central reference 38">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=Anti-CCR4%20mAb%20selectively%20depletes%20effector-type%20FoxP3%2BCD4%2B%20regulatory%20T%20cells%2C%20evoking%20antitumor%20immune%20responses%20in%20humans&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.1316796110&amp;volume=110&amp;pages=17945-17950&amp;publication_year=2013&amp;author=Sugiyama%2CD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Mizukami, Y. et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3<sup>+</sup> regulatory T-cells in gastric cancer. <i>Int. J. Cancer</i> <b>122</b>, 2286–2293 (2008).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/ijc.23392" data-track-item_id="10.1002/ijc.23392" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fijc.23392" aria-label="Article reference 39" data-doi="10.1002/ijc.23392">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXkslyntr8%3D" aria-label="CAS reference 39">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18224687" aria-label="PubMed reference 39">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=CCL17%20and%20CCL22%20chemokines%20within%20tumor%20microenvironment%20are%20related%20to%20accumulation%20of%20Foxp3%2B%20regulatory%20T-cells%20in%20gastric%20cancer&amp;journal=Int.%20J.%20Cancer&amp;doi=10.1002%2Fijc.23392&amp;volume=122&amp;pages=2286-2293&amp;publication_year=2008&amp;author=Mizukami%2CY">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Kochenderfer, J. N. et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. <i>J. Clin. Oncol.</i> <b>35</b>, 1803–1813 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2016.71.3024" data-track-item_id="10.1200/JCO.2016.71.3024" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2016.71.3024" aria-label="Article reference 40" data-doi="10.1200/JCO.2016.71.3024">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvFSntLvO" aria-label="CAS reference 40">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28291388" aria-label="PubMed reference 40">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455597" aria-label="PubMed Central reference 40">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=Lymphoma%20remissions%20caused%20by%20anti-CD19%20chimeric%20antigen%20receptor%20T%20cells%20are%20associated%20with%20high%20serum%20interleukin-15%20levels&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2016.71.3024&amp;volume=35&amp;pages=1803-1813&amp;publication_year=2017&amp;author=Kochenderfer%2CJN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="41."><p class="c-article-references__text" id="ref-CR41">Conlon, K. C., Miljkovic, M. D. &amp; Waldmann, T. A. Cytokines in the treatment of cancer. <i>J. Interferon Cytokine Res.</i> <b>39</b>, 6–21 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1089/jir.2018.0019" data-track-item_id="10.1089/jir.2018.0019" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1089%2Fjir.2018.0019" aria-label="Article reference 41" data-doi="10.1089/jir.2018.0019">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXms1ehsg%3D%3D" aria-label="CAS reference 41">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29889594" aria-label="PubMed reference 41">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350412" aria-label="PubMed Central reference 41">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=Cytokines%20in%20the%20treatment%20of%20cancer&amp;journal=J.%20Interferon%20Cytokine%20Res.&amp;doi=10.1089%2Fjir.2018.0019&amp;volume=39&amp;pages=6-21&amp;publication_year=2019&amp;author=Conlon%2CKC&amp;author=Miljkovic%2CMD&amp;author=Waldmann%2CTA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="42."><p class="c-article-references__text" id="ref-CR42">Cappell, K. M. et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. <i>J. Clin. Oncol.</i> <b>38</b>, 3805–3815 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.20.01467" data-track-item_id="10.1200/JCO.20.01467" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.20.01467" aria-label="Article reference 42" data-doi="10.1200/JCO.20.01467">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXisVKls7nJ" aria-label="CAS reference 42">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33021872" aria-label="PubMed reference 42">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655016" aria-label="PubMed Central reference 42">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=Long-term%20follow-up%20of%20anti-CD19%20chimeric%20antigen%20receptor%20T-cell%20therapy&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.20.01467&amp;volume=38&amp;pages=3805-3815&amp;publication_year=2020&amp;author=Cappell%2CKM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="43."><p class="c-article-references__text" id="ref-CR43">Arpaia, N. et al. A distinct function of regulatory T cells in tissue protection. <i>Cell</i> <b>162</b>, 1078–1089 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2015.08.021" data-track-item_id="10.1016/j.cell.2015.08.021" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2015.08.021" aria-label="Article reference 43" data-doi="10.1016/j.cell.2015.08.021">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsVensLfO" aria-label="CAS reference 43">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26317471" aria-label="PubMed reference 43">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603556" aria-label="PubMed Central reference 43">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20distinct%20function%20of%20regulatory%20T%20cells%20in%20tissue%20protection&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2015.08.021&amp;volume=162&amp;pages=1078-1089&amp;publication_year=2015&amp;author=Arpaia%2CN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="44."><p class="c-article-references__text" id="ref-CR44">Campbell, C. &amp; Rudensky, A. Roles of regulatory T cells in tissue pathophysiology and metabolism. <i>Cell Metab.</i> <b>31</b>, 18–25 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cmet.2019.09.010" data-track-item_id="10.1016/j.cmet.2019.09.010" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cmet.2019.09.010" aria-label="Article reference 44" data-doi="10.1016/j.cmet.2019.09.010">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhvFKku7bE" aria-label="CAS reference 44">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31607562" aria-label="PubMed reference 44">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 44" href="http://scholar.google.com/scholar_lookup?&amp;title=Roles%20of%20regulatory%20T%20cells%20in%20tissue%20pathophysiology%20and%20metabolism&amp;journal=Cell%20Metab.&amp;doi=10.1016%2Fj.cmet.2019.09.010&amp;volume=31&amp;pages=18-25&amp;publication_year=2020&amp;author=Campbell%2CC&amp;author=Rudensky%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="45."><p class="c-article-references__text" id="ref-CR45">Okeke, E. B. &amp; Uzonna, J. E. The pivotal role of regulatory T cells in the regulation of innate immune cells. <i>Front. Immunol.</i> <b>10</b>, 680 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3389/fimmu.2019.00680" data-track-item_id="10.3389/fimmu.2019.00680" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3389%2Ffimmu.2019.00680" aria-label="Article reference 45" data-doi="10.3389/fimmu.2019.00680">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtlKhu7%2FJ" aria-label="CAS reference 45">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31024539" aria-label="PubMed reference 45">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465517" aria-label="PubMed Central reference 45">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20pivotal%20role%20of%20regulatory%20T%20cells%20in%20the%20regulation%20of%20innate%20immune%20cells&amp;journal=Front.%20Immunol.&amp;doi=10.3389%2Ffimmu.2019.00680&amp;volume=10&amp;publication_year=2019&amp;author=Okeke%2CEB&amp;author=Uzonna%2CJE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="46."><p class="c-article-references__text" id="ref-CR46">Galon, J., Angell, H. K., Bedognetti, D. &amp; Marincola, F. M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. <i>Immunity</i> <b>39</b>, 11–26 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.immuni.2013.07.008" data-track-item_id="10.1016/j.immuni.2013.07.008" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.immuni.2013.07.008" aria-label="Article reference 46" data-doi="10.1016/j.immuni.2013.07.008">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXhtFOhsbfL" aria-label="CAS reference 46">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23890060" aria-label="PubMed reference 46">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20continuum%20of%20cancer%20immunosurveillance%3A%20prognostic%2C%20predictive%2C%20and%20mechanistic%20signatures&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2013.07.008&amp;volume=39&amp;pages=11-26&amp;publication_year=2013&amp;author=Galon%2CJ&amp;author=Angell%2CHK&amp;author=Bedognetti%2CD&amp;author=Marincola%2CFM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="47."><p class="c-article-references__text" id="ref-CR47">Galon, J. &amp; Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. <i>Nat. Rev. Drug Discov.</i> <b>18</b>, 197–218 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41573-018-0007-y" data-track-item_id="10.1038/s41573-018-0007-y" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41573-018-0007-y" aria-label="Article reference 47" data-doi="10.1038/s41573-018-0007-y">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXlslKlsrw%3D" aria-label="CAS reference 47">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30610226" aria-label="PubMed reference 47">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 47" href="http://scholar.google.com/scholar_lookup?&amp;title=Approaches%20to%20treat%20immune%20hot%2C%20altered%20and%20cold%20tumours%20with%20combination%20immunotherapies&amp;journal=Nat.%20Rev.%20Drug%20Discov.&amp;doi=10.1038%2Fs41573-018-0007-y&amp;volume=18&amp;pages=197-218&amp;publication_year=2019&amp;author=Galon%2CJ&amp;author=Bruni%2CD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="48."><p class="c-article-references__text" id="ref-CR48">Chen, P. H. et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. <i>JCI Insight</i> <b>5</b>, e134612 (2020).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="49."><p class="c-article-references__text" id="ref-CR49">Coutinho, R. et al. Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. <i>Haematologica</i> <b>100</b>, 363–369 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3324/haematol.2014.110189" data-track-item_id="10.3324/haematol.2014.110189" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3324%2Fhaematol.2014.110189" aria-label="Article reference 49" data-doi="10.3324/haematol.2014.110189">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXks1CisLo%3D" aria-label="CAS reference 49">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25425693" aria-label="PubMed reference 49">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349275" aria-label="PubMed Central reference 49">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 49" href="http://scholar.google.com/scholar_lookup?&amp;title=Revisiting%20the%20immune%20microenvironment%20of%20diffuse%20large%20B-cell%20lymphoma%20using%20a%20tissue%20microarray%20and%20immunohistochemistry%3A%20robust%20semi-automated%20analysis%20reveals%20CD3%20and%20FoxP3%20as%20potential%20predictors%20of%20response%20to%20R-CHOP&amp;journal=Haematologica&amp;doi=10.3324%2Fhaematol.2014.110189&amp;volume=100&amp;pages=363-369&amp;publication_year=2015&amp;author=Coutinho%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="50."><p class="c-article-references__text" id="ref-CR50">Faramand, R. et al. Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Clin. Cancer Res.</i> <b>26</b>, 4823–4831 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-20-1434" data-track-item_id="10.1158/1078-0432.CCR-20-1434" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-20-1434" aria-label="Article reference 50" data-doi="10.1158/1078-0432.CCR-20-1434">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXisFSrsbfI" aria-label="CAS reference 50">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32669372" aria-label="PubMed reference 50">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501265" aria-label="PubMed Central reference 50">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 50" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20microenvironment%20composition%20and%20severe%20cytokine%20release%20syndrome%20%28CRS%29%20influence%20toxicity%20in%20patients%20with%20large%20B-cell%20lymphoma%20treated%20with%20axicabtagene%20ciloleucel&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-20-1434&amp;volume=26&amp;pages=4823-4831&amp;publication_year=2020&amp;author=Faramand%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="51."><p class="c-article-references__text" id="ref-CR51">Chou, C. K. &amp; Turtle, C. J. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. <i>Expert Opin. Biol. Ther.</i> <b>20</b>, 653–664 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1080/14712598.2020.1729735" data-track-item_id="10.1080/14712598.2020.1729735" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1080%2F14712598.2020.1729735" aria-label="Article reference 51" data-doi="10.1080/14712598.2020.1729735">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXjs1Oltrs%3D" aria-label="CAS reference 51">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32067497" aria-label="PubMed reference 51">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393694" aria-label="PubMed Central reference 51">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 51" href="http://scholar.google.com/scholar_lookup?&amp;title=Assessment%20and%20management%20of%20cytokine%20release%20syndrome%20and%20neurotoxicity%20following%20CD19%20CAR-T%20cell%20therapy&amp;journal=Expert%20Opin.%20Biol.%20Ther.&amp;doi=10.1080%2F14712598.2020.1729735&amp;volume=20&amp;pages=653-664&amp;publication_year=2020&amp;author=Chou%2CCK&amp;author=Turtle%2CCJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="52."><p class="c-article-references__text" id="ref-CR52">Anderson, K. G., Stromnes, I. M. &amp; Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. <i>Cancer Cell</i> <b>31</b>, 311–325 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ccell.2017.02.008" data-track-item_id="10.1016/j.ccell.2017.02.008" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ccell.2017.02.008" aria-label="Article reference 52" data-doi="10.1016/j.ccell.2017.02.008">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXksVeqsLw%3D" aria-label="CAS reference 52">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28292435" aria-label="PubMed reference 52">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423788" aria-label="PubMed Central reference 52">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 52" href="http://scholar.google.com/scholar_lookup?&amp;title=Obstacles%20posed%20by%20the%20tumor%20microenvironment%20to%20T%20cell%20activity%3A%20a%20case%20for%20synergistic%20therapies&amp;journal=Cancer%20Cell&amp;doi=10.1016%2Fj.ccell.2017.02.008&amp;volume=31&amp;pages=311-325&amp;publication_year=2017&amp;author=Anderson%2CKG&amp;author=Stromnes%2CIM&amp;author=Greenberg%2CPD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="53."><p class="c-article-references__text" id="ref-CR53">Lanitis, E., Coukos, G. &amp; Irving, M. All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy. <i>Curr. Opin. Biotechnol.</i> <b>65</b>, 75–87 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.copbio.2020.01.009" data-track-item_id="10.1016/j.copbio.2020.01.009" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.copbio.2020.01.009" aria-label="Article reference 53" data-doi="10.1016/j.copbio.2020.01.009">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXjtFWmu7g%3D" aria-label="CAS reference 53">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32109718" aria-label="PubMed reference 53">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 53" href="http://scholar.google.com/scholar_lookup?&amp;title=All%20systems%20go%3A%20converging%20synthetic%20biology%20and%20combinatorial%20treatment%20for%20CAR-T%20cell%20therapy&amp;journal=Curr.%20Opin.%20Biotechnol.&amp;doi=10.1016%2Fj.copbio.2020.01.009&amp;volume=65&amp;pages=75-87&amp;publication_year=2020&amp;author=Lanitis%2CE&amp;author=Coukos%2CG&amp;author=Irving%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="54."><p class="c-article-references__text" id="ref-CR54">Hudolin, T. et al. Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma. <i>J. Transl. Med.</i> <b>11</b>, 123 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/1479-5876-11-123" data-track-item_id="10.1186/1479-5876-11-123" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/1479-5876-11-123" aria-label="Article reference 54" data-doi="10.1186/1479-5876-11-123">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXptlyhsbs%3D" aria-label="CAS reference 54">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23680437" aria-label="PubMed reference 54">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663708" aria-label="PubMed Central reference 54">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 54" href="http://scholar.google.com/scholar_lookup?&amp;title=Immunohistochemical%20analysis%20of%20the%20expression%20of%20MAGE-A%20and%20NY-ESO-1%20cancer%2Ftestis%20antigens%20in%20diffuse%20large%20B-cell%20testicular%20lymphoma&amp;journal=J.%20Transl.%20Med.&amp;doi=10.1186%2F1479-5876-11-123&amp;volume=11&amp;publication_year=2013&amp;author=Hudolin%2CT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="55."><p class="c-article-references__text" id="ref-CR55">Teater, M. et al. AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. <i>Nat. Commun.</i> <b>9</b>, 222 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41467-017-02595-w" data-track-item_id="10.1038/s41467-017-02595-w" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-017-02595-w" aria-label="Article reference 55" data-doi="10.1038/s41467-017-02595-w">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29335468" aria-label="PubMed reference 55">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768781" aria-label="PubMed Central reference 55">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 55" href="http://scholar.google.com/scholar_lookup?&amp;title=AICDA%20drives%20epigenetic%20heterogeneity%20and%20accelerates%20germinal%20center-derived%20lymphomagenesis&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-017-02595-w&amp;volume=9&amp;publication_year=2018&amp;author=Teater%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="56."><p class="c-article-references__text" id="ref-CR56">Khan, O. et al. TOX transcriptionally and epigenetically programs CD8<sup>+</sup> T cell exhaustion. <i>Nature</i> <b>571</b>, 211–218 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41586-019-1325-x" data-track-item_id="10.1038/s41586-019-1325-x" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41586-019-1325-x" aria-label="Article reference 56" data-doi="10.1038/s41586-019-1325-x">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtlSms7bI" aria-label="CAS reference 56">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31207603" aria-label="PubMed reference 56">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713202" aria-label="PubMed Central reference 56">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 56" href="http://scholar.google.com/scholar_lookup?&amp;title=TOX%20transcriptionally%20and%20epigenetically%20programs%20CD8%2B%20T%20cell%20exhaustion&amp;journal=Nature&amp;doi=10.1038%2Fs41586-019-1325-x&amp;volume=571&amp;pages=211-218&amp;publication_year=2019&amp;author=Khan%2CO">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="57."><p class="c-article-references__text" id="ref-CR57">Brudno, J. N. et al. Safety and feasibility of anti-CD19 CAR T-cells with fully human binding domains in patients with B-cell lymphoma. <i>Nat. Med.</i> <b>26</b>, 270–280 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-019-0737-3" data-track-item_id="10.1038/s41591-019-0737-3" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-019-0737-3" aria-label="Article reference 57" data-doi="10.1038/s41591-019-0737-3">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXislensr8%3D" aria-label="CAS reference 57">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31959992" aria-label="PubMed reference 57">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781235" aria-label="PubMed Central reference 57">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 57" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%20and%20feasibility%20of%20anti-CD19%20CAR%20T-cells%20with%20fully%20human%20binding%20domains%20in%20patients%20with%20B-cell%20lymphoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-019-0737-3&amp;volume=26&amp;pages=270-280&amp;publication_year=2020&amp;author=Brudno%2CJN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="58."><p class="c-article-references__text" id="ref-CR58">Singh, N. et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. <i>Cancer Discov.</i> <b>10</b>, 552–567 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-19-0813" data-track-item_id="10.1158/2159-8290.CD-19-0813" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-19-0813" aria-label="Article reference 58" data-doi="10.1158/2159-8290.CD-19-0813">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXit1Cgt77E" aria-label="CAS reference 58">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32001516" aria-label="PubMed reference 58">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416790" aria-label="PubMed Central reference 58">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 58" href="http://scholar.google.com/scholar_lookup?&amp;title=Impaired%20death%20receptor%20signaling%20in%20leukemia%20causes%20antigen-independent%20resistance%20by%20inducing%20CAR%20T-cell%20dysfunction&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-19-0813&amp;volume=10&amp;pages=552-567&amp;publication_year=2020&amp;author=Singh%2CN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="59."><p class="c-article-references__text" id="ref-CR59">Upadhyay, R. et al. A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy. <i>Cancer Discov.</i> <b>11</b>, 599–613 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-20-0756" data-track-item_id="10.1158/2159-8290.CD-20-0756" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-20-0756" aria-label="Article reference 59" data-doi="10.1158/2159-8290.CD-20-0756">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXosV2hsbo%3D" aria-label="CAS reference 59">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33334730" aria-label="PubMed reference 59">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 59" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20critical%20role%20for%20Fas-mediated%20off-target%20tumor%20killing%20in%20T-cell%20immunotherapy&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-20-0756&amp;volume=11&amp;pages=599-613&amp;publication_year=2021&amp;author=Upadhyay%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="60."><p class="c-article-references__text" id="ref-CR60">Plaks, V. et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Blood</i> <b>138</b>, 1081–1085 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood.2021010930" data-track-item_id="10.1182/blood.2021010930" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood.2021010930" aria-label="Article reference 60" data-doi="10.1182/blood.2021010930">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXitFWgs7zE" aria-label="CAS reference 60">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34041526" aria-label="PubMed reference 60">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462361" aria-label="PubMed Central reference 60">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 60" href="http://scholar.google.com/scholar_lookup?&amp;title=CD19%20target%20evasion%20as%20a%20mechanism%20of%20relapse%20in%20large%20B-cell%20lymphoma%20treated%20with%20axicabtagene%20ciloleucel&amp;journal=Blood&amp;doi=10.1182%2Fblood.2021010930&amp;volume=138&amp;pages=1081-1085&amp;publication_year=2021&amp;author=Plaks%2CV">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="61."><p class="c-article-references__text" id="ref-CR61">Marliot, F. et al. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. <i>J. Immunother. Cancer</i> <b>8</b>, e000272 (2020).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="62."><p class="c-article-references__text" id="ref-CR62">Panda, A. et al. Immune activation and benefit from avelumab in EBV-positive gastric cancer. <i>J. Natl Cancer Inst.</i> <b>110</b>, 316–320 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/jnci/djx213" data-track-item_id="10.1093/jnci/djx213" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fjnci%2Fdjx213" aria-label="Article reference 62" data-doi="10.1093/jnci/djx213">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXpt1amtbc%3D" aria-label="CAS reference 62">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29155997" aria-label="PubMed reference 62">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 62" href="http://scholar.google.com/scholar_lookup?&amp;title=Immune%20activation%20and%20benefit%20from%20avelumab%20in%20EBV-positive%20gastric%20cancer&amp;journal=J.%20Natl%20Cancer%20Inst.&amp;doi=10.1093%2Fjnci%2Fdjx213&amp;volume=110&amp;pages=316-320&amp;publication_year=2018&amp;author=Panda%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="63."><p class="c-article-references__text" id="ref-CR63">Agocs, G. R. et al. LAG-3 expression predicts outcome in stage II colon cancer. <i>J. Pers. Med.</i> <b>11</b>, 749 (2021).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="64."><p class="c-article-references__text" id="ref-CR64">Syed Khaja, A. S. et al. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. <i>Oncotarget</i> <b>8</b>, 33159–33171 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.18632/oncotarget.16565" data-track-item_id="10.18632/oncotarget.16565" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.18632%2Foncotarget.16565" aria-label="Article reference 64" data-doi="10.18632/oncotarget.16565">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28388539" aria-label="PubMed reference 64">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 64" href="http://scholar.google.com/scholar_lookup?&amp;title=Preferential%20accumulation%20of%20regulatory%20T%20cells%20with%20highly%20immunosuppressive%20characteristics%20in%20breast%20tumor%20microenvironment&amp;journal=Oncotarget&amp;doi=10.18632%2Foncotarget.16565&amp;volume=8&amp;pages=33159-33171&amp;publication_year=2017&amp;author=Syed%20Khaja%2CAS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="65."><p class="c-article-references__text" id="ref-CR65">Maestre, L. et al. High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations. <i>PLoS ONE</i> <b>15</b>, e0229743 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0229743" data-track-item_id="10.1371/journal.pone.0229743" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0229743" aria-label="Article reference 65" data-doi="10.1371/journal.pone.0229743">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXnvVKnur4%3D" aria-label="CAS reference 65">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32106280" aria-label="PubMed reference 65">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046285" aria-label="PubMed Central reference 65">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 65" href="http://scholar.google.com/scholar_lookup?&amp;title=High-mobility%20group%20box%20%28TOX%29%20antibody%20a%20useful%20tool%20for%20the%20identification%20of%20B%20and%20T%20cell%20subpopulations&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0229743&amp;volume=15&amp;publication_year=2020&amp;author=Maestre%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="66."><p class="c-article-references__text" id="ref-CR66">Liu, W. et al. Prognostic value of MTA1, SOX4 and EZH2 expression in esophageal squamous cell carcinoma. <i>Exp. Ther. Med.</i> <b>22</b>, 722 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3892/etm.2021.10154" data-track-item_id="10.3892/etm.2021.10154" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3892%2Fetm.2021.10154" aria-label="Article reference 66" data-doi="10.3892/etm.2021.10154">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34007331" aria-label="PubMed reference 66">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120658" aria-label="PubMed Central reference 66">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 66" href="http://scholar.google.com/scholar_lookup?&amp;title=Prognostic%20value%20of%20MTA1%2C%20SOX4%20and%20EZH2%20expression%20in%20esophageal%20squamous%20cell%20carcinoma&amp;journal=Exp.%20Ther.%20Med.&amp;doi=10.3892%2Fetm.2021.10154&amp;volume=22&amp;publication_year=2021&amp;author=Liu%2CW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="67."><p class="c-article-references__text" id="ref-CR67">Yuan, J. et al. Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients. <i>Cancer Cell Int.</i> <b>19</b>, 238 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s12935-019-0957-0" data-track-item_id="10.1186/s12935-019-0957-0" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s12935-019-0957-0" aria-label="Article reference 67" data-doi="10.1186/s12935-019-0957-0">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31528120" aria-label="PubMed reference 67">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737685" aria-label="PubMed Central reference 67">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 67" href="http://scholar.google.com/scholar_lookup?&amp;title=Combined%20high%20expression%20of%20CD47%20and%20CD68%20is%20a%20novel%20prognostic%20factor%20for%20breast%20cancer%20patients&amp;journal=Cancer%20Cell%20Int.&amp;doi=10.1186%2Fs12935-019-0957-0&amp;volume=19&amp;publication_year=2019&amp;author=Yuan%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="68."><p class="c-article-references__text" id="ref-CR68">Xia, S. et al. SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. <i>Cell Death Dis.</i> <b>12</b>, 570 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41419-021-03853-y" data-track-item_id="10.1038/s41419-021-03853-y" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41419-021-03853-y" aria-label="Article reference 68" data-doi="10.1038/s41419-021-03853-y">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhvFWrtr7I" aria-label="CAS reference 68">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34108444" aria-label="PubMed reference 68">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190073" aria-label="PubMed Central reference 68">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 68" href="http://scholar.google.com/scholar_lookup?&amp;title=SLC7A2%20deficiency%20promotes%20hepatocellular%20carcinoma%20progression%20by%20enhancing%20recruitment%20of%20myeloid-derived%20suppressors%20cells&amp;journal=Cell%20Death%20Dis.&amp;doi=10.1038%2Fs41419-021-03853-y&amp;volume=12&amp;publication_year=2021&amp;author=Xia%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="69."><p class="c-article-references__text" id="ref-CR69">Marmey, B. et al. CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14<sup>+</sup>CD169<sup>−</sup> monocyte-derived cells in diffuse large B-cell lymphomas. <i>Hum. Pathol.</i> <b>37</b>, 68–77 (2006).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.humpath.2005.09.016" data-track-item_id="10.1016/j.humpath.2005.09.016" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.humpath.2005.09.016" aria-label="Article reference 69" data-doi="10.1016/j.humpath.2005.09.016">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXhtlajtLrK" aria-label="CAS reference 69">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16360418" aria-label="PubMed reference 69">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 69" href="http://scholar.google.com/scholar_lookup?&amp;title=CD14%20and%20CD169%20expression%20in%20human%20lymph%20nodes%20and%20spleen%3A%20specific%20expansion%20of%20CD14%2BCD169%E2%88%92%20monocyte-derived%20cells%20in%20diffuse%20large%20B-cell%20lymphomas&amp;journal=Hum.%20Pathol.&amp;doi=10.1016%2Fj.humpath.2005.09.016&amp;volume=37&amp;pages=68-77&amp;publication_year=2006&amp;author=Marmey%2CB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="70."><p class="c-article-references__text" id="ref-CR70">Hashimoto, A. et al. Upregulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer. <i>Clin. Cancer Res.</i> <b>27</b>, 5961–5978 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-21-0986" data-track-item_id="10.1158/1078-0432.CCR-21-0986" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-21-0986" aria-label="Article reference 70" data-doi="10.1158/1078-0432.CCR-21-0986">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXislKgtrnJ" aria-label="CAS reference 70">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34407972" aria-label="PubMed reference 70">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756351" aria-label="PubMed Central reference 70">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 70" href="http://scholar.google.com/scholar_lookup?&amp;title=Upregulation%20of%20C%2FEBP%CE%B1%20inhibits%20suppressive%20activity%20of%20myeloid%20cells%20and%20potentiates%20antitumor%20response%20in%20mice%20and%20patients%20with%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-21-0986&amp;volume=27&amp;pages=5961-5978&amp;publication_year=2021&amp;author=Hashimoto%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="71."><p class="c-article-references__text" id="ref-CR71">Scott, D. W. et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> <b>123</b>, 1214–1217 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2013-11-536433" data-track-item_id="10.1182/blood-2013-11-536433" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2013-11-536433" aria-label="Article reference 71" data-doi="10.1182/blood-2013-11-536433">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXjs1ygu74%3D" aria-label="CAS reference 71">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24398326" aria-label="PubMed reference 71">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931191" aria-label="PubMed Central reference 71">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 71" href="http://scholar.google.com/scholar_lookup?&amp;title=Determining%20cell-of-origin%20subtypes%20of%20diffuse%20large%20B-cell%20lymphoma%20using%20gene%20expression%20in%20formalin-fixed%20paraffin-embedded%20tissue&amp;journal=Blood&amp;doi=10.1182%2Fblood-2013-11-536433&amp;volume=123&amp;pages=1214-1217&amp;publication_year=2014&amp;author=Scott%2CDW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="72."><p class="c-article-references__text" id="ref-CR72">Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. <i>Science</i> <b>313</b>, 1960–1964 (2006).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/science.1129139" data-track-item_id="10.1126/science.1129139" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.1129139" aria-label="Article reference 72" data-doi="10.1126/science.1129139">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD28XhtVSnsrnK" aria-label="CAS reference 72">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17008531" aria-label="PubMed reference 72">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 72" href="http://scholar.google.com/scholar_lookup?&amp;title=Type%2C%20density%2C%20and%20location%20of%20immune%20cells%20within%20human%20colorectal%20tumors%20predict%20clinical%20outcome&amp;journal=Science&amp;doi=10.1126%2Fscience.1129139&amp;volume=313&amp;pages=1960-1964&amp;publication_year=2006&amp;author=Galon%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-022-01916-x?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>The authors thank G. Houghton and G. Rahimi for support with sample inventory, tracking and consent. They also thank INSERM, Cancer Research for Personalized Medicine (CARPEM), LabEx Immuno-Oncology, the National Cancer Institute of France, La Ligue Contre le Cancer, Association pour la Recherche Contre le Cancer (ARC), the Louis Jeantet Prize foundation and the patients and their caregivers. Medical writing support was provided by A. Skorusa and S. Franco of Nexus Global Group Science, funded by Kite, a Gilead company. This study was funded by Kite, a Gilead company.</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Kite, a Gilead company, Santa Monica, CA, USA</p><p class="c-article-author-affiliation__authors-list">Nathalie Scholler,&nbsp;Edmund C. Chang,&nbsp;Jenny J. Kim,&nbsp;Justin Chou,&nbsp;Vicki Plaks,&nbsp;Zixing Wang,&nbsp;Allen Xue,&nbsp;Mike Mattie,&nbsp;John M. Rossi&nbsp;&amp;&nbsp;Adrian Bot</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Gilead Sciences, Foster City, CA, USA</p><p class="c-article-author-affiliation__authors-list">Nathalie Scholler</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Veracyte SAS, Marseille, France</p><p class="c-article-author-affiliation__authors-list">Regis Perbost,&nbsp;Sarah Turcan,&nbsp;Corinne Danan&nbsp;&amp;&nbsp;Jérôme Galon</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Moffitt Cancer Center, Tampa, FL, USA</p><p class="c-article-author-affiliation__authors-list">Frederick L. Locke&nbsp;&amp;&nbsp;Michael D. Jain</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">The University of Texas MD Anderson Cancer Center, Houston, TX, USA</p><p class="c-article-author-affiliation__authors-list">Sattva S. Neelapu</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">Stanford University School of Medicine, Stanford, CA, USA</p><p class="c-article-author-affiliation__authors-list">David B. Miklos</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">Dana-Farber Cancer Institute, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">Caron A. Jacobson</p></li><li id="Aff8"><p class="c-article-author-affiliation__address">University of Miami Health System, Sylvester Comprehensive Cancer Center, Miami, FL, USA</p><p class="c-article-author-affiliation__authors-list">Lazaros J. Lekakis</p></li><li id="Aff9"><p class="c-article-author-affiliation__address">Mayo Clinic, Rochester, MN, USA</p><p class="c-article-author-affiliation__authors-list">Yi Lin</p></li><li id="Aff10"><p class="c-article-author-affiliation__address">Washington University School of Medicine, St. Louis, MO, USA</p><p class="c-article-author-affiliation__authors-list">Armin Ghobadi</p></li><li id="Aff11"><p class="c-article-author-affiliation__address">Capstan Therapeutics, San Diego, CA, USA</p><p class="c-article-author-affiliation__authors-list">Adrian Bot</p></li><li id="Aff12"><p class="c-article-author-affiliation__address">INSERM, Sorbonne Université, Université Paris Cité, Centre de Recherche des Cordeliers, Equipe Labellisée Ligue Contre le Cancer, Laboratory of Integrative Cancer Immunology, Paris, France</p><p class="c-article-author-affiliation__authors-list">Jérôme Galon</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Nathalie-Scholler-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Nathalie Scholler</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Nathalie%20Scholler" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Nathalie%20Scholler" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Nathalie%20Scholler%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Regis-Perbost-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Regis Perbost</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Regis%20Perbost" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Regis%20Perbost" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Regis%20Perbost%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Frederick_L_-Locke-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Frederick L. Locke</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Frederick%20L.%20Locke" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Frederick%20L.%20Locke" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Frederick%20L.%20Locke%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Michael_D_-Jain-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Michael D. Jain</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Michael%20D.%20Jain" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Michael%20D.%20Jain" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Michael%20D.%20Jain%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Sarah-Turcan-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Sarah Turcan</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Sarah%20Turcan" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Sarah%20Turcan" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Sarah%20Turcan%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Corinne-Danan-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Corinne Danan</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Corinne%20Danan" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Corinne%20Danan" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Corinne%20Danan%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Edmund_C_-Chang-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Edmund C. Chang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Edmund%20C.%20Chang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Edmund%20C.%20Chang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Edmund%20C.%20Chang%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Sattva_S_-Neelapu-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Sattva S. Neelapu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Sattva%20S.%20Neelapu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Sattva%20S.%20Neelapu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Sattva%20S.%20Neelapu%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-David_B_-Miklos-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">David B. Miklos</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=David%20B.%20Miklos" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=David%20B.%20Miklos" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22David%20B.%20Miklos%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Caron_A_-Jacobson-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Caron A. Jacobson</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Caron%20A.%20Jacobson" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Caron%20A.%20Jacobson" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Caron%20A.%20Jacobson%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Lazaros_J_-Lekakis-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Lazaros J. Lekakis</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Lazaros%20J.%20Lekakis" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Lazaros%20J.%20Lekakis" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Lazaros%20J.%20Lekakis%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Yi-Lin-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Yi Lin</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Yi%20Lin" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Yi%20Lin" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Yi%20Lin%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Armin-Ghobadi-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Armin Ghobadi</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Armin%20Ghobadi" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Armin%20Ghobadi" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Armin%20Ghobadi%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jenny_J_-Kim-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Jenny J. Kim</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jenny%20J.%20Kim" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jenny%20J.%20Kim" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jenny%20J.%20Kim%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Justin-Chou-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Justin Chou</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Justin%20Chou" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Justin%20Chou" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Justin%20Chou%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Vicki-Plaks-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Vicki Plaks</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Vicki%20Plaks" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Vicki%20Plaks" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Vicki%20Plaks%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Zixing-Wang-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Zixing Wang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Zixing%20Wang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Zixing%20Wang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Zixing%20Wang%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Allen-Xue-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Allen Xue</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Allen%20Xue" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Allen%20Xue" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Allen%20Xue%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Mike-Mattie-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Mike Mattie</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Mike%20Mattie" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Mike%20Mattie" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Mike%20Mattie%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-John_M_-Rossi-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">John M. Rossi</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=John%20M.%20Rossi" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=John%20M.%20Rossi" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22John%20M.%20Rossi%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Adrian-Bot-Aff1-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Adrian Bot</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Adrian%20Bot" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Adrian%20Bot" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Adrian%20Bot%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-J_r_me-Galon-Aff3-Aff12"><span class="c-article-authors-search__title u-h3 js-search-name">Jérôme Galon</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=J%C3%A9r%C3%B4me%20Galon" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=J%C3%A9r%C3%B4me%20Galon" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22J%C3%A9r%C3%B4me%20Galon%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>J.G., J.M.R., A.X., N.S. and A.B. designed the study. F.F.L., S.S.N., D.B.M., C.A.J., L.J.L., Y.L. and A.G. participated in axi-cel clinical trials. F.F.L. and M.J. participated in the commercial axi-cel data collection. R.P., S.T. and C.D. participated in the data collection. All authors participated in the data analysis, data interpretation, manuscript writing and approval of the final submitted version.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding author</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:jerome.galon@crc.jussieu.fr">Jérôme Galon</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
              
                <h3 class="c-article__sub-heading" id="FPar4">Competing interests</h3>
                <p>N.S. reports employment with Kite, a Gilead company, and stock or other ownership in Gilead Sciences, Bristol Myers Squibb and Seattle Genetics. R.P. reports employment with HalioDx. F.L.L. reports a scientific advisory role for Kite, a Gilead company, Novartis, Amgen, Celgene/Bristol Myers Squibb, GammaDelta Therapeutics, Wugen, Calibr and Allogene; a consultancy with grant options for Cellular Biomedicine Group; and research support from Kite, a Gilead company. M.D.J. reports a consultancy/advisory for Kite, a Gilead company, Novartis, Bristol Myers Squibb and Takeda. S.T. reports employment with, a leadership role at, stock or other ownership in and travel support from HalioDx. C.D. reports stock or other ownership in HalioDx. E.C.C., J.J.K., A.X., M.M. and J.M.R. report employment with Kite, a Gilead company, and stock or other ownership in Gilead Sciences. S.S.N. has received personal fees from Kite, a Gilead company, Merck, Bristol Myers Squibb, Novartis, Celgene, Pfizer, Allogene Therapeutics, Cell Medica/Kuur, Incyte, Precision Biosciences, Legend Biotech, Adicet Bio, Calibr and Unum Therapeutics; has received research support from Kite, a Gilead company, Bristol Myers Squibb, Merck, Poseida, Cellectis, Celgene, Karus Therapeutics, Unum Therapeutics, Allogene Therapeutics, Precision Biosciences and Acerta; has received royalties from Takeda; and has intellectual property related to cell therapy. D.B.M. reports a consultancy or advisory role for Kite-Gilead, Novartis, Juno-Celgene-Bristol Myers Squibb, Adaptive Biotech, Pharmacyclics and Janssen; research funding from Kite-Gilead, Novartis, Juno-Celgene-Bristol Myers Squibb, Adaptive Biotech and Pharmacyclics; patents, royalties or other intellectual property from Pharmacyclics; and travel support from Kite-Gilead, Novartis, Juno-Celgene-Bristol Myers Squibb, Adaptive Biotech, Pharmacyclics and Janssen. C.A.J. reports honoraria from Kite, a Gilead company, Celgene, Novartis, Pfizer, Humanigen, Precision Biosciences, Nkarta, Lonza and AbbVie; a consulting or advisory role with Kite, a Gilead company, Celgene, Novartis, Pfizer, Humanigen, Precision Biosciences, Nkarta, Lonza and AbbVie; speakers bureau participation for Axis and Clinical Care Options; research funding from Pfizer; and travel, accommodations and expenses from Kite, a Gilead company, Celgene, Novartis, Pfizer, Humanigen, Precision Biosciences and Lonza. L.J.L. has no relevant financial relationships to disclose. Y.L. reports a consultancy or advisory role for Kite, a Gilead company, Janssen, Novartis, Celgene, Bluebird Bio, Juno, Legend, Sorrento, Gamida Cells and Vineti; and research funding from Kite, a Gilead company, Janssen, Celgene, Bluebird Bio, Merck and Takeda. A.G. reports a consultancy or advisory role for Kite, a Gilead company, Amgen, Atara, Wugen and Celgene; and honoraria from Kite, a Gilead company. J.C. reports employment with Gilead Sciences; stock or other ownership in Five Prime Therapeutics and Gilead Sciences; patents, royalties or other intellectual property from Five Prime Therapeutics; and travel support from Kite, a Gilead company. V.P. reports employment with, and travel support from, Kite, a Gilead company; and stock or other ownership in Gilead Sciences. Z.W. reports previous employment with Seattle Genetics and current employment with Kite, a Gilead company; and stock or other ownership with Seattle Genetics and Gilead Sciences. A.B. reports employment with Kite, a Gilead company; and stock or other ownership in, a consultancy or advisory role for and travel support from Gilead Sciences. J.G. reports stock or other ownership in HalioDx; honoraria from, and a consultancy or advisory role for, HalioDx, Bristol Myers Squibb, Merck Serono, IO Biotech, Illumina, Northwest Biotherapeutics, Amgen, Catalym, Lunaphore and Merck; research funding from MedImmune, AstraZeneca, IO Biotech, Janssen, Imcheck Therapeutics and PerkinElmer; and patents, royalties or other intellectual property from INSERM. Immunoscore is a registered trademark from INSERM, licensed to HalioDx.</p>
              
            </div></div></section><section data-title="Peer review"><div class="c-article-section" id="peer-review-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="peer-review">Peer review</h2><div class="c-article-section__content" id="peer-review-content">
              
              
                <h3 class="c-article__sub-heading" id="FPar3">Peer review information</h3>
                <p><i>Nature Medicine</i> thanks Joshua Brody and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary handling editor: Saheli Sadanand, in collaboration with the <i>Nature Medicine</i> team.</p>
              
            </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Extended data"><div class="c-article-section" id="Sec20-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec20">Extended data</h2><div class="c-article-section__content" id="Sec20-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 1 characterization of zuma-1 tu" href="/articles/s41591-022-01916-x/figures/7" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig7_ESM.jpg">Extended Data Fig. 1 Characterization of ZUMA-1 tumour biopsy specimens analysed in this study.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>a, Number of tumour biopsies per known anatomic location from Zuma 1 patients analysed in the manuscript; b, PCA of Zuma 1 baseline biopsies (subset 1) with the two first principal components of all gene expression. Data are colored by biopsy origin; lymph node, blue, n = 12; not lymph node origin (as indicated in a), yellow, n = 7; unknown origin, red, n = 10; c. Number of Zuma 1 patients analyzed in the manuscript, classification per subset, and overview of the longitudinal biopsies; d. Number of Zuma 1 patients analyzed in the manuscript with FF and/or FFPE biopsies classified per subset. FF, fresh frozen; FFPE, formalin-fixed paraffin embedded; PCA, principal component analysis.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 2 evolution of the tumour infil" href="/articles/s41591-022-01916-x/figures/8" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig8_ESM.jpg">Extended Data Fig. 2 Evolution of the tumour infiltrate in ZUMA-1 patients after axi-cel infusion associated with clinical outcomes independently of tumour burden.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>a, Heatmap of gene expression measured by PanCancer Immune Profiling panel (NanoString) in FFPE tumour biopsy specimens pretreatment (subset 1, n = 29) or posttreatment (subset 2, n = 14) from Zuma 1 patients with high or low tumour burden at pretreatment. Among the genes with significant differential expression between pre and post treatment (Two-sided t.test without adjustment, p.value &lt;0.05), shown genes were selected according to their belonging to a specific TME related signature. Patients with CR and low tumour burden, n = 17 (Subset 1, n = 12; Subset 2, n = 5); with CR and high tumour burden, n = 15 (Subset 1, n = 8; Subset 2, n = 7); without CR and low tumour burden, n = 2 (Subset 1); without CR and high tumour burden, n = 9 (Subset 1, n = 7; Subset 2, n = 2). PR (n=4, as noted by asterisks [2 pretreatment; 2 within 2 weeks posttreatment]. The color range is set to log-transform scaled values. Scaled values are calculated by dividing by the standard deviation. b-e, Gene expression measured by PanCancer Immune Profiling panel in paired specimens; (two sided t.test without adjustment); b,c, T-cell functional genes (b) and myeloid- and cytokine-related genes (c) in FF biopsies; d,e, CXCL10 and CXCL11 genes in FF (d) vs. FFPE (e) biopsies. *P &lt; 0.1 and ***P &lt; 0.01. f,g, Volcano plots of gene expression from pre- vs. posttreatment biopsies of patients with SD/PD or CR/PR (as indicated) for B-cell lineage (f) and CTA genes (g). The plots were constructed using log2(fold change) and log10 (P values) for all genes. Red dots represent the top differentially expressed genes with P&lt;0.01. h, Comparative gene expression of B-cell lineage selected markers in pre- vs posttreatment biopsies. *P &lt; 0.1 and **P &lt; 0.05.(Two-sided t.test without adjustment). axi-cel, axicabtagene ciloleucel; CCL, chemokine ligand; CR, complete response; CTA, cancer testis antigen; CTLA-4, cytotoxic T lymphocyte–associated protein 4; CXCL, chemokine C-X-C motif ligand; DC, dendritic cell; MAGE-B2, melanoma-associated antigen B2; PD, progressive disease; PD-L1, programmed death-ligand 1; PF: Fresh frozen; FFPE, formalin-fixed paraffin-embedded; POU2AF1, POU domain class 2-associating factor 1; PR, partial response; SD, stable disease.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 3 overview of immunoscore index" href="/articles/s41591-022-01916-x/figures/9" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig9_ESM.jpg">Extended Data Fig. 3 Overview of Immunoscore index, Immunoscore TCE/TCE+ panels, and Immunoscore SC panel.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>a,b, Following the pathologist selection of a digital image area, IHC staining of CD3 and CD8 was quantified by the application of a prespecified bioinformatics algorithm that generated analysis cutoffs and a numerical index named Immunoscore. Because the majority of lymph node biopsy specimens lacked an identifiable invasive margin, as expected for lymphoma, cell densities were calculated from the core tumour only. a, Representative images (250- and 1000-µm scales) of CD3 and CD8 T-cell densities (low, medium, or high) in tumour biopsy specimens. b, Representative images (50- µm scale) of CD3 and CD8 T-cell densities in patients with a high (top panels) or low (bottom panels) Immunoscore index. c,d, Representative images (250-µm scale) of successive stainings with Immunoscore TCE (c) and Immunoscore SC (d) panels of tumour biopsy specimens from patients in ZUMA-1 with CR (top panels) or without CR (bottom panels). e, Representative images (50-µm scale) of stainings with Immunoscore TCE+ panel of tumour biopsy specimens. One staining per sample per marker. EZH2, enhancer of zeste homolog 2; FOXP3, forkhead box P3; H&amp;E, haematoxylin and eosin; IHC, immunohistochemistry; LAG-3, lymphocyte-activation gene 3; LOX-1, lectin-type oxidised LDL receptor 1; PD-1, programmed cell death protein 1; SC, Suppressive Cell; TCE, T-cell Exhaustion; TIM-3, T-cell immunoglobulin and mucin domain 3; TOX, thymocyte selection–associated high mobility group box.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig10"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 4 overview of immunoscore tce+ " href="/articles/s41591-022-01916-x/figures/10" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig10_ESM.jpg">Extended Data Fig. 4 Overview of Immunoscore TCE+ panel.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>a, Representative images (50-µm scale; 40× magnification) of staining with Immunoscore TCE+ panel of ZUMA-1 tumour biopsy specimens from patients with ongoing CR versus relapse after PR, at pre- (top panels) and posttreatment (bottom panels). b, Representative images (50-µm scale; 40× magnification) of cell phenotyping with Immunoscore TCE+ panel in ZUMA-1 tumour biopsy specimens. Arrows point to helper T-cells (CD3+CD8–PD-1+LAG-3+TIM-3–FoxP3–TOX–EZH2+), cytotoxic T-cells (CD3+CD8+PD-1+LAG-3–TIM-3+FoxP3–TOX–EZH2+), regulatory T-cells (CD3+CD8–PD-1+LAG-3+/–TIM-3–FoxP3+TOX–EZH2+), exhausted helper T-cells (CD3+CD8–PD-1+LAG-3+TIM-3–FoxP3–TOX+EZH2+), and tumour cells (EZH2+CD3–). One staining per sample per marker. axi-cel, axicabtagene ciloleucel; CR, complete response; EZH2, enhancer of zeste homolog 2; FOXP3, forkhead box P3; LAG-3, lymphocyte-activation gene 3; PD-1, programmed cell death protein 1; PR, partial response; TCE, T-cell Exhaustion; TIM-3, T-cell immunoglobulin and mucin domain 3; TOX, thymocyte selection-associated high mobility group box.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig11"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 5 correlative analyses with imm" href="/articles/s41591-022-01916-x/figures/11" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig11_ESM.jpg">Extended Data Fig. 5 Correlative analyses with Immunoscore panels.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>a,b, Correlations of CD3+ (a) and CD8+ (b) T-cell densities measured with Immunoscore TL (X-axis) versus Immunoscore TCE (Y-axis) panels in ZUMA-1 patient biopsies at pretreatment (subset 1, n = 19). The grey ribbons represent the 95% Confidence Interval of the regression line. c, Correlation between cell phenotypes measured with Immunoscore TCE (X-axis) versus Immunoscore TCE+ (Y-axis) panels in two adjacent tissue slides (1 slide per panel) from ZUMA-1 patient biopsies (subset 1, n = 8). Statistical significance of the spearman coefficient level (two-sided P value) as shown. d, Association between cell densities of tumour-infiltrating immune subsets (T-cells or myeloid cells, as indicated) and Immunoscore index (low versus high) in ZUMA-1 patient biopsies (subset 1, n = 24 and n = 18, respectively). Two-sided Wilcoxon test, p values as shown. ABC, activated B-cell DLBCL subtype; DLBCL, diffuse large B-cell lymphoma; GCB, germinal centre B-cell DLBCL subtype; LAG-3, lymphocyte-activation gene 3; IC, immune checkpoint; M-MDSC, monocytic myeloid-derived suppressor cell; PD-1, programmed cell death protein 1; PMN-MDSC, polymorphonuclear myeloid-derived suppressor cell; Tc, cytotoxic T-cell; TCE, T-cell Exhaustion; Th, helper T-cell; TIM-3, T-cell immunoglobulin and mucin domain 3; Treg, regulatory T-cell.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig12"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 6 correlative studies of immuno" href="/articles/s41591-022-01916-x/figures/12" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig12_ESM.jpg">Extended Data Fig. 6 Correlative studies of Immunosign 21 score with cell subsets across 3 independent datasets.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>a, Definition of the Immunosign 21 score cutoff. The Immunosign 21 scoring function is an algorithm derived from the Immunoscore algorithm, is independent of clinical outcome, and is predefined as the 25th percentile of the observed scores among samples. b-d, Correlation of Immunosign 21 (low versus high) with cell subsets in 3 independent datasets (Two-sided Wilcoxon test). b,c, Immunosign 21 correlations with cell subset densities analysed by Immunoscore TCE/TCE+ panels in b, ZUMA-1 pretreatment tumour biopsy specimens from third line, r/r DLBCL patients (subset 1, n = 22 for T-cell subsets; n = 15 for myeloid subsets) and c, DLBCL biopsy specimens at diagnosis from treatment-naïve patients (n = 67). d, Immunosign 21 correlations with normalised gene expression of T-cells or of myeloid cells analysed by IO360 NanoString panel in pretreatment tumour biopsy specimens from second line DLBCL patients (n = 252). The number of samples per group is indicated on each panel. DLBCL, diffuse large B-cell lymphoma; FOXP3, forkhead box P3; LAG-3, lymphocyte-activation gene 3; M-MDSC, monocytic myeloid-derived suppressor cell; PD-1, programmed cell death protein 1; PMN-MDSC, polymorphonuclear myeloid-derived suppressor cell; SC, Suppressive cell; TCE, T-cell Exhaustion; TIM-3, T-cell immunoglobulin and mucin domain 3; Treg, regulatory T-cell.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig13"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 7 circulating peak car t-cell l" href="/articles/s41591-022-01916-x/figures/13" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig13_ESM.jpg">Extended Data Fig. 7 Circulating peak CAR T-cell levels normalised to pretreatment tumour burden correlated to Immunoscore.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>T-cell densities were measured with Immunoscore TCE+ panel in ZUMA-1 patient biopsies, 7 to 14 days after axi-cel infusion (Subset 2, n = 18). Tc (left panels) and Th (right panels) phenotypes were classified by checkpoint expression (PD-1+/–, LAG-3+/–, TIM-3+/–, TOX+/–). The grey ribbon represents the 95% Confidence Interval of the regression line. Statistical significance of the spearman coefficient level (two-sided P values) were calculated and significant p values (&lt; 0.05) are shown in red squares. From top to bottom: all phenotypes (any checkpoint), 0 IC (no checkpoint), 1 IC (any 1 checkpoint: PD-1 or LAG-3 or TIM-3 or TOX), 2 IC (any 2 checkpoints: PD-1+/LAG-3+ or PD-1+/TIM-3+ or PD-1+/TOX+ or LAG-3+/TIM-3+ or LAG-3+/TOX+ or TIM-3+/TOX+), 3 IC (any 3 checkpoints: PD-1+LAG-3+TIM-3+ or PD-1+LAG-3+TOX+ or LAG-3+TIM-3+TOX+), 4 IC (all 4 checkpoints: PD-1+LAG-3+TIM-3+TOX+), TOX+ (TOX+ in combination with any checkpoint(s): TOX+PD-1+/–LAG-3+/–TIM-3+/–), TOX– (any combination of checkpoint(s) without TOX: TOX–PD-1+/–LAG-3+/–TIM-3+/–), and TOX only (TOX+PD-1–LAG-3–TIM-3–). axi-cel, axicabtagene ciloleucel; CAR, chimeric antigen receptor; LAG-3, lymphocyte-activation gene 3; IC, immune checkpoint; PD-1, programmed cell death protein 1; Tc, cytotoxic T-cell; Th, helper T-cell; TIM-3, T-cell immunoglobulin and mucin domain 3; TME, tumour microenvironment; TOX, thymocyte selection–associated high mobility group box.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig14"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 8 evolution of immune gene expr" href="/articles/s41591-022-01916-x/figures/14" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig14_ESM.jpg">Extended Data Fig. 8 Evolution of immune gene expression in tumour biopsies of ZUMA-1 patients who relapsed.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Gene expression was measured with PanCancer Immune Profiling panel in tumour biopsies from unpaired or paired samples (as indicated) of Zuma 1 patients from subset 1 (n=39; 19 unpaired FFPE; 23 unpaired FF; 3 paired FF), subset 2 (n=22; 14 unpaired FFPE; 12 unpaired FF; 3 paired FF), and subset 3 (n=4; 2 unpaired FFPE; 3 unpaired FF; 3 paired FF,). a-c, Gene expression related to anti-tumour immune response. a, Cytotoxic T-cell–related genes; b, cytokine and IFN-related genes; c, MHC class I–related genes. P values were derived with a Kruskal-Wallis test. d-i, Gene expression related to immunosuppressive response. d, Comparative gene expression of FoxP3, CTLA-4, CCR4, and CCL22 genes (Kruskal-Wallis test; P values as indicated) in biopsies from subset 1 (n = 19), subset 2 (n = 14), and subset 3 (n = 2); e-i, Ratios of gene expression for CTLA-4 with (e) CD3D or (f) CD3E (statistical significance of the spearman coefficient level (two-sided P value) embedded in panels; grey ribbons represent the 95% Confidence Interval of the regression line) and of FoxP3 with (g) CD3D, (h) CD3E, or (i) CD8A (Kruskal-Wallis test, P values as indicated). j,k, Correlations between gene expression of CCL22 and cell density of Treg measured by Immunoscore TCE panel (j) or gene expression of CCR4 (k) in tumour biopsies from Zuma 1 subset 1 pts (n = 14 and n = 16, respectively),two-sided Wilcoxon tests. axi-cel, axicabtagene ciloleucel; CCL, chemokine ligand; CCR, chemokine receptor; CTLA-4, cytotoxic T lymphocyte–associated protein 4; FOXP3, forkhead box P3; GZMA, granzyme A; HLA, human leucocyte antigen; IL, interleukin; IRF1, interferon regulatory factor 1; LAG-3, lymphocyte-activation gene 3; MHC, major histocompatibility complex; TCE, T-cell Exhaustion; TME, tumour microenvironment; Treg, regulatory T-cell.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig15"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 9 b-cell lineage and cta gene e" href="/articles/s41591-022-01916-x/figures/15" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig15_ESM.jpg">Extended Data Fig. 9 B-cell lineage and CTA gene expression in tumour biopsies of ZUMA-1 patients.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Gene expression was measured with PanCancer Immune Profiling panel in Zuma 1 (a,b) tumour biopsies from subsets 1, 2, and 3, and (c,d) in pretreatment tumour biopsies from patients with CR (n=22 total [20 CR, 2 PR]) vs. nonCR (n=7 total [4 SD, 3 PD]) a, Volcano plots of B-cell lineage (top panel) and CTA (bottom panel) gene expression from subset 2 (n = 12) and subset 3 (n = 3). The plot was constructed using log2(fold change) and –log10(P value) for all genes analysed by PanCancer Immune Profiling panel. Red dots represent the top differentially expressed genes with P&lt;0.01 (two-sided t.test without adjustment). b, Evolution of B-cell and CTA gene expression across FFPE biopsies from subsets 1 (n=19), 2 (n=14), and 3 (n=2). c, Volcano plots of B-cell lineage (left) and CTA-related (right) gene expression in pretreatment tumour biopsies of patients with CR vs. nonCR outcomes. P values were derived with a Kruskal-Wallis test. d, Gene expression of CTA-related genes (MAGE-B2 and PRAME) in pretreatment tumour biopsies of patients with CR/PR vs. SD/PD outcomes. P values were derived with two-sided Wilcoxon test.AICDA, activation-induced cytidine deaminase; axi-cel, axicabtagene ciloleucel; BTK, Bruton tyrosine kinase; CR, complete response; CTA, cancer testis antigen; FFPE, formalin-fixed paraffin-embedded; IKBKB, inhibitor of nuclear factor kappa B kinase subunit B; ; IS21, Immunosign21; MAGE, melanoma-associated antigen; PAX5, paired box protein 5; PD, progressive disease; POU2AF1, POU domain class 2-associating factor 1; PR, partial response; PRAME, preferentially expressed antigen in melanoma; SAA1, serum amyloid A1; SD, stable disease; TME, tumour microenvironment.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig16"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 10 correlative studies in zuma " href="/articles/s41591-022-01916-x/figures/16" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig16_ESM.jpg">Extended Data Fig. 10 Correlative studies in Zuma 1 and commercial axi-cel patient datasets.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>a,b,d. Pretreatment tumour biopsies from commercial patients (r/r DLBCL) were analysed with IO360 NanoString panel (n=33; 20 CR and 10 non-CR; 3 samples failed nanostring QC). a, Correlation matrix for myeloid-secreted and/or T-cell–produced cytokine/chemokines (horizontal axis) with T-cell subset–related genes (vertical axis) (Spearman R). The scale bar (-1 to 1) represents the R value. b, Gene expression correlation of CCL5 chemokine and cytotoxic T-cells–produced serine protease GZMA. Statistical significance of the spearman coefficient level (two-sided P value) in the panels. The grey ribbon represents the 95% Confidence Interval of the regression line. c,d. Comparison of regulation of three functional pathways (“Positive regulation of leukocyte cell-cell adhesion", "Lymphocyte costimulation", and "Antigen processing and peptide antigen presentation") in pretreatment, CR vs. non-CR, tumour biopsies from Zuma 1 (c, 20 CR, 9 non-CR) and commercial (d, 20 CR, 10 non-CR) patients. Functional pathways with statistically significant p values &lt; 0.005 were selected and GSEA adjusted p.values were calculated with Benjamini-Hochberg method. Adjusted two-sided p.values of less than 0.5 in at least one of the two panels are shown. axi-cel, axicabtagene ciloleucel; CCL, chemokine ligand; CXCL, chemokine C-X-C motif ligand; DLBCL, diffuse large B-cell lymphoma; CR, complete response; non-CR, non-complete response; FoxP3, forkhead box P3; GNLY, granulysin; GZMA, granzyme A; IL, interleukin; IRF1, interferon regulatory factor 1; QC, quality control; r/r, relapse, refractory; STAT, signal transducer and activator of transcription; TNFRSF14, tumour necrosis factor receptor.</p></div></div></div></div></div></section><section data-title="Supplementary information"><div class="c-article-section" id="Sec21-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec21">Supplementary information</h2><div class="c-article-section__content" id="Sec21-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary information" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_MOESM1_ESM.pdf" data-supp-info-image="">Supplementary Information</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Supplementary Legend Figs. 1–4, Supplementary Figs. 1-4, Supplementary Legend Tables 1–14 and Supplementary Tables 1, 2, 3, 4, 5, 11 and 13</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="reporting summary" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_MOESM2_ESM.pdf" data-supp-info-image="">Reporting Summary</a></h3></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM3"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="excel workbook 1" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_MOESM3_ESM.xlsx" data-supp-info-image="">Excel Workbook 1</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Large Supplementary Tables</p></div></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content">
                <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
              <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Tumor%20immune%20contexture%20is%20a%20determinant%20of%20anti-CD19%20CAR%20T%20cell%20efficacy%20in%20large%20B%20cell%20lymphoma&amp;author=Nathalie%20Scholler%20et%20al&amp;contentID=10.1038%2Fs41591-022-01916-x&amp;copyright=The%20Author%28s%29&amp;publication=1078-8956&amp;publicationDate=2022-08-29&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41591-022-01916-x" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-022-01916-x" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Scholler, N., Perbost, R., Locke, F.L. <i>et al.</i> Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
                    <i>Nat Med</i> <b>28</b>, 1872–1882 (2022). https://doi.org/10.1038/s41591-022-01916-x</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-022-01916-x?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-02-12">12 February 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-06-27">27 June 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-08-29">29 August 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Issue Date<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-09">September 2022</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41591-022-01916-x</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-block"><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/cancer-microenvironment" data-track="click" data-track-action="view subject" data-track-label="link">Cancer microenvironment</a></li><li class="c-article-subject-list__subject"><a href="/subjects/immunotherapy" data-track="click" data-track-action="view subject" data-track-label="link">Immunotherapy</a></li><li class="c-article-subject-list__subject"><a href="/subjects/translational-research" data-track="click" data-track-action="view subject" data-track-label="link">Translational research</a></li><li class="c-article-subject-list__subject"><a href="/subjects/tumour-immunology" data-track="click" data-track-action="view subject" data-track-label="link">Tumour immunology</a></li>
        </ul>
    </div></div></div></div></div></section>
            </div>

            
        <section>
            <div class="c-article-section js-article-section" id="further-reading-section" data-test="further-reading-section">
                <h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="further-reading">This article is cited by</h2>
                <div class="c-article-section__content js-collapsible-section" id="further-reading-content">
                    <ul class="c-article-further-reading__list" id="further-reading-list">
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:A 6-tsRNA signature for early detection, treatment response monitoring, and prognosis prediction in diffuse large B cell lymphoma" href="https://doi.org/10.1038/s41408-025-01267-z">
                                        A 6-tsRNA signature for early detection, treatment response monitoring, and prognosis prediction in diffuse large B cell lymphoma
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Jun Rao</li><li>Lin Xia</li><li>Xi Zhang</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Blood Cancer Journal</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma" href="https://doi.org/10.1038/s41571-025-00992-5">
                                        Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Tamara J. Bock</li><li>Chanukya K. Colonne</li><li>Cameron J. Turtle</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Reviews Clinical Oncology</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:The transition between M1 and M2 macrophage phenotypes is associated with the disease status following CD19 CAR-T therapy for B cell lymphoma/leukemia" href="https://doi.org/10.1038/s41419-025-07610-3">
                                        The transition between M1 and M2 macrophage phenotypes is associated with the disease status following CD19 CAR-T therapy for B cell lymphoma/leukemia
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Li Zhao</li><li>Fen Yan</li><li>Kai Zhao</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Cell Death &amp; Disease</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:MYC networks associate with decreased CD8 T-cell presence in diffuse large B-cell lymphoma and may be addressed by the synergistic combination of AZD4573 and Selinexor – a preliminary analysis" href="https://doi.org/10.1007/s00277-025-06298-x">
                                        MYC networks associate with decreased CD8 T-cell presence in diffuse large B-cell lymphoma and may be addressed by the synergistic combination of AZD4573 and Selinexor – a preliminary analysis
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Alison C. Rutz</li><li>Kennedee S. Weber</li><li>Keenan T. Hartert</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Annals of Hematology</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms" href="https://doi.org/10.1007/s10555-024-10228-0">
                                        CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Tyce J. Kearl</li><li>Fateeha Furqan</li><li>Nirav N. Shah</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Cancer and Metastasis Reviews</i> (2025)</p>
                            </li>
                        
                    </ul>
                </div>
            </div>
        </section>
    

        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion="" data-container-type="reading-companion" data-track-component="reading companion">
    <div class="js-context-bar-sticky-point-desktop" data-track-context="reading companion">
        

        
            
                
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01916-x.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                
            
        
    </div>

    
        
    

    
    
        <div class="c-article-associated-content__container">
            <section>
                <h2 class="c-article-associated-content__title u-mb-24">Associated content</h2>
                
                    
                    
                        <div class="u-full-height u-mb-24">
                            
    <article class="u-full-height c-card c-card--flush">
        <div class="c-card__layout u-full-height">
            <div class="c-card__body">
                <h3 class="c-card__title">
                    <a href="https://www.nature.com/articles/s41591-022-01922-z" class="c-card__link u-link-inherit" data-track="click" data-track-action="view article" data-track-category="associated content" data-track-label="news_and_views">In CAR T cell-treated lymphomas, the T cell rich get richer</a>
                </h3>
                
<ul data-test="author-list" class="app-author-list app-author-list--compact">
    <li>Theodora Anagnostou</li><li>Joshua D. Brody</li>
</ul>

                
    <div class="c-card__section c-meta">
        
            <span class="c-meta__item">Nature Medicine</span>
        
        <span class="c-meta__item" data-test="article.type"><span class="c-meta__type">News &amp; Views</span></span>
        
        
            <time class="c-meta__item" datetime="2022-08-29">29 Aug 2022</time>
        
    </div>

            </div>
        </div>
    </article>


                        </div>
                    
                
            </section>
        </div>
        <script>
            window.dataLayer = window.dataLayer || [];
            window.dataLayer[0] = window.dataLayer[0] || {};
            window.dataLayer[0].content = window.dataLayer[0].content || {};
            window.dataLayer[0].content.associatedContentTypes = "news_and_views";
            
        </script>
    

    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky" style="top: 40px;">
            <ul class="c-reading-companion__tabs" role="tablist"><li role="presentation"><button data-tab-target="sections" role="tab" id="tab-sections" aria-controls="tabpanel-sections" aria-selected="true" class="c-reading-companion__tab c-reading-companion__tab--active" data-track="click" data-track-action="sections tab" data-track-label="tab">Sections</button></li><li role="presentation"><button data-tab-target="figures" role="tab" id="tab-figures" aria-controls="tabpanel-figures" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="figures tab" data-track-label="tab">Figures</button></li><li role="presentation"><button data-tab-target="references" role="tab" id="tab-references" aria-controls="tabpanel-references" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="references tab" data-track-label="tab">References</button></li></ul><div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections" aria-labelledby="tab-sections" role="tabpanel"><div class="c-reading-companion__scroll-pane" style="max-height: none;"><ul class="c-reading-companion__sections-list"><li id="rc-sec-Abs1" class="c-reading-companion__section-item"><a href="#Abs1" data-track="click" data-track-action="section anchor" data-track-label="link:Abstract">Abstract</a></li><li id="rc-sec-Sec1" class="c-reading-companion__section-item"><a href="#Sec1" data-track="click" data-track-action="section anchor" data-track-label="link:Main">Main</a></li><li id="rc-sec-Sec2" class="c-reading-companion__section-item"><a href="#Sec2" data-track="click" data-track-action="section anchor" data-track-label="link:Results">Results</a></li><li id="rc-sec-Sec9" class="c-reading-companion__section-item"><a href="#Sec9" data-track="click" data-track-action="section anchor" data-track-label="link:Discussion">Discussion</a></li><li id="rc-sec-Sec10" class="c-reading-companion__section-item"><a href="#Sec10" data-track="click" data-track-action="section anchor" data-track-label="link:Methods">Methods</a></li><li id="rc-sec-data-availability" class="c-reading-companion__section-item"><a href="#data-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Data availability">Data availability</a></li><li id="rc-sec-Bib1" class="c-reading-companion__section-item"><a href="#Bib1" data-track="click" data-track-action="section anchor" data-track-label="link:References">References</a></li><li id="rc-sec-Ack1" class="c-reading-companion__section-item"><a href="#Ack1" data-track="click" data-track-action="section anchor" data-track-label="link:Acknowledgements">Acknowledgements</a></li><li id="rc-sec-author-information" class="c-reading-companion__section-item"><a href="#author-information" data-track="click" data-track-action="section anchor" data-track-label="link:Author information">Author information</a></li><li id="rc-sec-ethics" class="c-reading-companion__section-item"><a href="#ethics" data-track="click" data-track-action="section anchor" data-track-label="link:Ethics declarations">Ethics declarations</a></li><li id="rc-sec-peer-review" class="c-reading-companion__section-item"><a href="#peer-review" data-track="click" data-track-action="section anchor" data-track-label="link:Peer review">Peer review</a></li><li id="rc-sec-additional-information" class="c-reading-companion__section-item"><a href="#additional-information" data-track="click" data-track-action="section anchor" data-track-label="link:Additional information">Additional information</a></li><li id="rc-sec-Sec20" class="c-reading-companion__section-item"><a href="#Sec20" data-track="click" data-track-action="section anchor" data-track-label="link:Extended data">Extended data</a></li><li id="rc-sec-Sec21" class="c-reading-companion__section-item"><a href="#Sec21" data-track="click" data-track-action="section anchor" data-track-label="link:Supplementary information">Supplementary information</a></li><li id="rc-sec-rightslink" class="c-reading-companion__section-item"><a href="#rightslink" data-track="click" data-track-action="section anchor" data-track-label="link:Rights and permissions">Rights and permissions</a></li><li id="rc-sec-article-info" class="c-reading-companion__section-item"><a href="#article-info" data-track="click" data-track-action="section anchor" data-track-label="link:About this article">About this article</a></li><li id="rc-sec-further-reading" class="c-reading-companion__section-item"><a href="#further-reading" data-track="click" data-track-action="section anchor" data-track-label="link:This article is cited by">This article is cited by</a></li></ul></div>
                <div class="u-lazy-ad-wrapper u-mt-16 u-show" data-component-mpu="" style="display: none !important;">
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2" class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide" data-ad-type="right" data-test="right-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="300x250" data-gpt-targeting="type=article;pos=right;artid=s41591-022-01916-x;doi=10.1038/s41591-022-01916-x;subjmeta=250,251,308,327,575,580,631,67,692;kwrd=Cancer+microenvironment,Immunotherapy,Translational+research,Tumour+immunology">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=998545372&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-022-01916-x%26doi%3D10.1038/s41591-022-01916-x%26subjmeta%3D250,251,308,327,575,580,631,67,692%26kwrd%3DCancer+microenvironment,Immunotherapy,Translational+research,Tumour+immunology">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=998545372&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-022-01916-x%26doi%3D10.1038/s41591-022-01916-x%26subjmeta%3D250,251,308,327,575,580,631,67,692%26kwrd%3DCancer+microenvironment,Immunotherapy,Translational+research,Tumour+immunology"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures" aria-labelledby="tab-figures" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ul class="c-reading-companion__figures-list"><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig1">Fig. 1: Evolution of TME after axi-cel infusion associated with clinical outcomes in ZUMA-1.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig1_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig1_HTML.png" alt="figure 1" aria-describedby="rc-Fig1"></picture><p class="c-reading-companion__figure-links"><a href="#Fig1" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/1" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig2">Fig. 2: Evolution of T cell subset densities in the TME after axi-cel infusion.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig2_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig2_HTML.png" alt="figure 2" aria-describedby="rc-Fig2"></picture><p class="c-reading-companion__figure-links"><a href="#Fig2" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/2" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig3">Fig. 3: Correlations between circulating CAR T cell levels and tumor immune contexture.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig3_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig3_HTML.png" alt="figure 3" aria-describedby="rc-Fig3"></picture><p class="c-reading-companion__figure-links"><a href="#Fig3" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/3" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig4">Fig. 4: Pre-treatment tumor immune contexture associated with survival probability of patients in ZUMA-1.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig4_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig4_HTML.png" alt="figure 4" aria-describedby="rc-Fig4"></picture><p class="c-reading-companion__figure-links"><a href="#Fig4" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/4" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig5">Fig. 5: T cell subsets in pre-treatment tumor biopsies associated with myeloid-secreted chemokines.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig5_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig5_HTML.png" alt="figure 5" aria-describedby="rc-Fig5"></picture><p class="c-reading-companion__figure-links"><a href="#Fig5" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/5" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig6">Fig. 6: Cell density of T cell subsets in pre-treatment tumor biopsies associated with axi-cel efficacy, NEs and CAR T cell expansion.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig6_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig6_HTML.png" alt="figure 6" aria-describedby="rc-Fig6"></picture><p class="c-reading-companion__figure-links"><a href="#Fig6" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/6" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig7">Extended Data Fig. 1 Characterization of ZUMA-1 tumour biopsy specimens analysed in this study.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig7_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig7_ESM.jpg" alt="extended data figure 7" aria-describedby="rc-Fig7"></picture><p class="c-reading-companion__figure-links"><a href="#Fig7" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/7" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig8">Extended Data Fig. 2 Evolution of the tumour infiltrate in ZUMA-1 patients after axi-cel infusion associated with clinical outcomes independently of tumour burden.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig8_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig8_ESM.jpg" alt="extended data figure 8" aria-describedby="rc-Fig8"></picture><p class="c-reading-companion__figure-links"><a href="#Fig8" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/8" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig9">Extended Data Fig. 3 Overview of Immunoscore index, Immunoscore TCE/TCE+ panels, and Immunoscore SC panel.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig9_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig9_ESM.jpg" alt="extended data figure 9" aria-describedby="rc-Fig9"></picture><p class="c-reading-companion__figure-links"><a href="#Fig9" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/9" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig10">Extended Data Fig. 4 Overview of Immunoscore TCE+ panel.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig10_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig10_ESM.jpg" alt="extended data figure 10" aria-describedby="rc-Fig10"></picture><p class="c-reading-companion__figure-links"><a href="#Fig10" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/10" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig11">Extended Data Fig. 5 Correlative analyses with Immunoscore panels.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig11_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig11_ESM.jpg" alt="extended data figure 11" aria-describedby="rc-Fig11"></picture><p class="c-reading-companion__figure-links"><a href="#Fig11" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/11" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig12">Extended Data Fig. 6 Correlative studies of Immunosign 21 score with cell subsets across 3 independent datasets.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig12_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig12_ESM.jpg" alt="extended data figure 12" aria-describedby="rc-Fig12"></picture><p class="c-reading-companion__figure-links"><a href="#Fig12" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/12" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig13">Extended Data Fig. 7 Circulating peak CAR T-cell levels normalised to pretreatment tumour burden correlated to Immunoscore.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig13_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig13_ESM.jpg" alt="extended data figure 13" aria-describedby="rc-Fig13"></picture><p class="c-reading-companion__figure-links"><a href="#Fig13" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/13" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig14">Extended Data Fig. 8 Evolution of immune gene expression in tumour biopsies of ZUMA-1 patients who relapsed.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig14_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig14_ESM.jpg" alt="extended data figure 14" aria-describedby="rc-Fig14"></picture><p class="c-reading-companion__figure-links"><a href="#Fig14" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/14" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig15">Extended Data Fig. 9 B-cell lineage and CTA gene expression in tumour biopsies of ZUMA-1 patients.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig15_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig15_ESM.jpg" alt="extended data figure 15" aria-describedby="rc-Fig15"></picture><p class="c-reading-companion__figure-links"><a href="#Fig15" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/15" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig16">Extended Data Fig. 10 Correlative studies in Zuma 1 and commercial axi-cel patient datasets.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig16_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01916-x/MediaObjects/41591_2022_1916_Fig16_ESM.jpg" alt="extended data figure 16" aria-describedby="rc-Fig16"></picture><p class="c-reading-companion__figure-links"><a href="#Fig16" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01916-x/figures/16" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li></ul></div></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references" aria-labelledby="tab-references" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ol class="c-reading-companion__references-list c-reading-companion__references-list--numeric" data-track-context="article references sidebar"><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR1">Jensen, M. C. &amp; Riddell, S. R. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. <i>Immunol. Rev.</i> <b>257</b>, 127–144 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1111%2Fimr.12139" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1111/imr.12139" data-track-item_id="10.1111/imr.12139">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXhvFequrjE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24329794" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991306" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Design%20and%20implementation%20of%20adoptive%20therapy%20with%20chimeric%20antigen%20receptor-modified%20T%20cells&amp;journal=Immunol.%20Rev.&amp;doi=10.1111%2Fimr.12139&amp;volume=257&amp;pages=127-144&amp;publication_year=2014&amp;author=Jensen%2CMC&amp;author=Riddell%2CSR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR2">Yang, J. C. &amp; Rosenberg, S. A. Adoptive T-cell therapy for cancer. <i>Adv. Immunol.</i> <b>130</b>, 279–294 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fbs.ai.2015.12.006" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/bs.ai.2015.12.006" data-track-item_id="10.1016/bs.ai.2015.12.006">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXotVGqsLY%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26923004" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293459" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Adoptive%20T-cell%20therapy%20for%20cancer&amp;journal=Adv.%20Immunol.&amp;doi=10.1016%2Fbs.ai.2015.12.006&amp;volume=130&amp;pages=279-294&amp;publication_year=2016&amp;author=Yang%2CJC&amp;author=Rosenberg%2CSA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR3">Dunbar, C.E. et al. Gene therapy comes of age. <i>Science</i> <b>359</b>, eaan4672 (2018).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR4">June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. &amp; Milone, M. C. CAR T cell immunotherapy for human cancer. <i>Science</i> <b>359</b>, 1361–1365 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscience.aar6711" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/science.aar6711" data-track-item_id="10.1126/science.aar6711">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXltFehtb4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29567707" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CAR%20T%20cell%20immunotherapy%20for%20human%20cancer&amp;journal=Science&amp;doi=10.1126%2Fscience.aar6711&amp;volume=359&amp;pages=1361-1365&amp;publication_year=2018&amp;author=June%2CCH&amp;author=O%E2%80%99Connor%2CRS&amp;author=Kawalekar%2COU&amp;author=Ghassemi%2CS&amp;author=Milone%2CMC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR5">Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. <i>Lancet Oncol.</i> <b>20</b>, 31–42 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS1470-2045%2818%2930864-7" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S1470-2045(18)30864-7" data-track-item_id="10.1016/S1470-2045(18)30864-7">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXisVSgt7bE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30518502" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Long-term%20safety%20and%20activity%20of%20axicabtagene%20ciloleucel%20in%20refractory%20large%20B-cell%20lymphoma%20%28ZUMA-1%29%3A%20a%20single-arm%2C%20multicentre%2C%20phase%201-2%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2818%2930864-7&amp;volume=20&amp;pages=31-42&amp;publication_year=2019&amp;author=Locke%2CFL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR6">Fu, K. et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. <i>J. Clin. Oncol.</i> <b>26</b>, 4587–4594 (2008).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2007.15.9277" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2007.15.9277" data-track-item_id="10.1200/JCO.2007.15.9277">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXht1KqtLfI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18662967" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Addition%20of%20rituximab%20to%20standard%20chemotherapy%20improves%20the%20survival%20of%20both%20the%20germinal%20center%20B-cell-like%20and%20non-germinal%20center%20B-cell-like%20subtypes%20of%20diffuse%20large%20B-cell%20lymphoma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2007.15.9277&amp;volume=26&amp;pages=4587-4594&amp;publication_year=2008&amp;author=Fu%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR7">Carbone, A., Gloghini, A., Kwong, Y. L. &amp; Younes, A. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. <i>Ann. Hematol.</i> <b>93</b>, 1263–1277 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1007/s00277-014-2116-y" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1007/s00277-014-2116-y" data-track-item_id="10.1007/s00277-014-2116-y">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXoslCkurY%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24870942" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082139" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Diffuse%20large%20B%20cell%20lymphoma%3A%20using%20pathologic%20and%20molecular%20biomarkers%20to%20define%20subgroups%20for%20novel%20therapy&amp;journal=Ann.%20Hematol.&amp;doi=10.1007%2Fs00277-014-2116-y&amp;volume=93&amp;pages=1263-1277&amp;publication_year=2014&amp;author=Carbone%2CA&amp;author=Gloghini%2CA&amp;author=Kwong%2CYL&amp;author=Younes%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR8">Locke, F. L. et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. <i>Mol. Ther.</i> <b>25</b>, 285–295 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ymthe.2016.10.020" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ymthe.2016.10.020" data-track-item_id="10.1016/j.ymthe.2016.10.020">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXmvFCmtbg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28129122" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363293" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%201%20results%20of%20ZUMA-1%3A%20a%20multicenter%20study%20of%20KTE-C19%20anti-CD19%20CAR%20T%20cell%20therapy%20in%20refractory%20aggressive%20lymphoma&amp;journal=Mol.%20Ther.&amp;doi=10.1016%2Fj.ymthe.2016.10.020&amp;volume=25&amp;pages=285-295&amp;publication_year=2017&amp;author=Locke%2CFL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR9">Galon, J., Fridman, W. H. &amp; Pages, F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. <i>Cancer Res.</i> <b>67</b>, 1883–1886 (2007).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F0008-5472.CAN-06-4806" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/0008-5472.CAN-06-4806" data-track-item_id="10.1158/0008-5472.CAN-06-4806">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXit12qtbo%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17332313" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20adaptive%20immunologic%20microenvironment%20in%20colorectal%20cancer%3A%20a%20novel%20perspective&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-06-4806&amp;volume=67&amp;pages=1883-1886&amp;publication_year=2007&amp;author=Galon%2CJ&amp;author=Fridman%2CWH&amp;author=Pages%2CF" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR10">Galon, J. et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. <i>J. Transl. Med.</i> <b>14</b>, 273 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/s12967-016-1029-z" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/s12967-016-1029-z" data-track-item_id="10.1186/s12967-016-1029-z">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC2svis1Shuw%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27650038" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029056" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Immunoscore%20and%20Immunoprofiling%20in%20cancer%3A%20an%20update%20from%20the%20melanoma%20and%20immunotherapy%20bridge%202015&amp;journal=J.%20Transl.%20Med.&amp;doi=10.1186%2Fs12967-016-1029-z&amp;volume=14&amp;publication_year=2016&amp;author=Galon%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR11">Spranger, S. &amp; Gajewski, T. F. Impact of oncogenic pathways on evasion of antitumour immune responses. <i>Nat. Rev. Cancer</i> <b>18</b>, 139–147 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnrc.2017.117" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nrc.2017.117" data-track-item_id="10.1038/nrc.2017.117">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXnvVKgsw%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29326431" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685071" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Impact%20of%20oncogenic%20pathways%20on%20evasion%20of%20antitumour%20immune%20responses&amp;journal=Nat.%20Rev.%20Cancer&amp;doi=10.1038%2Fnrc.2017.117&amp;volume=18&amp;pages=139-147&amp;publication_year=2018&amp;author=Spranger%2CS&amp;author=Gajewski%2CTF" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR12">Angelova, M. et al. Evolution of metastases in space and time under immune selection. <i>Cell</i> <b>175</b>, 751–765 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2018.09.018" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2018.09.018" data-track-item_id="10.1016/j.cell.2018.09.018">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvFSqsrvM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30318143" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Evolution%20of%20metastases%20in%20space%20and%20time%20under%20immune%20selection&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2018.09.018&amp;volume=175&amp;pages=751-765&amp;publication_year=2018&amp;author=Angelova%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR13">Bedognetti, D. et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. <i>J. Immunother. Cancer</i> <b>7</b>, 131 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/s40425-019-0602-4" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/s40425-019-0602-4" data-track-item_id="10.1186/s40425-019-0602-4">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31113486" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529999" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Toward%20a%20comprehensive%20view%20of%20cancer%20immune%20responsiveness%3A%20a%20synopsis%20from%20the%20SITC%20workshop&amp;journal=J.%20Immunother.%20Cancer&amp;doi=10.1186%2Fs40425-019-0602-4&amp;volume=7&amp;publication_year=2019&amp;author=Bedognetti%2CD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR14">Mascaux, C. et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. <i>Nature</i> <b>571</b>, 570–575 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41586-019-1330-0" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41586-019-1330-0" data-track-item_id="10.1038/s41586-019-1330-0">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXht1yktL7N" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31243362" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Immune%20evasion%20before%20tumour%20invasion%20in%20early%20lung%20squamous%20carcinogenesis&amp;journal=Nature&amp;doi=10.1038%2Fs41586-019-1330-0&amp;volume=571&amp;pages=570-575&amp;publication_year=2019&amp;author=Mascaux%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR15">Galon, J. &amp; Bruni, D. Tumor immunology and tumor evolution: intertwined histories. <i>Immunity</i> <b>52</b>, 55–81 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.immuni.2019.12.018" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.immuni.2019.12.018" data-track-item_id="10.1016/j.immuni.2019.12.018">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXnslWksbY%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31940273" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20immunology%20and%20tumor%20evolution%3A%20intertwined%20histories&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2019.12.018&amp;volume=52&amp;pages=55-81&amp;publication_year=2020&amp;author=Galon%2CJ&amp;author=Bruni%2CD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR16">Bindea, G., Mlecnik, B., Angell, H. K. &amp; Galon, J. The immune landscape of human tumors: implications for cancer immunotherapy. <i>Oncoimmunology</i> <b>3</b>, e27456 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.4161%2Fonci.27456" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.4161/onci.27456" data-track-item_id="10.4161/onci.27456">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24800163" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006852" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20immune%20landscape%20of%20human%20tumors%3A%20implications%20for%20cancer%20immunotherapy&amp;journal=Oncoimmunology&amp;doi=10.4161%2Fonci.27456&amp;volume=3&amp;publication_year=2014&amp;author=Bindea%2CG&amp;author=Mlecnik%2CB&amp;author=Angell%2CHK&amp;author=Galon%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR17">Kirilovsky, A. et al. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. <i>Int. Immunol.</i> <b>28</b>, 373–382 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fintimm%2Fdxw021" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/intimm/dxw021" data-track-item_id="10.1093/intimm/dxw021">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xhs1Ontr3E" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27121213" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986234" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Rational%20bases%20for%20the%20use%20of%20the%20Immunoscore%20in%20routine%20clinical%20settings%20as%20a%20prognostic%20and%20predictive%20biomarker%20in%20cancer%20patients&amp;journal=Int.%20Immunol.&amp;doi=10.1093%2Fintimm%2Fdxw021&amp;volume=28&amp;pages=373-382&amp;publication_year=2016&amp;author=Kirilovsky%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR18">Pages, F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet</i> <b>391</b>, 2128–2139 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS0140-6736%2818%2930789-X" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S0140-6736(18)30789-X" data-track-item_id="10.1016/S0140-6736(18)30789-X">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29754777" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=International%20validation%20of%20the%20consensus%20Immunoscore%20for%20the%20classification%20of%20colon%20cancer%3A%20a%20prognostic%20and%20accuracy%20study&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2818%2930789-X&amp;volume=391&amp;pages=2128-2139&amp;publication_year=2018&amp;author=Pages%2CF" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR19">Van den Eynde, M. et al. The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients. <i>Cancer Cell</i> <b>34</b>, 1012–1026 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ccell.2018.11.003" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ccell.2018.11.003" data-track-item_id="10.1016/j.ccell.2018.11.003">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30537506" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20link%20between%20the%20multiverse%20of%20immune%20microenvironments%20in%20metastases%20and%20the%20survival%20of%20colorectal%20cancer%20patients&amp;journal=Cancer%20Cell&amp;doi=10.1016%2Fj.ccell.2018.11.003&amp;volume=34&amp;pages=1012-1026&amp;publication_year=2018&amp;author=Eynde%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR20">Angell, H. K., Bruni, D., Barrett, J. C., Herbst, R. &amp; Galon, J. The Immunoscore: colon cancer and beyond. <i>Clin. Cancer Res.</i> <b>26</b>, 332–339 (2019).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR21">Yomoda, T. et al. The Immunoscore is a superior prognostic tool in stages II and III colorectal cancer and is significantly correlated with programmed death-ligand 1 (PD-L1) expression on tumor-infiltrating mononuclear cells. <i>Ann. Surg. Oncol.</i> <b>26</b>, 415–424 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1245%2Fs10434-018-07110-z" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1245/s10434-018-07110-z" data-track-item_id="10.1245/s10434-018-07110-z">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30569297" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20Immunoscore%20is%20a%20superior%20prognostic%20tool%20in%20stages%20II%20and%20III%20colorectal%20cancer%20and%20is%20significantly%20correlated%20with%20programmed%20death-ligand%201%20%28PD-L1%29%20expression%20on%20tumor-infiltrating%20mononuclear%20cells&amp;journal=Ann.%20Surg.%20Oncol.&amp;doi=10.1245%2Fs10434-018-07110-z&amp;volume=26&amp;pages=415-424&amp;publication_year=2019&amp;author=Yomoda%2CT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR22">Bruni, D., Angell, H. K. &amp; Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. <i>Nat. Rev. Cancer</i> <b>20</b>, 662–680 (2020).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR23">Sharma, P. et al. The next decade of immune checkpoint therapy. <i>Cancer Discov.</i> <b>11</b>, 838–857 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-20-1680" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-20-1680" data-track-item_id="10.1158/2159-8290.CD-20-1680">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtlKqurbN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33811120" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20next%20decade%20of%20immune%20checkpoint%20therapy&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-20-1680&amp;volume=11&amp;pages=838-857&amp;publication_year=2021&amp;author=Sharma%2CP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR24">Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. <i>N. Engl. J. Med.</i> <b>377</b>, 2531–2544 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1707447" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1707447" data-track-item_id="10.1056/NEJMoa1707447">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVGjtbw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29226797" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882485" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Axicabtagene%20ciloleucel%20CAR%20T-cell%20therapy%20in%20refractory%20large%20B-cell%20lymphoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1707447&amp;volume=377&amp;pages=2531-2544&amp;publication_year=2017&amp;author=Neelapu%2CSS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR25">Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. <i>N. Engl. J. Med.</i> <b>386</b>, 640–654 (2021).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR26">Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells associate with CAR T-cell failure in large B-cell lymphoma. <i>Blood</i> <b>137</b>, 2621–2633 (2021).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR27">Moschella, F. et al. Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients’ blood cells: implications for cancer chemoimmunotherapy. <i>Clin. Cancer Res.</i> <b>19</b>, 4249–4261 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-12-3666" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-12-3666" data-track-item_id="10.1158/1078-0432.CCR-12-3666">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXht1amt7zO" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23759676" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Cyclophosphamide%20induces%20a%20type%20I%20interferon-associated%20sterile%20inflammatory%20response%20signature%20in%20cancer%20patients%E2%80%99%20blood%20cells%3A%20implications%20for%20cancer%20chemoimmunotherapy&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-12-3666&amp;volume=19&amp;pages=4249-4261&amp;publication_year=2013&amp;author=Moschella%2CF" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR28">Stamenkovic, I. et al. The B cell antigen CD75 is a cell surface sialytransferase. <i>J. Exp. Med.</i> <b>172</b>, 641–643 (1990).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1084%2Fjem.172.2.641" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1084/jem.172.2.641" data-track-item_id="10.1084/jem.172.2.641">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK3cXmtV2ntL8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=2373995" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20B%20cell%20antigen%20CD75%20is%20a%20cell%20surface%20sialytransferase&amp;journal=J.%20Exp.%20Med.&amp;doi=10.1084%2Fjem.172.2.641&amp;volume=172&amp;pages=641-643&amp;publication_year=1990&amp;author=Stamenkovic%2CI" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR29">Okuyama, K. et al. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia. <i>PLoS Genet.</i> <b>15</b>, e1008280 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pgen.1008280" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pgen.1008280" data-track-item_id="10.1371/journal.pgen.1008280">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtFKmtb0%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31381561" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695195" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=PAX5%20is%20part%20of%20a%20functional%20transcription%20factor%20network%20targeted%20in%20lymphoid%20leukemia&amp;journal=PLoS%20Genet.&amp;doi=10.1371%2Fjournal.pgen.1008280&amp;volume=15&amp;publication_year=2019&amp;author=Okuyama%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR30">Park, H. Y. et al. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma. <i>Oncotarget</i> <b>7</b>, 86433–86445 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.18632%2Foncotarget.13239" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.18632/oncotarget.13239" data-track-item_id="10.18632/oncotarget.13239">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27835906" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349924" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Whole-exome%20and%20transcriptome%20sequencing%20of%20refractory%20diffuse%20large%20B-cell%20lymphoma&amp;journal=Oncotarget&amp;doi=10.18632%2Foncotarget.13239&amp;volume=7&amp;pages=86433-86445&amp;publication_year=2016&amp;author=Park%2CHY" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR31">Whitehurst, A. W. Cause and consequence of cancer/testis antigen activation in cancer. <i>Annu. Rev. Pharmacol. Toxicol.</i> <b>54</b>, 251–272 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1146%2Fannurev-pharmtox-011112-140326" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1146/annurev-pharmtox-011112-140326" data-track-item_id="10.1146/annurev-pharmtox-011112-140326">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXjsVSqtrc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24160706" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Cause%20and%20consequence%20of%20cancer%2Ftestis%20antigen%20activation%20in%20cancer&amp;journal=Annu.%20Rev.%20Pharmacol.%20Toxicol.&amp;doi=10.1146%2Fannurev-pharmtox-011112-140326&amp;volume=54&amp;pages=251-272&amp;publication_year=2014&amp;author=Whitehurst%2CAW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR32">Autio, M. et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. <i>Haematologica</i> <b>106</b>, 718–729 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3324%2Fhaematol.2019.243626" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3324/haematol.2019.243626" data-track-item_id="10.3324/haematol.2019.243626">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXnslyntLo%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32079690" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Immune%20cell%20constitution%20in%20the%20tumor%20microenvironment%20predicts%20the%20outcome%20in%20diffuse%20large%20B-cell%20lymphoma&amp;journal=Haematologica&amp;doi=10.3324%2Fhaematol.2019.243626&amp;volume=106&amp;pages=718-729&amp;publication_year=2021&amp;author=Autio%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR33">Angell, H. &amp; Galon, J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. <i>Curr. Opin. Immunol.</i> <b>25</b>, 261–267 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.coi.2013.03.004" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.coi.2013.03.004" data-track-item_id="10.1016/j.coi.2013.03.004">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXls1SntL8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23579076" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=From%20the%20immune%20contexture%20to%20the%20Immunoscore%3A%20the%20role%20of%20prognostic%20and%20predictive%20immune%20markers%20in%20cancer&amp;journal=Curr.%20Opin.%20Immunol.&amp;doi=10.1016%2Fj.coi.2013.03.004&amp;volume=25&amp;pages=261-267&amp;publication_year=2013&amp;author=Angell%2CH&amp;author=Galon%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR34">Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Adv.</i> <b>4</b>, 4898–4911 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fbloodadvances.2020002394" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/bloodadvances.2020002394" data-track-item_id="10.1182/bloodadvances.2020002394">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXis12ktrnP" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33035333" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556133" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20burden%2C%20inflammation%2C%20and%20product%20attributes%20determine%20outcomes%20of%20axicabtagene%20ciloleucel%20in%20large%20B-cell%20lymphoma&amp;journal=Blood%20Adv.&amp;doi=10.1182%2Fbloodadvances.2020002394&amp;volume=4&amp;pages=4898-4911&amp;publication_year=2020&amp;author=Locke%2CFL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR35">Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. <i>N. Engl. J. Med.</i> <b>359</b>, 2313–2323 (2008).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa0802885" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa0802885" data-track-item_id="10.1056/NEJMoa0802885">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXhsVehtbvF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19038878" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103713" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Stromal%20gene%20signatures%20in%20large-B-cell%20lymphomas&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa0802885&amp;volume=359&amp;pages=2313-2323&amp;publication_year=2008&amp;author=Lenz%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR36">Liu, Y. &amp; Barta, S. K. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. <i>Am. J. Hematol.</i> <b>94</b>, 604–616 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1002%2Fajh.25460" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1002/ajh.25460" data-track-item_id="10.1002/ajh.25460">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXntVCnsLc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30859597" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Diffuse%20large%20B-cell%20lymphoma%3A%202019%20update%20on%20diagnosis%2C%20risk%20stratification%2C%20and%20treatment&amp;journal=Am.%20J.%20Hematol.&amp;doi=10.1002%2Fajh.25460&amp;volume=94&amp;pages=604-616&amp;publication_year=2019&amp;author=Liu%2CY&amp;author=Barta%2CSK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR37">Galon, J. et al. Characterization of anti-CD19 chimeric antigen receptor (CAR) T-cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19). <i>J. Clin. Oncol.</i> <b>35</b>, 3025 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2017.35.15_suppl.3025" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2017.35.15_suppl.3025" data-track-item_id="10.1200/JCO.2017.35.15_suppl.3025">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Characterization%20of%20anti-CD19%20chimeric%20antigen%20receptor%20%28CAR%29%20T-cell-mediated%20tumor%20microenvironment%20immune%20gene%20profile%20in%20a%20multicenter%20trial%20%28ZUMA-1%29%20with%20axicabtagene%20ciloleucel%20%28axi-cel%2C%20KTE-C19%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2017.35.15_suppl.3025&amp;volume=35&amp;publication_year=2017&amp;author=Galon%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR38">Sugiyama, D. et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3<sup>+</sup>CD4<sup>+</sup> regulatory T cells, evoking antitumor immune responses in humans. <i>Proc. Natl Acad. Sci. USA</i> <b>110</b>, 17945–17950 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1073%2Fpnas.1316796110" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1073/pnas.1316796110" data-track-item_id="10.1073/pnas.1316796110">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXhvVWmurzL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24127572" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816454" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Anti-CCR4%20mAb%20selectively%20depletes%20effector-type%20FoxP3%2BCD4%2B%20regulatory%20T%20cells%2C%20evoking%20antitumor%20immune%20responses%20in%20humans&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.1316796110&amp;volume=110&amp;pages=17945-17950&amp;publication_year=2013&amp;author=Sugiyama%2CD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR39">Mizukami, Y. et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3<sup>+</sup> regulatory T-cells in gastric cancer. <i>Int. J. Cancer</i> <b>122</b>, 2286–2293 (2008).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1002%2Fijc.23392" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1002/ijc.23392" data-track-item_id="10.1002/ijc.23392">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXkslyntr8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18224687" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CCL17%20and%20CCL22%20chemokines%20within%20tumor%20microenvironment%20are%20related%20to%20accumulation%20of%20Foxp3%2B%20regulatory%20T-cells%20in%20gastric%20cancer&amp;journal=Int.%20J.%20Cancer&amp;doi=10.1002%2Fijc.23392&amp;volume=122&amp;pages=2286-2293&amp;publication_year=2008&amp;author=Mizukami%2CY" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR40">Kochenderfer, J. N. et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. <i>J. Clin. Oncol.</i> <b>35</b>, 1803–1813 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2016.71.3024" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2016.71.3024" data-track-item_id="10.1200/JCO.2016.71.3024">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvFSntLvO" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28291388" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455597" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Lymphoma%20remissions%20caused%20by%20anti-CD19%20chimeric%20antigen%20receptor%20T%20cells%20are%20associated%20with%20high%20serum%20interleukin-15%20levels&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2016.71.3024&amp;volume=35&amp;pages=1803-1813&amp;publication_year=2017&amp;author=Kochenderfer%2CJN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR41">Conlon, K. C., Miljkovic, M. D. &amp; Waldmann, T. A. Cytokines in the treatment of cancer. <i>J. Interferon Cytokine Res.</i> <b>39</b>, 6–21 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1089%2Fjir.2018.0019" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1089/jir.2018.0019" data-track-item_id="10.1089/jir.2018.0019">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXms1ehsg%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29889594" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350412" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Cytokines%20in%20the%20treatment%20of%20cancer&amp;journal=J.%20Interferon%20Cytokine%20Res.&amp;doi=10.1089%2Fjir.2018.0019&amp;volume=39&amp;pages=6-21&amp;publication_year=2019&amp;author=Conlon%2CKC&amp;author=Miljkovic%2CMD&amp;author=Waldmann%2CTA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR42">Cappell, K. M. et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. <i>J. Clin. Oncol.</i> <b>38</b>, 3805–3815 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.20.01467" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.20.01467" data-track-item_id="10.1200/JCO.20.01467">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXisVKls7nJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33021872" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655016" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Long-term%20follow-up%20of%20anti-CD19%20chimeric%20antigen%20receptor%20T-cell%20therapy&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.20.01467&amp;volume=38&amp;pages=3805-3815&amp;publication_year=2020&amp;author=Cappell%2CKM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR43">Arpaia, N. et al. A distinct function of regulatory T cells in tissue protection. <i>Cell</i> <b>162</b>, 1078–1089 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2015.08.021" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2015.08.021" data-track-item_id="10.1016/j.cell.2015.08.021">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsVensLfO" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26317471" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603556" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20distinct%20function%20of%20regulatory%20T%20cells%20in%20tissue%20protection&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2015.08.021&amp;volume=162&amp;pages=1078-1089&amp;publication_year=2015&amp;author=Arpaia%2CN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR44">Campbell, C. &amp; Rudensky, A. Roles of regulatory T cells in tissue pathophysiology and metabolism. <i>Cell Metab.</i> <b>31</b>, 18–25 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cmet.2019.09.010" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cmet.2019.09.010" data-track-item_id="10.1016/j.cmet.2019.09.010">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhvFKku7bE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31607562" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Roles%20of%20regulatory%20T%20cells%20in%20tissue%20pathophysiology%20and%20metabolism&amp;journal=Cell%20Metab.&amp;doi=10.1016%2Fj.cmet.2019.09.010&amp;volume=31&amp;pages=18-25&amp;publication_year=2020&amp;author=Campbell%2CC&amp;author=Rudensky%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR45">Okeke, E. B. &amp; Uzonna, J. E. The pivotal role of regulatory T cells in the regulation of innate immune cells. <i>Front. Immunol.</i> <b>10</b>, 680 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3389%2Ffimmu.2019.00680" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3389/fimmu.2019.00680" data-track-item_id="10.3389/fimmu.2019.00680">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtlKhu7%2FJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31024539" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465517" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20pivotal%20role%20of%20regulatory%20T%20cells%20in%20the%20regulation%20of%20innate%20immune%20cells&amp;journal=Front.%20Immunol.&amp;doi=10.3389%2Ffimmu.2019.00680&amp;volume=10&amp;publication_year=2019&amp;author=Okeke%2CEB&amp;author=Uzonna%2CJE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR46">Galon, J., Angell, H. K., Bedognetti, D. &amp; Marincola, F. M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. <i>Immunity</i> <b>39</b>, 11–26 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.immuni.2013.07.008" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.immuni.2013.07.008" data-track-item_id="10.1016/j.immuni.2013.07.008">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXhtFOhsbfL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23890060" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20continuum%20of%20cancer%20immunosurveillance%3A%20prognostic%2C%20predictive%2C%20and%20mechanistic%20signatures&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2013.07.008&amp;volume=39&amp;pages=11-26&amp;publication_year=2013&amp;author=Galon%2CJ&amp;author=Angell%2CHK&amp;author=Bedognetti%2CD&amp;author=Marincola%2CFM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR47">Galon, J. &amp; Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. <i>Nat. Rev. Drug Discov.</i> <b>18</b>, 197–218 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41573-018-0007-y" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41573-018-0007-y" data-track-item_id="10.1038/s41573-018-0007-y">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXlslKlsrw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30610226" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Approaches%20to%20treat%20immune%20hot%2C%20altered%20and%20cold%20tumours%20with%20combination%20immunotherapies&amp;journal=Nat.%20Rev.%20Drug%20Discov.&amp;doi=10.1038%2Fs41573-018-0007-y&amp;volume=18&amp;pages=197-218&amp;publication_year=2019&amp;author=Galon%2CJ&amp;author=Bruni%2CD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR48">Chen, P. H. et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. <i>JCI Insight</i> <b>5</b>, e134612 (2020).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR49">Coutinho, R. et al. Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. <i>Haematologica</i> <b>100</b>, 363–369 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3324%2Fhaematol.2014.110189" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3324/haematol.2014.110189" data-track-item_id="10.3324/haematol.2014.110189">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXks1CisLo%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25425693" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349275" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Revisiting%20the%20immune%20microenvironment%20of%20diffuse%20large%20B-cell%20lymphoma%20using%20a%20tissue%20microarray%20and%20immunohistochemistry%3A%20robust%20semi-automated%20analysis%20reveals%20CD3%20and%20FoxP3%20as%20potential%20predictors%20of%20response%20to%20R-CHOP&amp;journal=Haematologica&amp;doi=10.3324%2Fhaematol.2014.110189&amp;volume=100&amp;pages=363-369&amp;publication_year=2015&amp;author=Coutinho%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR50">Faramand, R. et al. Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Clin. Cancer Res.</i> <b>26</b>, 4823–4831 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-20-1434" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-20-1434" data-track-item_id="10.1158/1078-0432.CCR-20-1434">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXisFSrsbfI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32669372" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501265" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20microenvironment%20composition%20and%20severe%20cytokine%20release%20syndrome%20%28CRS%29%20influence%20toxicity%20in%20patients%20with%20large%20B-cell%20lymphoma%20treated%20with%20axicabtagene%20ciloleucel&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-20-1434&amp;volume=26&amp;pages=4823-4831&amp;publication_year=2020&amp;author=Faramand%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR51">Chou, C. K. &amp; Turtle, C. J. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. <i>Expert Opin. Biol. Ther.</i> <b>20</b>, 653–664 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1080%2F14712598.2020.1729735" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1080/14712598.2020.1729735" data-track-item_id="10.1080/14712598.2020.1729735">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXjs1Oltrs%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32067497" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393694" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Assessment%20and%20management%20of%20cytokine%20release%20syndrome%20and%20neurotoxicity%20following%20CD19%20CAR-T%20cell%20therapy&amp;journal=Expert%20Opin.%20Biol.%20Ther.&amp;doi=10.1080%2F14712598.2020.1729735&amp;volume=20&amp;pages=653-664&amp;publication_year=2020&amp;author=Chou%2CCK&amp;author=Turtle%2CCJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR52">Anderson, K. G., Stromnes, I. M. &amp; Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. <i>Cancer Cell</i> <b>31</b>, 311–325 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ccell.2017.02.008" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ccell.2017.02.008" data-track-item_id="10.1016/j.ccell.2017.02.008">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXksVeqsLw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28292435" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423788" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Obstacles%20posed%20by%20the%20tumor%20microenvironment%20to%20T%20cell%20activity%3A%20a%20case%20for%20synergistic%20therapies&amp;journal=Cancer%20Cell&amp;doi=10.1016%2Fj.ccell.2017.02.008&amp;volume=31&amp;pages=311-325&amp;publication_year=2017&amp;author=Anderson%2CKG&amp;author=Stromnes%2CIM&amp;author=Greenberg%2CPD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR53">Lanitis, E., Coukos, G. &amp; Irving, M. All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy. <i>Curr. Opin. Biotechnol.</i> <b>65</b>, 75–87 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.copbio.2020.01.009" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.copbio.2020.01.009" data-track-item_id="10.1016/j.copbio.2020.01.009">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXjtFWmu7g%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32109718" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=All%20systems%20go%3A%20converging%20synthetic%20biology%20and%20combinatorial%20treatment%20for%20CAR-T%20cell%20therapy&amp;journal=Curr.%20Opin.%20Biotechnol.&amp;doi=10.1016%2Fj.copbio.2020.01.009&amp;volume=65&amp;pages=75-87&amp;publication_year=2020&amp;author=Lanitis%2CE&amp;author=Coukos%2CG&amp;author=Irving%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR54">Hudolin, T. et al. Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma. <i>J. Transl. Med.</i> <b>11</b>, 123 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/1479-5876-11-123" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/1479-5876-11-123" data-track-item_id="10.1186/1479-5876-11-123">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXptlyhsbs%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23680437" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663708" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Immunohistochemical%20analysis%20of%20the%20expression%20of%20MAGE-A%20and%20NY-ESO-1%20cancer%2Ftestis%20antigens%20in%20diffuse%20large%20B-cell%20testicular%20lymphoma&amp;journal=J.%20Transl.%20Med.&amp;doi=10.1186%2F1479-5876-11-123&amp;volume=11&amp;publication_year=2013&amp;author=Hudolin%2CT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR55">Teater, M. et al. AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. <i>Nat. Commun.</i> <b>9</b>, 222 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41467-017-02595-w" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41467-017-02595-w" data-track-item_id="10.1038/s41467-017-02595-w">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29335468" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768781" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=AICDA%20drives%20epigenetic%20heterogeneity%20and%20accelerates%20germinal%20center-derived%20lymphomagenesis&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-017-02595-w&amp;volume=9&amp;publication_year=2018&amp;author=Teater%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR56">Khan, O. et al. TOX transcriptionally and epigenetically programs CD8<sup>+</sup> T cell exhaustion. <i>Nature</i> <b>571</b>, 211–218 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41586-019-1325-x" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41586-019-1325-x" data-track-item_id="10.1038/s41586-019-1325-x">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtlSms7bI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31207603" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713202" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=TOX%20transcriptionally%20and%20epigenetically%20programs%20CD8%2B%20T%20cell%20exhaustion&amp;journal=Nature&amp;doi=10.1038%2Fs41586-019-1325-x&amp;volume=571&amp;pages=211-218&amp;publication_year=2019&amp;author=Khan%2CO" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR57">Brudno, J. N. et al. Safety and feasibility of anti-CD19 CAR T-cells with fully human binding domains in patients with B-cell lymphoma. <i>Nat. Med.</i> <b>26</b>, 270–280 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-019-0737-3" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-019-0737-3" data-track-item_id="10.1038/s41591-019-0737-3">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXislensr8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31959992" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781235" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%20and%20feasibility%20of%20anti-CD19%20CAR%20T-cells%20with%20fully%20human%20binding%20domains%20in%20patients%20with%20B-cell%20lymphoma&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-019-0737-3&amp;volume=26&amp;pages=270-280&amp;publication_year=2020&amp;author=Brudno%2CJN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR58">Singh, N. et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. <i>Cancer Discov.</i> <b>10</b>, 552–567 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-19-0813" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-19-0813" data-track-item_id="10.1158/2159-8290.CD-19-0813">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXit1Cgt77E" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32001516" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416790" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Impaired%20death%20receptor%20signaling%20in%20leukemia%20causes%20antigen-independent%20resistance%20by%20inducing%20CAR%20T-cell%20dysfunction&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-19-0813&amp;volume=10&amp;pages=552-567&amp;publication_year=2020&amp;author=Singh%2CN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR59">Upadhyay, R. et al. A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy. <i>Cancer Discov.</i> <b>11</b>, 599–613 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-20-0756" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-20-0756" data-track-item_id="10.1158/2159-8290.CD-20-0756">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXosV2hsbo%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33334730" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20critical%20role%20for%20Fas-mediated%20off-target%20tumor%20killing%20in%20T-cell%20immunotherapy&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-20-0756&amp;volume=11&amp;pages=599-613&amp;publication_year=2021&amp;author=Upadhyay%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR60">Plaks, V. et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Blood</i> <b>138</b>, 1081–1085 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood.2021010930" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood.2021010930" data-track-item_id="10.1182/blood.2021010930">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXitFWgs7zE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34041526" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462361" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD19%20target%20evasion%20as%20a%20mechanism%20of%20relapse%20in%20large%20B-cell%20lymphoma%20treated%20with%20axicabtagene%20ciloleucel&amp;journal=Blood&amp;doi=10.1182%2Fblood.2021010930&amp;volume=138&amp;pages=1081-1085&amp;publication_year=2021&amp;author=Plaks%2CV" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR61">Marliot, F. et al. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. <i>J. Immunother. Cancer</i> <b>8</b>, e000272 (2020).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR62">Panda, A. et al. Immune activation and benefit from avelumab in EBV-positive gastric cancer. <i>J. Natl Cancer Inst.</i> <b>110</b>, 316–320 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fjnci%2Fdjx213" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/jnci/djx213" data-track-item_id="10.1093/jnci/djx213">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXpt1amtbc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29155997" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Immune%20activation%20and%20benefit%20from%20avelumab%20in%20EBV-positive%20gastric%20cancer&amp;journal=J.%20Natl%20Cancer%20Inst.&amp;doi=10.1093%2Fjnci%2Fdjx213&amp;volume=110&amp;pages=316-320&amp;publication_year=2018&amp;author=Panda%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR63">Agocs, G. R. et al. LAG-3 expression predicts outcome in stage II colon cancer. <i>J. Pers. Med.</i> <b>11</b>, 749 (2021).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR64">Syed Khaja, A. S. et al. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. <i>Oncotarget</i> <b>8</b>, 33159–33171 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.18632%2Foncotarget.16565" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.18632/oncotarget.16565" data-track-item_id="10.18632/oncotarget.16565">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28388539" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Preferential%20accumulation%20of%20regulatory%20T%20cells%20with%20highly%20immunosuppressive%20characteristics%20in%20breast%20tumor%20microenvironment&amp;journal=Oncotarget&amp;doi=10.18632%2Foncotarget.16565&amp;volume=8&amp;pages=33159-33171&amp;publication_year=2017&amp;author=Syed%20Khaja%2CAS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR65">Maestre, L. et al. High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations. <i>PLoS ONE</i> <b>15</b>, e0229743 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pone.0229743" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pone.0229743" data-track-item_id="10.1371/journal.pone.0229743">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXnvVKnur4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32106280" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046285" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=High-mobility%20group%20box%20%28TOX%29%20antibody%20a%20useful%20tool%20for%20the%20identification%20of%20B%20and%20T%20cell%20subpopulations&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0229743&amp;volume=15&amp;publication_year=2020&amp;author=Maestre%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR66">Liu, W. et al. Prognostic value of MTA1, SOX4 and EZH2 expression in esophageal squamous cell carcinoma. <i>Exp. Ther. Med.</i> <b>22</b>, 722 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3892%2Fetm.2021.10154" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3892/etm.2021.10154" data-track-item_id="10.3892/etm.2021.10154">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34007331" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120658" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Prognostic%20value%20of%20MTA1%2C%20SOX4%20and%20EZH2%20expression%20in%20esophageal%20squamous%20cell%20carcinoma&amp;journal=Exp.%20Ther.%20Med.&amp;doi=10.3892%2Fetm.2021.10154&amp;volume=22&amp;publication_year=2021&amp;author=Liu%2CW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR67">Yuan, J. et al. Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients. <i>Cancer Cell Int.</i> <b>19</b>, 238 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/s12935-019-0957-0" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/s12935-019-0957-0" data-track-item_id="10.1186/s12935-019-0957-0">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31528120" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737685" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Combined%20high%20expression%20of%20CD47%20and%20CD68%20is%20a%20novel%20prognostic%20factor%20for%20breast%20cancer%20patients&amp;journal=Cancer%20Cell%20Int.&amp;doi=10.1186%2Fs12935-019-0957-0&amp;volume=19&amp;publication_year=2019&amp;author=Yuan%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR68">Xia, S. et al. SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. <i>Cell Death Dis.</i> <b>12</b>, 570 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41419-021-03853-y" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41419-021-03853-y" data-track-item_id="10.1038/s41419-021-03853-y">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhvFWrtr7I" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34108444" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190073" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=SLC7A2%20deficiency%20promotes%20hepatocellular%20carcinoma%20progression%20by%20enhancing%20recruitment%20of%20myeloid-derived%20suppressors%20cells&amp;journal=Cell%20Death%20Dis.&amp;doi=10.1038%2Fs41419-021-03853-y&amp;volume=12&amp;publication_year=2021&amp;author=Xia%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR69">Marmey, B. et al. CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14<sup>+</sup>CD169<sup>−</sup> monocyte-derived cells in diffuse large B-cell lymphomas. <i>Hum. Pathol.</i> <b>37</b>, 68–77 (2006).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.humpath.2005.09.016" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.humpath.2005.09.016" data-track-item_id="10.1016/j.humpath.2005.09.016">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXhtlajtLrK" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16360418" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD14%20and%20CD169%20expression%20in%20human%20lymph%20nodes%20and%20spleen%3A%20specific%20expansion%20of%20CD14%2BCD169%E2%88%92%20monocyte-derived%20cells%20in%20diffuse%20large%20B-cell%20lymphomas&amp;journal=Hum.%20Pathol.&amp;doi=10.1016%2Fj.humpath.2005.09.016&amp;volume=37&amp;pages=68-77&amp;publication_year=2006&amp;author=Marmey%2CB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR70">Hashimoto, A. et al. Upregulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer. <i>Clin. Cancer Res.</i> <b>27</b>, 5961–5978 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-21-0986" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-21-0986" data-track-item_id="10.1158/1078-0432.CCR-21-0986">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXislKgtrnJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34407972" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756351" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Upregulation%20of%20C%2FEBP%CE%B1%20inhibits%20suppressive%20activity%20of%20myeloid%20cells%20and%20potentiates%20antitumor%20response%20in%20mice%20and%20patients%20with%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-21-0986&amp;volume=27&amp;pages=5961-5978&amp;publication_year=2021&amp;author=Hashimoto%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR71">Scott, D. W. et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> <b>123</b>, 1214–1217 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2013-11-536433" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2013-11-536433" data-track-item_id="10.1182/blood-2013-11-536433">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXjs1ygu74%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24398326" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931191" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Determining%20cell-of-origin%20subtypes%20of%20diffuse%20large%20B-cell%20lymphoma%20using%20gene%20expression%20in%20formalin-fixed%20paraffin-embedded%20tissue&amp;journal=Blood&amp;doi=10.1182%2Fblood-2013-11-536433&amp;volume=123&amp;pages=1214-1217&amp;publication_year=2014&amp;author=Scott%2CDW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR72">Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. <i>Science</i> <b>313</b>, 1960–1964 (2006).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscience.1129139" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/science.1129139" data-track-item_id="10.1126/science.1129139">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD28XhtVSnsrnK" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17008531" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Type%2C%20density%2C%20and%20location%20of%20immune%20cells%20within%20human%20colorectal%20tumors%20predict%20clinical%20outcome&amp;journal=Science&amp;doi=10.1126%2Fscience.1129139&amp;volume=313&amp;pages=1960-1964&amp;publication_year=2006&amp;author=Galon%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li></ol></div></div>
        </div>
    </div>
</aside>
</div>


    
        
    
    
        
            
        

        
            
        
    
    <script>
        window.dataLayer = window.dataLayer || [];
        window.dataLayer.push({
            page: {
                content: {
                    fundingWidget: "true",
                        }
                    }
                });
    </script>




<footer class="composite-layer" itemscope="" itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <div class="c-meta u-ma-0 u-flex-shrink">
                <p class="c-meta__item c-meta__type u-mt-0">
                    <span itemprop="name">
                        Nature Medicine
                    </span>
                    (<i itemprop="alternateName">Nat Med</i>)
                </p>
                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1546-170X</span> (online)
        </p>
    

                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1078-8956</span> (print)
        </p>
    

            </div>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/company_info/index.html" data-track="click" data-track-action="about us" data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/press_room/press_releases.html" data-track="click" data-track-action="press releases" data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/" data-track="click" data-track-action="press office" data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home" data-track="click" data-track-action="contact us" data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex" data-track="click" data-track-action="journals a-z" data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects" data-track="click" data-track-action="article by subject" data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.protocols.io/" data-track="click" data-track-action="protocols.io" data-track-label="link">protocols.io</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/" data-track="click" data-track-action="nature index" data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/authors/editorial_policies" data-track="click" data-track-action="Nature portfolio policies" data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nature-research/open-access" data-track="click" data-track-action="open access" data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints" data-track="click" data-track-action="reprints and permissions" data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/authors/research-data" data-track="click" data-track-action="data research service" data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/language-editing/" data-track="click" data-track-action="language editing" data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/scientific-editing/" data-track="click" data-track-action="scientific editing" data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/" data-track="click" data-track-action="nature masterclasses" data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/" data-track="click" data-track-action="research solutions" data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/tools-services" data-track="click" data-track-action="librarian service and tools" data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal" data-track="click" data-track-action="librarian portal" data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/openresearch/about-open-access/information-for-institutions" data-track="click" data-track-action="open research" data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/recommend-to-your-library" data-track="click" data-track-action="Recommend to library" data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/digital-advertising/" data-track="click" data-track-action="advertising" data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/" data-track="click" data-track-action="partnerships and services" data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/media-kits/" data-track="click" data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/branded-content-native-advertising/" data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/" data-track="click" data-track-action="nature careers" data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com" data-track="click" data-track-action="nature conferences" data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica" data-track="click" data-track-action="nature africa" data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com" data-track="click" data-track-action="nature china" data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia" data-track="click" data-track-action="nature india" data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natitaly" data-track="click" data-track-action="nature Italy" data-track-label="link">Nature Italy</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp" data-track="click" data-track-action="nature japan" data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast" data-track="click" data-track-action="nature middle east" data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy" data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies" data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;" data-cc-action="preferences" data-track="click" data-track-action="manage cookies" data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice" data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/accessibility-statement" data-track="click" data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions" data-track="click" data-track-action="terms and conditions" data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa" data-track="click" data-track-action="california privacy statement" data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-ea63208b81.svg" alt="Springer Nature" loading="lazy" width="200" height="20">
    </a>
    <p class="c-footer__legal" data-test="copyright">© 2025 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <!--?xml version="1.0" encoding="UTF-8"?--><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"></path></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"></path></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"></path></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"></path></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"></path></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"></path></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"></path></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"></path></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"></path></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"></path></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"></path></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"></path></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"></path></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"></path></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"></path></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"></path></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"></path></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"></path></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"></path></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"></path></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"></path></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"></path></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"></path></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"></path></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"></path></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"></path></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"></path></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"></path></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"></path></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"></path></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"></path></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"></path><clipPath id="b"><use xlink:href="#a" style="overflow:visible"></use></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"></path><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"></path></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"></path></symbol><symbol id="icon-eds-i-check-circle-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1Zm0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18Zm5.125 4.72a1 1 0 0 1 .156 1.405l-6 7.5a1 1 0 0 1-1.421.143l-3-2.5a1 1 0 0 1 1.28-1.536l2.217 1.846 5.362-6.703a1 1 0 0 1 1.406-.156Z"></path></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"></path></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-copy-link" viewBox="0 0 24 24"><path fill-rule="evenodd" clip-rule="evenodd" d="M19.4594 8.57015C19.0689 8.17963 19.0689 7.54646 19.4594 7.15594L20.2927 6.32261C20.2927 6.32261 20.2927 6.32261 20.2927 6.32261C21.0528 5.56252 21.0528 4.33019 20.2928 3.57014C19.5327 2.81007 18.3004 2.81007 17.5404 3.57014L16.7071 4.40347C16.3165 4.794 15.6834 4.794 15.2928 4.40348C14.9023 4.01296 14.9023 3.3798 15.2928 2.98927L16.1262 2.15594C17.6673 0.614803 20.1659 0.614803 21.707 2.15593C23.2481 3.69705 23.248 6.19569 21.707 7.7368L20.8737 8.57014C20.4831 8.96067 19.85 8.96067 19.4594 8.57015Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M18.0944 5.90592C18.4849 6.29643 18.4849 6.9296 18.0944 7.32013L16.4278 8.9868C16.0373 9.37733 15.4041 9.37734 15.0136 8.98682C14.6231 8.59631 14.6231 7.96314 15.0136 7.57261L16.6802 5.90594C17.0707 5.51541 17.7039 5.5154 18.0944 5.90592Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M13.5113 6.32243C13.9018 6.71295 13.9018 7.34611 13.5113 7.73664L12.678 8.56997C12.678 8.56997 12.678 8.56997 12.678 8.56997C11.9179 9.33006 11.9179 10.5624 12.6779 11.3224C13.438 12.0825 14.6703 12.0825 15.4303 11.3224L16.2636 10.4891C16.6542 10.0986 17.2873 10.0986 17.6779 10.4891C18.0684 10.8796 18.0684 11.5128 17.6779 11.9033L16.8445 12.7366C15.3034 14.2778 12.8048 14.2778 11.2637 12.7366C9.72262 11.1955 9.72266 8.69689 11.2637 7.15578L12.097 6.32244C12.4876 5.93191 13.1207 5.93191 13.5113 6.32243Z"></path><path d="M8 20V22H19.4619C20.136 22 20.7822 21.7311 21.2582 21.2529C21.7333 20.7757 22 20.1289 22 19.4549V15C22 14.4477 21.5523 14 21 14C20.4477 14 20 14.4477 20 15V19.4549C20 19.6004 19.9426 19.7397 19.8408 19.842C19.7399 19.9433 19.6037 20 19.4619 20H8Z"></path><path d="M4 13H2V19.4619C2 20.136 2.26889 20.7822 2.74705 21.2582C3.22434 21.7333 3.87105 22 4.5451 22H9C9.55228 22 10 21.5523 10 21C10 20.4477 9.55228 20 9 20H4.5451C4.39957 20 4.26028 19.9426 4.15804 19.8408C4.05668 19.7399 4 19.6037 4 19.4619V13Z"></path><path d="M4 13H2V4.53808C2 3.86398 2.26889 3.21777 2.74705 2.74178C3.22434 2.26666 3.87105 2 4.5451 2H9C9.55228 2 10 2.44772 10 3C10 3.55228 9.55228 4 9 4H4.5451C4.39957 4 4.26028 4.05743 4.15804 4.15921C4.05668 4.26011 4 4.39633 4 4.53808V13Z"></path></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-institution-medium" viewBox="0 0 24 24"><g><path fill-rule="evenodd" clip-rule="evenodd" d="M11.9967 1C11.6364 1 11.279 1.0898 10.961 1.2646C10.9318 1.28061 10.9035 1.29806 10.8761 1.31689L2.79765 6.87C2.46776 7.08001 2.20618 7.38466 2.07836 7.76668C1.94823 8.15561 1.98027 8.55648 2.12665 8.90067C2.42086 9.59246 3.12798 10 3.90107 10H4.99994V16H4.49994C3.11923 16 1.99994 17.1193 1.99994 18.5V19.5C1.99994 20.8807 3.11923 22 4.49994 22H19.4999C20.8807 22 21.9999 20.8807 21.9999 19.5V18.5C21.9999 17.1193 20.8807 16 19.4999 16H18.9999V10H20.0922C20.8653 10 21.5725 9.59252 21.8667 8.90065C22.0131 8.55642 22.0451 8.15553 21.9149 7.7666C21.7871 7.38459 21.5255 7.07997 21.1956 6.86998L13.1172 1.31689C13.0898 1.29806 13.0615 1.28061 13.0324 1.2646C12.7143 1.0898 12.357 1 11.9967 1ZM4.6844 8L11.9472 3.00755C11.9616 3.00295 11.9783 3 11.9967 3C12.015 3 12.0318 3.00295 12.0461 3.00755L19.3089 8H4.6844ZM16.9999 16V10H14.9999V16H16.9999ZM12.9999 16V10H10.9999V16H12.9999ZM8.99994 16V10H6.99994V16H8.99994ZM3.99994 18.5C3.99994 18.2239 4.2238 18 4.49994 18H19.4999C19.7761 18 19.9999 18.2239 19.9999 18.5V19.5C19.9999 19.7761 19.7761 20 19.4999 20H4.49994C4.2238 20 3.99994 19.7761 3.99994 19.5V18.5Z"></path></g></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"></path></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"></path></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"></path></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"></path></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"></path></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"></path></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"></path></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"></path></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"></path></symbol></svg>
</div>
</footer>




    

    

<div class="c-site-messages message u-hide u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif c-site-messages--nature-briefing-cancer" data-component-id="nature-briefing-banner" data-component-expirydays="30" data-component-trigger-scroll-percentage="15" data-track="in-view" data-track-action="in-view" data-track-category="nature briefing" data-track-label="Briefing banner visible: Cancer">

    
    <div class="c-site-messages__banner-large">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Cancer">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__form-container">

            <div class="grid grid-12 last">
                <div class="grid grid-4">
                    <img alt="Nature Briefing: Cancer" src="/static/images/logos/nature-briefing-logo-cancer-white-bc263e7d57.svg" width="373" height="40">
                    <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing: Cancer</em> newsletter — what matters in cancer research, free to your inbox weekly.</p>
                </div>
                <div class="grid grid-8 last">
                    <form action="https://www.nature.com/briefing/cancer" method="post" data-location="banner" data-track="signup_nature_briefing_banner" data-track-action="transmit-form" data-track-category="nature briefing" data-track-label="Briefing banner submit: Cancer">
                        <input id="briefing-banner-signup-form-input-track-originReferralPoint" type="hidden" name="track_originReferralPoint" value="CancerBriefingBanner">
                        <input id="briefing-banner-signup-form-input-track-formType" type="hidden" name="track_formType" value="DirectEmailBanner">

                        <input type="hidden" value="false" name="gdpr_tick" id="gdpr_tick_banner">
                        <input type="hidden" value="false" name="marketing" id="marketing_input_banner">
                        <input type="hidden" value="false" name="marketing_tick" id="marketing_tick_banner">
                        <input type="hidden" value="CancerBriefingBanner" name="brieferEntryPoint" id="brieferEntryPoint_banner">

                        <label class="nature-briefing-banner__email-label" for="emailAddress">Email address</label>

                        <div class="nature-briefing-banner__email-wrapper">
                            <input class="nature-briefing-banner__email-input box-sizing text14" type="email" id="emailAddress" name="emailAddress" value="" placeholder="e.g. jo.smith@university.ac.uk" required="" data-test-element="briefing-emailbanner-email-input">
                            
                            <input type="hidden" value="true" name="N:cancer" id="defaultNewsletter_banner">
                            <button type="submit" class="nature-briefing-banner__submit-button box-sizing text14" data-test-element="briefing-emailbanner-signup-button">Sign up</button>
                        </div>

                        <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
                            <input class="nature-briefing-banner__checkbox-checkbox" id="gdpr-briefing-banner-checkbox" type="checkbox" name="gdpr" value="true" data-test-element="briefing-emailbanner-gdpr-checkbox" required="">
                            <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for="gdpr-briefing-banner-checkbox">I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href="https://www.nature.com/info/privacy">Privacy Policy</a>.</label>
                        </div>
                    </form>
                </div>
            </div>

        </div>

    </div>

    
    <div class="c-site-messages__banner-small">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Cancer">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__content text14">
            <span class="c-site-messages--nature-briefing__strapline strong">Get what matters in cancer research, free to your inbox weekly.</span>
            <a class="nature-briefing__link text14 sans-serif" data-track="click" data-track-category="nature briefing" data-track-label="Small-screen banner CTA to site" data-test-element="briefing-banner-link" target="_blank" rel="noreferrer noopener" href="/briefing/cancer/?brieferEntryPoint=CancerBriefingBanner">Sign up for Nature Briefing: Cancer
            </a>
        </div>

    </div>

</div>

    




<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41591-022-01916-x&amp;format=js&amp;last_modified=2022-08-29" async=""></script>

<hmn-dckuzprkaoah></hmn-dckuzprkaoah><div data-cc-ghost="" style="height: 352px;"></div><script type="text/javascript" id="fetch-contextual-ads-campaign-data" charset="">(function(){var g=function(a){a=new CustomEvent("campaignDataLoaded",{detail:a});document.dispatchEvent(a)},b=google_tag_manager["rm"]["50443292"](18);if(b){var k=1500;b=google_tag_manager["rm"]["50443292"](19);b="link"===b?google_tag_manager["rm"]["50443292"](20):google_tag_manager["rm"]["50443292"](21);var m=function(a,c){var h=!1,l=setTimeout(function(){h=!0;c(null)},k),d=new XMLHttpRequest;d.onload=function(){var e=null,f=[];if(200===d.status){try{e=JSON.parse(d.responseText)}catch(p){e={}}f=e.campaigns||[]}h||(clearTimeout(l),c(f.length?f.join(","):null))};d.open("GET",
"/platform/contextual?doi\x3d"+a);d.send()},n=function(a,c){a&&-1===a.indexOf("not set")?m(a,c):setTimeout(c,1)};n(b,function(a){window.campaignsForContextualAds=a;g(a);window.dataLayer.push({content:{article:{campaignID:a}}})})}else window.campaignsForContextualAds="",g(null)})();</script>
<script type="text/javascript" id="gtm-setup-accessdetailsloaded-handler" charset="">document.addEventListener("accessdetailsloaded",function(a){a=a.detail||{};var b={event:"update-access-details"};a.institutional_business_partner_ids&&a.resolved_by||console.log("BPID data could not be retrieved from /exposed-details");a.logged_in_to_sn_profile||console.log("logged_in_to_sn_profile could not be retrieved from /exposed-details");var c=a.institutional_business_partner_ids&&a.institutional_business_partner_ids.join?a.institutional_business_partner_ids.join(";"):"",d=a.resolved_by&&a.resolved_by.join?
a.resolved_by.join(";"):"",e=a.personal_business_partner_id_found,f=a.logged_in_to_sn_profile,g=a.snid;b.user={};b.user.profile={};b.user.profile.profileInfo={resolvedBy:d||null,bpid:c||null,personal:e||null,logged_in_to_sn_profile:f,snid:g||null};b.session={};b.session.authentication={};b.session.authentication.token=a.token||null;b.session.authentication.legacy={};window.dataLayer.push(b);window.idpUserDataLoaded=!0},!1);window.dataLayer.push({event:"accessdetailsloaded-handler-added"});
window.accessDetailsLoadedHandlerAdded=!0;</script><script type="text/javascript" id="gtm-mediatrust" charset="">var s=document.getElementsByTagName("script")[0],p=document.createElement("script");p.async="async";p.src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2";s.parentNode.insertBefore(p,s);</script><script id="crossmark-script" text="" charset="" type="text/javascript" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script><script type="text/javascript" id="polyfill-matches" charset="">Element.prototype.matches||(Element.prototype.matches=Element.prototype.matchesSelector||Element.prototype.mozMatchesSelector||Element.prototype.msMatchesSelector||Element.prototype.oMatchesSelector||Element.prototype.webkitMatchesSelector||function(a){a=(this.document||this.ownerDocument).querySelectorAll(a);for(var b=a.length;0<=--b&&a.item(b)!==this;);return-1<b});</script><script type="text/javascript" id="fetch-idp-user-data" charset="">(function(a){if("function"===typeof window.CustomEvent)return!1;var c=function(d,b){b=b||{};var e=document.createEvent("CustomEvent");e.initCustomEvent(d,b.bubbles||!1,b.cancelable||!1,b.detail||a);return e};c.prototype=window.Event.prototype;window.CustomEvent=c})();var parse=function(a,c){try{return 200===a?JSON.parse(c):null}catch(d){return null}},dispatch=function(a){a=new CustomEvent("accessdetailsloaded",{detail:a});document.dispatchEvent(a)},site=google_tag_manager["rm"]["50443292"](59),idpUrl;
switch(site){case "nature":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?"https://staging-idp.nature.com/exposed-details":"https://idp.nature.com/exposed-details";break;case "link":idpUrl=-1<window.location.hostname.indexOf("link-qa")?"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details";break;case "springer":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?
"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details"}if(void 0!==idpUrl){var transport=new XMLHttpRequest;transport.open("GET",idpUrl,!0);transport.withCredentials=!0;transport.onreadystatechange=function(){4===transport.readyState&&dispatch(parse(transport.status,transport.responseText))};transport.send()}else dispatch(null);</script><script src="https://verify.nature.com/verify/nature.min.js"></script><script type="text/javascript" id="create-ad-slots" charset="">function createAndLoadAds(){function h(b){"nature"===a&&google_tag_manager["rm"]["50443292"](87)(b);"bmc"!==a&&"springeropen"!==a||google_tag_manager["rm"]["50443292"](99)(b);("link"===a&&"oscar"===google_tag_manager["rm"]["50443292"](100)||"springer"===a||"link"===a&&!0===google_tag_manager["rm"]["50443292"](101))&&google_tag_manager["rm"]["50443292"](126)(b);"link"===a&&"bunsen"===google_tag_manager["rm"]["50443292"](127)&&google_tag_manager["rm"]["50443292"](152)(b);"link"===a&&"Core"===google_tag_manager["rm"]["50443292"](153)&&google_tag_manager["rm"]["50443292"](165)(b)}window.googletag=window.googletag||{cmd:[]};var a=google_tag_manager["rm"]["50443292"](166),e=google_tag_manager["rm"]["50443292"](168);
if(-1===window.location.search.indexOf("hide_ads\x3dtrue"))if(window.adSlots&&0!==Object.keys(window.adSlots).length)console.log("Ads previously loaded. Will not update ad slots until next page load.");else{window.adSlots||(window.adSlots={});window.getAd=function(b,f){for(var c in window.adSlots)if(-1<c.indexOf(b)){if("object"===f)return adSlots[c];if("slot"===f)return adSlots[c].slot}};googletag.cmd.push(function(){googletag.pubads().setPrivacySettings({limitedAds:e});console.log("limitedAds is ",
e);googletag.pubads().setRequestNonPersonalizedAds(google_tag_manager["rm"]["50443292"](170));googletag.pubads().enableSingleRequest();googletag.pubads().disableInitialLoad()});for(var g=document.querySelectorAll("[data-gpt]"),d=0;g[d];++d)h(g[d]);googletag.cmd.push(function(){googletag.enableServices()})}}createAndLoadAds();</script>
</body></html>